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CDKN2A, P16-LEIDEN AND FAMILIAL MELANOMA-PANCREATIC 
CANCER SYNDROME 
Familial clustering of cutaneous melanoma has increasingly been documented since 
the 1970s, and one of the first studies that reported an excess of pancreatic ductal 
adenocarcinoma (henceforth referred to as pancreatic cancer; PC) in unbiased 
melanoma families was published in 1990 by Bergman and colleagues.1 The families in 
this study originated from two genetically isolated towns in the vicinity of Leiden, the 
Netherlands. Shortly after the identification of the first melanoma predisposition gene 
CDKN2A (MIM #600160*) in 1994,2,3 a specific Dutch founder mutation† in the CDKN2A gene 
was described in these melanoma-pancreatic cancer prone families, a 19-base-pair deletion 
in exon 2 known as p16-Leiden (c.225_243del).4,5 An excess of PC in CDKN2A-mutated 
melanoma families was subsequently observed in other populations as well.6,7 
To date, the CDKN2A gene has remained the major high-risk predisposition gene for familial 
melanoma and germline mutations are identified in 10-40% of melanoma families.8,9 The 
CDKN2A gene encodes two distinct proteins by using different first exons (1α and 1β) that 
are translated in alternate reading frames (figure 1). The proteins, p16INK4a and p14ARF, are 
both tumour-suppressors that act in two different pathways. The p16-retinoblastoma(Rb)-
pathway controls cell-cycle G1-phase exit, and the p14ARF-p53 pathway induces cell 
cycle arrest or apoptosis.10 Germline mutations associated with familial melanoma occur 
across the entire coding region of the CDKN2A gene, including both exon 1α and exon 1β. 
Heterozygous carriers of a germline mutation have a 70% lifetime risk for developing one 
or more cutaneous melanomas, and the first melanoma generally occurs at a young age 
(mean <45 years).11-15 In a study that included 182 p16-Leiden mutation carriers, the mean 
age at melanoma diagnosis was 39 years and the risk of multiple primary melanomas was 
approximately 40%. Moreover, p16-Leiden mutation carriers that had a melanoma before 
age 40 had a twice as high risk to develop a second primary melanoma than carriers with 
a first melanoma after age 40.15 
An increased risk for PC has been reported for various mutations in CDKN2A that affect 
the p16INK4a protein (exon 1α and exon 2, see figure 1).16,17 The PC risk is particularly high 
for p16-Leiden mutation carriers, approximately 15-20% with a mean age at diagnosis of 
58 years.18-20 In addition to melanoma and PC, several other cancers have been described 
in CDKN2A mutation carriers, including upper and lower respiratory tract cancers 21-24, 
digestive tract cancers 21,25 and breast cancer 26,27. De Snoo et al specifically evaluated 
the non-melanoma cancer risks in a large cohort of 221 p16-Leiden mutation carriers and 
* Mendelian Inheritance in Man; Catalog of Human Genes and Genetic Disorders (http://www.omim.org) 




668 first-degree relatives. They confirmed that these (proven or implied) carriers have a 
high risk for PC (RR 46.6) and additionally found an increased risk for particularly cancers 
of the lip, mouth and pharynx (RR 10.8), cancers of the respiratory system (RR 5.7, including 
laryngeal cancer), eye/brain tumours (RR 11.4) and non-melanoma skin cancers (RR 22.3).21 
Germline mutations in the CDKN2A gene, including p16-Leiden, thus seem to cause a 
broad cancer predisposition syndrome.
FIGURE 1. The CDKN2A gene and its two products, p16INK4a and p14ARF. The p16-Leiden mutation is 
located in exon 2 and affects both p16INK4a and p14ARF.
Adapted with permission from Pigment Cell Melanoma Research, 28, Aoude LG, Wadt KA, Pritchard AL, 
Hayward NK, Genetics of familial melanoma: 20 years after CDKN2A, 148-60 (2015)
 
In the first part of this thesis (chapters 2-6), we use the term Familial Atypical Multiple Mole 
Melanoma (FAMMM) syndrome when referring to familial melanoma with or without a known 
germline CDKN2A mutation. However, use of this term is avoided nowadays because the 
correlation between atypical multiple moles (nevi) and melanoma is more complex and 
the atypical nevi phenotype is often absent or shows incomplete co-segregation with the 
melanoma phenotype in many CDKN2A-mutated families.28-30 Therefore, in the second 
part of this thesis (chapters 7-9) we solely use the term familial melanoma, or hereditary 
melanoma when an underlying germline mutation has been identified. 
CANCER SURVEILLANCE OF P16-LEIDEN MUTATION 
CARRIERS
MELANOMA SURVEILLANCE 
Since the early 1980s, Dutch individuals from melanoma-prone families are offered yearly 




Medical Center (LUMC). A study from 1989 showed that melanomas that were detected 
during this surveillance (screen-detected) were at an earlier stage, i.e. lower Breslow 
thickness, and therefore had a more favorable prognosis than melanomas occurring in 
patients not participating in the surveillance program.31 Comparable studies in other high-
risk cohorts confirmed this beneficial effect of regular surveillance on prognosis.32,33 When 
the p16-Leiden founder mutation was identified in the mid-1990s, many families participating 
in the Dutch surveillance program were found to carry this mutation. Van der Rhee et 
al subsequently studied the surveillance program in specifically p16-Leiden mutation 
carriers and again concluded that surveillance melanomas were significantly thinner than 
non-surveillance melanomas (Breslow thickness 0.50 mm and 0.98 mm, respectively).34 
The majority of melanomas in this study were detected within six months after the last 
surveillance and a considerable proportion were interval-melanomas (detected between 
regular screens; 20%). Carriers of the p16-Leiden mutation are therefore currently under 
more intensified, semi-annual, dermatologic surveillance.  
PANCREATIC CANCER SURVEILLANCE – BACKGROUND
PC surveillance programs were first initiated in the United States two decades ago for 
families with a condition called Familial PC (FPC).35,36 Families with at least two first-degree 
relatives with a diagnosis of PC without an identifiable genetic cause are, by definition, 
referred to as FPC.37 Although several cancer predisposition genes are currently known that 
confer an increased risk for PC, germline mutations are identified in only a small minority 
(<10%) of families predisposed to PC.38-41 Therefore, most PC surveillance programs to date 
have focused on FPC families and generally have included only few individuals with a 
known underlying germline mutation.42-44 
The 2013 guideline of the International Cancer of the Pancreas Screening (CAPS) 
Consortium defines the resection of potentially curable lesions, that is early-stage cancer 
or its high-grade precursor lesions, as a general goal of surveillance.45 The dismal 
prognosis of PC (5-year survival rate <5%) is generally a consequence of late diagnosis, 
but when a tumour is resected at an early stage, the 5-year survival rate could improve 
drastically.46,47 Moreover, timely resection of high-grade precursor lesions of PC might 
prevent the development of PC at all. Intraductal papillary mucinous neoplasms (IPMN) 
and the more common pancreatic intraepithelial neoplasms (PanIN) are the most important 
precursor lesions that can be targeted by surveillance.45 IPMNs are macroscopic cystic 
lesions, usually ≥5 mm, that have a high malignant potential when located in the main 
pancreatic duct (MD-IPMN) (figure 2).48 A longitudinal study showed that approximately 
60% of MD-IPMN displays high-grade dysplasia within 5 years, compared to 15% when the 




lesions divided in grade 1 to 3 according to the degree of dysplasia and are located 
in the smaller pancreatic ducts (figure 3).50 Low-grade PanINs (PanIN1-2) are found in a 
substantial proportion (28%) of non-PC specimens and can be indolent for many years 
or not progress to invasive cancer at all, whereas PanIN3 lesions are present in 58% of 
PC specimens and are considered carcinoma in situ.51 Precursor lesions, in particular 
IPMNs, can be detected with imaging of the pancreas because they manifest as small 
cystic lesions of the pancreatic ducts, i.e. ductectasias. Abdominal MRI combined with 
magnetic resonance cholangiopancreatography (MRCP) is considered the most sensitive 
imaging modality to detect these cystic lesions.52 Endoscopic ultrasonography (EUS) is 
better in detecting small solid pancreatic lesions, i.e. early-stage PC, compared to MRI/
MRCP 52 and it is able to detect secondary parenchymal changes caused by PanIN and 
IPMN lesions.53 Current surveillance programs for PC generally use one of these modalities 
or a combination of both.42-45 PC surveillance programs have not (yet) implemented non-
invasive (serum) biomarkers for PC in their protocols, since the only clinically approved 
biomarker carbohydrate antigen 19-9 (CA 19-9) has very limited diagnostic accuracy.54 
However, this is a subject of widespread investigation and various other biomarkers have 
shown promising results in detecting early-stage PC.55,56 
FIGURE 2. Surgical pathology specimen of resected pancreas that includes a branch-duct IPMN (arrows) 
PD = main pancreatic duct
Reprinted with permission from Lancet, 378, Vincent A, Herman J, Schulick R, Hruban RH, Goggins M, 




FIGURE 3. Progression model of pancreatic cancer from PanIN lesions. Normal ductal epithelial cells are 
short and cuboidal, while PanIN-1A lesions are flat and columnar. PanIN-1B lesions are identical to PanIN-1A, 
although papillary architecture can be observed in these lesions. PanIN-2 lesions can be flat or papillary 
and show moderate nuclear and architectural abnormalities. PanIN-3 lesions are papillary and show 
significant nuclear and cytological abnormalities, without the invasion of basement membrane. Pancreatic 
cancer (ductal adenocarcinoma) shows significant architecture and cytological abnormalities followed by 
basement membrane invasion.
Reprinted with permission from Susanto, J.M., 2017, Investigating the use of retinoids and epigenetic 
modification agents as new therapeutic strategies for the treatment of pancreatic cancer, PhD 
thesis, University of New South Wales, Sydney, available at https://sites.google.com/site/josus123/
pancreaticcancer (accessed on December 2018). 
Originally adapted from Modern Pathology, 16, Maitra A, Adsay NV, Argani P, Iacobuzio-Donahue C, De 
Marzo A, Cameron JL, Yeo CJ, Hruban RH, Multicomponent analysis of the pancreatic adenocarcinoma 
progression model using a pancreatic intraepithelial neoplasia tissue microarray, 902-12 (2003), with 
permission.
PANCREATIC CANCER SURVEILLANCE PROGRAM IN LEIDEN
At the LUMC, a PC surveillance program for high-risk individuals was started in the year 
2000. The program is distinctive from other PC surveillance programs worldwide since 
it specifically focuses on the large and unique cohort of p16-Leiden mutation carriers 
that historically live in or originated from the vicinity of Leiden. All p16-Leiden mutation 
carriers, regardless of family history for PC, are eligible from age 45 and are offered annual 
surveillance by MRI/MRCP and, optionally, EUS. In the first evaluation by Vasen et al in 
2011, PC was diagnosed in seven of 79 included individuals (9%) at a mean age of 59 
years.57 All patients had a resectable tumour with a size ranging 5-40 mm, although it was 




increased in size by 10 mm or more in six months. Cystic duct lesions were detected in 11% 
of individuals, but ‘prophylactic’ surgery was performed in only one of these individuals, 
which revealed PanIN2 lesions on histologic examination. The authors concluded that 
small solid pancreatic tumours as well as small possible precursor lesions can be detected 
with MRI/MRCP-based surveillance of p16-Leiden mutation carriers, but the role of these 
precursor lesions in the development of PC and the timing and extent of (prophylactic) 
surgery remained to be determined.  
GENETIC TESTING IN FAMILIAL MELANOMA
INDICATIONS FOR GERMLINE CDKN2A ANALYSIS
Criteria for performing germline CDKN2A mutation analysis in a melanoma family have 
been proposed in an international guideline published in 2009.58 These criteria are based 
on the patient’s personal and family history for melanoma and PC and the geographic 
location of the family. In countries with a moderate to high incidence of melanoma such 
as the Netherlands and other Northern European countries, the guideline recommends 
CDKN2A mutation analysis to patients with melanoma if they have at least three primary 
melanomas, or when there are at least two additional diagnoses of melanoma and/
or PC among close (first or second-degree) family members (“rule of threes”). For lower 
incidence countries such as those in Southern Europe, a comparable “rule of twos” was 
proposed. These patients/families have a presumed 10% or greater mutation probability. 
Current Dutch referral guidelines generally adhere to this international guideline, although 
patients with a juvenile melanoma (<18 years) and patients with both melanoma and PC are 
also eligible for CDKN2A diagnostics regardless of family history (table 1).
OTHER GENES ASSOCIATED WITH FAMILIAL MELANOMA
Several melanoma predisposition genes other than CDKN2A are currently known, but 
mutations in these genes are much rarer compared to mutations in CDKN2A (table 2).8,9 
The CDK4 gene, which functions in the same cell-cycle pathway as CDKN2A, i.e. the p16-
retinoblastoma(Rb) pathway, was identified shortly after CDKN2A by using a candidate 
gene sequencing approach. CDK4 mutations found in melanoma families are all located 
in codon 24 (p.R24H and p.R24C), leading to reduced p16INK4a inhibition of CDK4 and 
therefore an increase in CDK4 kinase activity and thus cell cycle progression. Melanoma 
families with a CDK4 mutation are phenotypically comparable to CDKN2A-mutated 





TABLE 1. Dutch referral criteria for germline CDKN2A diagnostics
Familial melanoma
(diagnostic criteria)
	 family with three relatives with melanoma, of which two are first-degree relatives 
(all first- and second-degree relatives)
	 family with two first-degree relatives with melanoma, of which one has multiple 
primary melanomas
Other families 	 family with two first-degree relatives with melanoma
	 family with two first- or second-degree relatives with melanoma and one first- or 
second-degree relative with pancreatic cancer
	 person with three or more primary melanomas
	 person with a juvenile melanoma (<18 years)
	 person with both melanoma and pancreatic cancer
Reference: Vasen HFA, Hes FJ and de Jong MM. Erfelijke en familiaire tumoren: Richtlijnen voor diagnostiek en pre-
ventie. Leiden: Stichting Opsporing Erfelijke Tumoren/Vereniging Klinische Genetica Nederland/Werkgroep Klinische 
Oncogenetica, 2017. Available from https://www.stoet.nl/wp-content/uploads/2017/02/Richtlijnen-2017.jpg 
TABLE 2. Established melanoma predisposition genes other than CDKN2A
Gene Pathway/Function Non-melanoma cancers Ref.
CDK4 Cell-cycle control - 59
TERT Telomere integrity - 60
POT1 Telomere integrity Glioma, leukaemia, 
possibly other cancers
61-64
ACD Telomere integrity Leukaemia 64,65
TERF2IP Telomere integrity Leukaemia 64,65
BAP1 DNA damage response Uveal melanoma, malignant mesothelioma, renal cell 
carcinoma, basal cell carcinoma
66,67
MITF Melanocyte homeostasis Renal cell carcinoma,
pancreatic cancer
68,69
The CDKN2A and CDK4 genes were for many years the only known high-penetrance 
melanoma predisposition genes. The rise of new sequencing technologies in the last 
decade resulted however in the recent identification of several new predisposition genes 
and key pathways. One of these pathways controls telomere integrity and germline 
mutations have been reported in multiple genes involved in the regulation of telomere 
length (TERT) and telomere maintenance (POT1, ACD, TERF2IP) (figure 4). A specific mutation 
in the promotor region of TERT (c.-57T>G) causes an increased transcription of TERT and 
is found in only a few, although heavily affected, melanoma families.60,70 It is hypothesized 
that overexpression of TERT results in longer telomeres and therefore enhanced survival of 
cancerous cells, although this has not been proven for the c.-57T>G variant.70 The shelterin 
complex protects the telomeres from DNA repair mechanisms and regulates TERT activity. 




TERF2IP, and it has been demonstrated that germline POT1 mutations do indeed result in 
increased telomere length.61,62,65 Mutations in these genes are also found in families with a 
predisposition for glioma or leukaemia 63,64 and these cancers are reported in some of the 
melanoma pedigrees as well. POT1 germline mutations are also increasingly being reported 
in patients and families with a wide range of other cancers, including thyroid cancer 71, 
colorectal cancer 72, Hodgkin’s lymphoma 73 and cancers in the Li-Fraumeni (TP53) spectrum, 
in particular (cardiac) angiosarcoma 74,75. The POT1 gene might thus be associated with many 
different types of cancer other than melanoma. The BAP1 (BRCA1-associated protein) gene 
is involved in several tumour suppressor pathways including the DNA damage response. 
FIGURE 4 Schematic view of the telomere. The shelterin complex (TERF1, TERF2, TERF2IP, TINF2, 
ACD, POT1) is depicted on the left and the telomerase complex (TERT and other associated proteins) 
is depicted on the right. The telomerase complex adds telomere repeat sequences to the 3’ end 
of the telomere. The shelterin complex is anchored to the double stranded TTAGGG region of the 
telomere by the subunits TERF1 and TERF2 and protects the telomeres from DNA repair mechanisms 
and regulates TERT activity.
Reprinted with permission from Pigment Cell Melanoma Research, 28, Aoude LG, Wadt KA, Pritchard 
AL, Hayward NK, Genetics of familial melanoma: 20 years after CDKN2A, 148-60 (2015)
Germline mutations in BAP1 cause a specific cancer predisposition syndrome with a 
high penetrance for uveal melanoma (28%), malignant mesothelioma (22%), cutaneous 
melanoma (18%), renal cell carcinoma (9%) and basal cell carcinoma (6.5%). Also, specific 
benign skin lesions called atypical Spitz tumours (AST) or melanocytic BAP1–mutated 
atypical intradermal tumours (MBAIT) are typically found in BAP1 mutation carriers.66,67 
MITF is a lower (medium) penetrance melanoma predisposition gene and is involved 
in melanocyte homeostasis. Only one specific gain-of-function mutation in codon 318 




sporadic and familial melanoma.76 MITF p.E318K carriers more frequently develop multiple 
primary melanomas and there is possibly an increased risk for renal cell carcinoma and 
pancreatic cancer as well.68,69 In figure 5, all these currently known melanoma predisposition 
genes are plotted relative to their frequency and effect size. More genes with a possible 
association with familial melanoma are presented in chapter 8. 
In addition to these high- and medium-penetrance melanoma predisposition genes, 
several common risk variants (single nucleotide polymorphisms; SNPs) derived from large 
population-based genome wide association studies (GWAS) have been associated with 
(sporadic) melanoma (figure 5).77-79 These individual SNPs only marginally or moderately 
influence melanoma risk, but an aggregation of risk variants might substantially increase 
risk. One of the best established of these risk factors is the MC1R gene. The MC1R gene 
plays an important role in skin pigmentation and specific variants that are most strongly 
associated with a red hair colour phenotype (RHC variants) increase melanoma risk 
approximately twofold.80 Other variants that are less strongly associated with red hair 
colour confer a much smaller melanoma risk and are called non-RHC variants. Studies 
have shown that both RHC and non-RHC variants also modify melanoma penetrance in 
CDKN2A-mutated families.81,82 Common susceptibility SNPs are typical candidates to be 
incorporated in a polygenic risk score (PRS) model, and such models have already shown 
to improve risk stratification in familial breast cancer.83,84




FIGURE 5. Graphic display of the phenotypic effect size of currently known genes involved in 
melanoma susceptibility, plotted against their frequency of occurrence. Note: the high-penetrance 
genes are randomly plotted within the blue circle. SNP = Single Nucleotide Polymorphism
Adapted with permission from Journal of Clinical Oncology, 28, Stadler ZK, Thom P, Robson ME, 
Weitzel JN, Kauff ND, Hurley KE, Devlin V, Gold B, Klein RJ, Offit K, Genome-wide association studies 
of cancer, 4255-67 (2010)
AIMS AND OUTLINE OF THIS THESIS
This thesis has three general aims. 
-	 Our first aim is to investigate the full cancer phenotype of p16-Leiden mutation carriers 
and to study potential modifiers of cancer risk in these carriers (PART I).
-	 Our second aim is to evaluate and improve the p16-Leiden pancreatic cancer (PC) 
surveillance program.
-	 Our third and final aim is to evaluate and improve genetic testing for hereditary 
melanoma (PART II).
PART I Cancer phenotype and pancreatic cancer surveillance of p16-Leiden mutation 
carriers
In chapter 2, we prospectively evaluate a cohort of p16-Leiden mutation carriers for the 
occurrence of any cancer and we investigate the influence of tobacco use on cancer 
risk. In chapter 3, we genotype seven PC-associated SNPs in a nation-wide cohort of 
p16-Leiden mutation carriers and we investigate if these SNPs modify PC risk and could 
explain the interfamilial variability in the occurrence of PC among these families. In chapter 
4, we compare the frequency, features and natural history of precursor lesions of PC and 
PC itself between two different high-risk groups (p16-Leiden vs. FPC surveillance cohorts). 
In chapter 5, we report two high-risk patients who developed a second primary PC after 
a limited resection of their first PC and we discuss the possible implications of these 
findings for the surgical management of patients with an early-stage screen-detected PC. 
In chapter 6, we investigate if a serum protein signature can differentiate between PC and 
non-PC in the p16-Leiden PC surveillance cohort and we discuss if this biomarker test has 
the potential to be implemented in the surveillance program.
PART II Genetic testing in familial melanoma; CDKN2A and beyond
In chapter 7, we study the association between germline CDKN2A mutations and several 
clinical features present in a melanoma family, and we develop a clinical scoring system 




families. In chapter 8, we investigate the role of other (candidate) melanoma predisposition 
genes in a large cohort of Dutch non-CDKN2A melanoma families through comprehensive 
multi-gene panel testing.
In the final chapter 9, we discuss the main findings of these studies in the context of the 
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The p16-Leiden germline variant in the CDKN2A gene is associated with a high risk 
of melanoma and pancreatic cancer. The aims of this study were to assess the risk of 
developing other cancers and to determine whether tobacco use would alter cancer 
risk in carriers of such a variant. We therefore prospectively evaluated individuals with 
a p16-Leiden germline variant, participating in a pancreatic surveillance program, for the 
occurrence of cancer (n=150). Tobacco use was assessed at the start of the surveillance 
program. We found a significantly increased risk for melanoma (RR 41.3; 95% CI 22.9-74.6) 
and pancreatic cancer (RR 80.8; 95% CI 44.7-146). In addition, increased risks were found 
for cancers of the lip, mouth and pharynx (RR 18.8; 95% CI 6.05-58.2) and respiratory 
tumours (RR 4.56; 95% CI 1.71-12.1). Current smokers developed significantly more cancers 
of lip, mouth and pharynx, respiratory system and pancreas compared to former and never-
smokers. In conclusion, this study shows that carriers of a p16-Leiden variant have an 
increased risk of developing various types of cancer and smoking significantly increases 
the risk of frequently occurring cancers. Smoking cessation should be an integral part of 





Familial atypical multiple mole melanoma (FAMMM) syndrome is an autosomal dominant 
tumour syndrome characterized by the development of melanoma and dysplastic naevi of 
the skin. Up to 40% of FAMMM families harbour a germline variant in the CDKN2A gene, 
making it the most frequently involved gene in FAMMM syndrome.1 More than 65 different 
variants in the CDKN2A gene have been identified worldwide.2 In the Netherlands, the 
p16-Leiden variant, a 19-base pair deletion (c.225_243del19; RefSeq NM_000077.4), is 
the most common CDKN2A germline variant.3 In a previous study,4 we demonstrated that 
carriers of such a variant have an increased risk of developing pancreatic cancer (15-20% 
lifetime risk). Since then a large cohort of patients is under pancreatic surveillance.5 
Several studies reported an increased risk of tumours other than melanoma and 
pancreatic cancer for various CDKN2A germline variants.6-10 However, these studies have 
used a variety of methodological approaches and some have been limited by inclusion of 
heterogeneous groups or by failure to determine individual mutation status. In addition, the 
influence of environmental factors (e.g. smoking) on the phenotypic variability in FAMMM 
syndrome is yet to be elucidated. 
In the present study, we analysed the prospective risk of cancer in a unique cohort of 
individuals with the same p16 germline variant (p16-Leiden). Additionally, we examined the 
association between a personal history of smoking and the development of cancer. 
PATIENTS AND METHODS
PATIENT COHORT
Individuals were included in this study on the basis of carrier status for the p16-Leiden 
germline variant and participation in a pancreatic surveillance program, which consisted 
of a yearly abdominal MRI combined with magnetic resonance cholangiopancreatography 
(MRCP) from age 45.5 
A complete medical history was obtained at the start of the surveillance study. Following 
this first visit, patients revisited the gastroenterologist annually, at which point the 
occurrence of new cancers or other diseases was assessed. For the current study, all 
medical records (with pathological confirmation) were obtained for each individual from the 
electronic hospital information system. Only cancers that occurred after the first contact 
were included in the analysis. The study inclusion and follow-up period was from January 
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2000 to April 2013. The follow-up time for each individual started from inclusion until the 
last documented appointment with a medical specialist at the Leiden University Medical 
Center, or the date of death. 
CANCER RISK ESTIMATES AND STATISTICAL ANALYSIS
The prospectively observed cancers were classified by International Classification of 
Diseases code 10 (ICD-10). To calculate the expected number of cancers, five-year cancer 
incidence rates of matching ICD codes, specific for sex and age, were obtained from the 
Netherlands Cancer Registry (NCR) for the province of South-Holland in the Netherlands.11 
To calculate the expected number of neuroendocrine tumours, national incidence rates 
were used for the period 2001-2010.12 The relative risks were computed by dividing the 
observed cancer numbers in each group by the expected cancer numbers. Confidence 
intervals for the relative risks were calculated with the use of Poisson probabilities. To 
compute the impact of tobacco use on cancer development, individuals were classified 
as either ever-smokers (current or former) or never-smokers at inclusion in the study; χ2 
analysis was used for comparison. Acquired data was submitted to a public CDKN2A gene 
variant database (http://chromium.liacs.nl/LOVD2/home.php; submission ID #0014954)
RESULTS
PATIENT CHARACTERISTICS
A total of 150 proven or implied carriers of the p16-Leiden germline variant were included 
(64 males, median age at inclusion 51 years (range, 36-72 years)). One hundred and forty-
four individuals had a proven p16-Leiden germline variant, including a homozygote for 
the p16-Leiden variant. The remaining 6 individuals had at least one melanoma in their 
medical history and a close relative with the p16-Leiden germline variant, which makes 
them highly likely of being a carrier (>97% according to Bayesian probabilities). The median 
time of follow-up was 43 months (range, 1-144 months; 1st-3rd quartile, 17-89 months). The 
total observation period was 682 person years. 
PROSPECTIVE TUMOURS
A total of 47 prospective tumours were diagnosed in 36 (24%) of the 150 individuals. Due 
to the relatively small numbers of observed cancers, classification was based on organ 
system rather than individual site, with the exceptions of melanoma and pancreatic cancer. 
Table 1 shows the relative risks for developing various types of cancer. Melanoma and 
pancreatic cancer were the most frequently occurring cancers (n=11 each, RR 41.3 (95% CI 




from the analysis, the risk of developing any type of cancer remained significantly 
increased (RR 4.31; 95% CI 2.91-6.37). The highest risks were found for cancers of the lip, 
mouth and pharynx (RR 18.8; 95% CI 6.05-58.2), respiratory tumours (RR 4.56; 95% CI 1.71-
12.1) and digestive tract tumours (RR 3.71; 95% CI 1.39-9.90). The relatively small numbers 
of observed cancers, however, resulted in broad confidence intervals, which is especially 
true for cancers of bone and soft tissue.
TABLE 1. Relative risk of developing cancer in a prospective series of p16-Leiden variant carriers 
(n=150)
Site/organ system ICD-10 code Observed (95% CI) Expected RR (95% CI)
Bone c40-c41 1 (0.141-7.10) 0.0149 66.9 (9.43-475)*
Digestive c15-c24, c26 4 (1.50-10.7) 1.08 3.71 (1.39-9.90)*
Female Breast c50 3 (0.967-9.30) 1.15 2.61 (0.840-8.08)
Haematological c81-c96 1 (0.141-7.10) 0.462 2.16 (0.305-15.3)
Lip, mouth, pharynx c00-c14 3 (0.968-9.30) 0.160 18.8 (6.05-58.2)*
Male genital c60-c63 1 (0.141-7.10) 0.689 1.45 (0.204-10.3)
Melanoma§ c43 11 (6.09-19.9) 0.266 41.3 (22.9-74.6)*
Nonmelanoma skin# c44 4 (1.50-10.7) 0.327 12.3 (4.60-32.6)*
Pancreas c25 11 (6.09-19.9) 0.136 80.8 (44.7-146)*
Respiratory c32-c34 4 (1.50-10.7) 0.877 4.56 (1.71-12.1)*
Soft tissue c38, c47-c49 2 (0.500-8.00) 0.0336 59.5 (14.9-238)*
Unknown primary site c80 1 (0.141-7.10) 0.138 7.22 (1.02-51.3)
Urinary c64-c68 1 (0.141-7.10) 0.333 3.00 (0.423-21.3)
All cancers 47 (35.3-62.6) 6.20 7.58 (5.69-10.1)*
All cancers except melanoma 
and pancreas
25 (16.9-37.0) 5.80 4.31 (2.91-6.37)*
* Significant
§ First as well as subsequent melanomas are registered In the Netherlands Cancer Registry (NCR)
# Basal cell carcinoma is not registered in the NCR and therefore not included in the calculation
Details of 21 prospective cancers (all cancers except those of skin and pancreas) are 
shown in table 2. Notably, the observed number of carcinoid tumours was higher than 
expected (0.0168; RR 119; 95% CI 29.7-475). When excluding carcinoid tumours from the 
risk calculation for digestive tract tumours, the increased risk for a digestive tract tumour 
no longer reached significance (RR 1.86; 95% CI 0.465-7.43). 
Seven individuals developed a total of 11 melanomas during the follow-up period. However, 
a much larger number of individuals (91 out of 150) had a diagnosed melanoma prior to 
33
2
PROSPECTIVE RISK OF CANCER AND THE INFLUENCE OF TOBACCO USE IN CARRIERS OF THE P16-LEIDEN GERMLINE VARIANT
starting surveillance for pancreatic cancer (median age at diagnosis of first melanoma 
40 years). Table 3 shows tumours diagnosed before inclusion, of which melanoma forms 
by far the major part. Only one individual developed a first melanoma during the follow-
up period. Melanoma therefore remains the most frequently occurring cancer in this p16-
Leiden study cohort and first melanomas mostly occur prior to the age of inclusion (45 
years). A more exhaustive description of the melanoma phenotype in carriers of the p16-
Leiden germline variant is given by van der Rhee et al.13  
TABLE 2. Characteristics of prospective cancers (excluding skin cancer and pancreatic cancer)
Subject number Sex Tumour type/organ Histopathology Age at diagnosis
1 F Caecum Carcinoid 72
2 M Appendix Carcinoid 58
Bone Papillary squamous cell carcinoma of 
mandible
62
3 M Stomach Adenocarcinoma of cardia 64
4 M Haematopoietic Multiple myeloma 67
Stomach Adenocarcinoma 67
5 F Breast Ductal adenocarcinoma 48
6 F Breast Ductal adenocarcinoma 53
7 F Breast Ductal adenocarcinoma 49
8 M Hypopharynx Squamous cell carcinoma 51
Lung Squamous cell carcinoma 52
9* M Floor of mouth Squamous cell carcinoma 58
Larynx Squamous cell carcinoma 58
10 F Tongue Carcinoma not specified 51
11 F Lung Non-small cell carcinoma 60
12 M Larynx Squamous cell carcinoma 55
13 F Bladder Small cell carcinoma 58
14 M Prostate Adenocarcinoma 69
15 F Knee Myxofibrosarcoma 48
16 M Neck Leiomyosarcoma 66
17 F Unknown Metastatic adenocarcinoma 67
*This patient had two primary tumours detected concurrently.
TOBACCO USE
With regard to a personal history of smoking, information was complete for 147 (98%) out of 
150 individuals. At inclusion, 92 individuals were ever-smokers (of which 26 were current 




pancreatic cancer, respiratory cancer or cancer of the lip, mouth and pharynx (p=0.364). 
Four of 11 patients with pancreatic cancer were never-smokers. When only current smokers 
were considered, seven of 26 (27%) developed above mentioned cancers, versus only 
eight of 121 (7%) of the former and never-smokers. Therefore, current smokers in our cohort 
have a fourfold increased risk of developing these types of cancer when compared to 
former and never-smokers (p=0.002).
CHRONIC DISEASES
We also evaluated the occurrence of other (chronic) diseases. We found that six out of 150 
individuals (4%) had a medical history of sarcoidosis, which is much higher than expected 
(estimated prevalence in Europe approximately 15-20 per 100,000 individuals).14 There was 
no kinship between these individuals. 
CAUSES OF DEATH 
Eighteen of the 150 individuals died during follow-up (median age of death 62 years 
(range, 49-78 years)). Seventeen individuals died from cancer; seven from pancreatic 
cancer (median age 59 years) and four from melanoma (median age 61 years).
TABLE 3. Tumours diagnosed before inclusion in the surveillance program
Site/organ system Observed cancer Individual(s)
Digestive 1 1
Female Breast 4 4
Female Genital 1 1
Lip, mouth, pharynx 3 2
Melanoma 194 91
Nonmelanoma skin 2 2
Respiratory 4 4
Urinary 1 1
All cancers 210 98
  
DISCUSSION
This prospective study analysed the risk of cancers in a cohort of homogeneous CDKN2A 
variant carriers (p16-Leiden). A significantly increased risk of both melanoma and pancreatic 
cancer was found. However, when excluding these cancers from the risk calculation, a 
marked increased risk for developing any cancer (RR 4.31; 95% CI 2.91-6.37) remained. 
Most notable were the increased risk of respiratory and lip, mouth and pharynx cancer, 
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and the relatively frequent occurrence of carcinoid tumours. Being a current smoker at the 
start of surveillance was significantly associated with the development of tumours of the 
pancreas, respiratory tract and head and neck region. In addition, we found an association 
between the p16-Leiden variant and sarcoidosis.
Without considering melanoma and pancreatic cancer, tumours of the respiratory tract 
(including laryngeal tumours) and of the lip, mouth and pharynx were the most frequently 
occurring tumours in our cohort. A previous retrospective study by de Snoo et al also found 
significantly increased risks for these tumours in a cohort of p16-Leiden variant carriers.9 
Oldenburg et al described a p16-Leiden variant positive family in which many relatives had 
developed lung cancer and head and neck tumours.15 Several other case reports have 
also described the occurrence of head and neck tumours in CDKN2A variant positive 
families.16,17 In sum, it seems that tumours of the head and neck and respiratory tract are 
part of the spectrum of cancers occurring in CDKN2A variant-positive FAMMM families. 
Two interesting observations were the relatively frequent occurrence of carcinoid tumours 
and sarcoidosis in unrelated variant carriers in our cohort. Both have not been previously 
reported in carriers of a CDKN2A variant. Although only two individuals developed a 
carcinoid tumour during follow up, another individual had a medical history of carcinoid. It 
has been shown that p16 inactivation plays a role in the pathogenesis of sporadic neuro-
endocrine tumours, as a substantial amount of these tumours show loss of p16 expression,18 
and also promoter methylation of the p16 gene is frequently found 19. Further studies are 
needed to confirm the possible association between a CDKN2A germline variant and 
carcinoid tumours or sarcoidosis.  
Our current study has several strengths. Due to its prospective design, patient participation 
was not influenced by the occurrence of tumours. In addition, due to the yearly follow-up 
at the outpatient Department of Gastroenterology, it is unlikely that cancers and other 
important medical information were missed. Another strength is the homogeneity of the 
cohort; all individuals have the same CDKN2A germline variant. An important limitation was, 
however, the relatively high age of inclusion of individuals (median age 51 years), which 
was due to the threshold of 45 years of age for inclusion in the pancreatic surveillance 
program. Tumours generally occurring before this age were therefore not included in the 
calculations, which is reflected by the observation of a high incidence of melanoma prior 
to start of the surveillance program. Because the number of participants and observed 





Pancreatic cancer is the leading cause of death in our cohort. Pancreatic cancer surveillance 
may improve survival, as most tumours are detected in a resectable stage.5 In view of the 
increased risk of head and neck tumours (including tumours of the larynx), patients should 
be advised to contact their doctor if they have complaints of hoarseness, dysphagia or 
ulcers in mouth or throat. A low threshold for reference to an otolaryngologist  should 
be advocated. A surveillance program for tumours of the head and neck region should 
possibly be considered in the future, which could simply consist of yearly inspection of 
the mouth and throat. The clear relation of many of the frequently occurring cancers in 
our cohort to smoking indicates that active intervention to quit smoking is of the utmost 
importance in this group.
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The p16-Leiden founder mutation in the CDKN2A gene is the most common cause of Familial 
Atypical Multiple Mole Melanoma (FAMMM) syndrome in the Netherlands. Individuals 
with this mutation are at increased risk for developing melanoma of the skin, as well as 
pancreatic cancer. However, there is a notable interfamilial variability in the occurrence 
of pancreatic cancer among p16-Leiden families. We aimed to test whether previously 
identified genetic risk factors for pancreatic cancer modify the risk for pancreatic cancer in 
p16-Leiden germline mutation carriers. 
METHODS
Seven pancreatic cancer-associated SNPs were selected from the literature and were 
genotyped in a cohort of 185 p16-Leiden germline mutation carriers from 88 families, 
including 50 cases (median age 55 years) with pancreatic cancer and 135 controls (median 
age 64 years) without pancreatic cancer. Allelic odds ratios per SNP were calculated. 
RESULTS
No significant association with pancreatic cancer was found for any of the seven SNPs. 
CONCLUSIONS
Since genetic modifiers for developing melanoma have already been identified in CDKN2A 
mutation carriers, this study does not exclude that genetic modifiers do not play a role in 
the individual pancreatic cancer risk in this cohort of p16-Leiden germline mutation carriers. 
The search for these modifiers should therefore continue, because they can potentially 





The melanoma gene CDKN2A produces two important proteins: p16INK4a, which is a cyclin-
dependent kinase inhibitor, and p14ARF, which binds the p53-stabilizing protein MDM2.1 In 
the Netherlands, a founder mutation in the CDKN2A gene, a 19-base pair deletion called 
p16-Leiden (c.225_243del19; RefSeq NM_000077.4), is the most common cause of Familial 
Atypical Multiple Mole Melanoma (FAMMM) syndrome.2 In addition to a marked increased 
risk of developing melanoma of the skin (70% lifetime risk), these mutation carriers also 
have a 15-20% lifetime risk of developing pancreatic cancer with a mean age of 58 years 
at diagnosis.3 Interestingly, there is a notable interfamilial variability in the occurrence of 
pancreatic cancer among p16-Leiden families.3 Therefore, the p16-Leiden mutation might 
not be the only genetic risk factor in these individuals causing an increased susceptibility 
for pancreatic cancer. Since pancreatic cancer has a very poor prognosis due to late 
occurrence of symptoms and therefore late detection, surveillance for pancreatic cancer 
is currently offered to p16-Leiden germline mutation carriers in a research setting to 
investigate whether pancreatic cancer, or, even more preferable, high-grade precursor 
lesions can be detected earlier in a potentially still curable stage.4 By identifying additional 
genetic risk factors (genetic modifiers) in these individuals, surveillance could possibly be 
more individualized. 
In recent years, genome-wide association studies (GWAS) have identified several common 
risk variants associated with pancreatic cancer.5-7 In this study, we genotyped a selected 
number of these variants (SNPs) in a unique cohort of p16-Leiden mutation carriers with 
and without pancreatic cancer. We hypothesized that these SNPs might modify the risk of 
pancreatic cancer in these p16-Leiden mutation carriers.
METHODS
STUDY POPULATION AND DNA SAMPLE COLLECTION 
For this case-control study, only proven carriers of the p16-Leiden germline mutation were 
included. From all Dutch p16-Leiden mutation carriers, DNA is stored in the Laboratory 
for Diagnostic Genome Analysis (LDGA) of the Leiden University Medical Center. All 
p16-Leiden germline mutation carriers diagnosed at the LDGA between the initiation of 
CDKN2A gene diagnostics at the LDGA in 1998 and January 1st 2014 were eligible for 
inclusion. Cases were defined as having been diagnosed with exocrine pancreatic cancer 
at the time of data collection; controls were at least 55 years old on January 1st 2014 or 
died beyond that age, and were not diagnosed with pancreatic cancer. Individuals who 
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were younger than 55 years or died before this age were excluded from the control group. 
Medical records were obtained for each individual from the electronic hospital information 
system of the medical center where this individual initially received genetic counselling by 
a clinical geneticist for CDKN2A gene diagnostics. Access to these medical records was 
granted for the (co)authors since they are clinical geneticists working in these medical 
centers. Additional follow up data was acquired from two ongoing pancreatic surveillance 
studies (a single-center study at Leiden University Medical Center and a multi-center 
study at Erasmus MC University Medical Center Rotterdam) and from the Netherlands 
Foundation for the Detection of Hereditary Tumours, a central registration institute for 
hereditary tumours (FAMMM, amongst others) in the Netherlands. This study was approved 
by the Ethics Committee of the Leiden University Medical Center, by issuing a declaration 
of no objection (#P14.148). This is an assessment of the study protocol on due diligence, 
that is, if it serves the codes of good practice and good conduct. It is not a formal ethical 
assessment, because the study does not fall within the scope of the Dutch law for medical 
research on human subjects; the medical records and the DNA were already available 
and the involved human subjects were not specifically recruited for the study and were 
not subjected to any actions. Therefore, no separate ethical assessment or approval was 
needed for the collection of data in the participating medical centers.
SNP selection and genotyping
SNPs for genotyping in this cohort were selected from recent GWAS studies with large 
cohorts of sporadic pancreatic cancer patients.5-7 Selection was based on significance of 
association with pancreatic cancer and reported odds ratios, as well as expected allele 
frequencies. In the first place, SNPs with the largest odds ratios and smallest p-values 
were selected. Subsequently, only those SNPs with a relatively high minor allele frequency 
(MAF) were considered for genotyping, because of the limited sample size of the cohort. 
This would optimize the number of carriers of the minor allele and thereby augment the 
potential of reaching significance between subgroups. In order to test a relatively wide 
variety of genes, a maximum of two different SNPs per gene was maintained. All included 
individuals were genotyped for the selected SNPs using high-resolution DNA melting 
curve analysis.8 Melting assays were performed with Lightscanner® (Biofire Defense Inc, 
Salt Lake City, UT). 
STATISTICAL ANALYSIS
Given our relatively small sample size, we performed a power calculation with Bonferroni 
correction for multiple testing prior to the study. Despite a calculated power of approximately 
15%, we wanted to pursuit this small but tangible chance of finding a trend of association. 




controls by calculating a SNP-specific allelic odds ratio, including the 95% confidence 
interval. Additional p-values were calculated using a basic χ2 test and the Bonferroni 
correction for multiple testing was applied. Therefore, a p-value of less than 0.007 was 
considered significant. All statistical analyses were performed using SPSS 20.0.0 (IBM Inc, 
Armonk, NY).
RESULTS
PATIENT CHARACTERISTICS (TABLE 1)
In total, 422 p16-Leiden germline mutation carriers were eligible for inclusion. Of these, 50 
individuals (18 males, 36%) were diagnosed with pancreatic cancer, with a median age at 
diagnosis of 55 years (range 21-76 years), and could all be included in the case group. The 
remaining 372 individuals were not diagnosed with pancreatic cancer, but 237 individuals 
were excluded from the control group because of not having reached the age of 55 years. 
The remaining control group consisted of 135 individuals (50 males, 37%) with a median 
age of 64 years (range 55-88 years). Thus, for this study a total of 185 p16-Leiden germline 
mutation carriers (from 88 families) were included. A considerable number of individuals (98 of 
185 [53%]) developed melanoma, and 37 of 98 individuals with melanoma (38%) had multiple 
melanoma. In the case group, 24 of 50 individuals (48%) had a medical history of melanoma, 
and in the control group 74 of 135 individuals (55%) had a medical history of melanoma.
TABLE 1. Patient characteristics
p16-Leiden mutation carriers (n=185)
Cases with pancreatic cancer 
(n=50)
Controls without pancreatic cancer 
(n=135)
Median age in years (range) 55 (21-76) 64 (55-88)
Gender (m:f) 18:32 50:88






SNP GENOTYPING AND ASSOCIATION WITH PANCREATIC CANCER
A total of seven SNPs in five different genes were selected for genotyping. Table 2 shows 
the minor allele frequencies of these SNPs in cases and controls, and the calculated 
association (allelic odds ratio and 95% confidence interval) with pancreatic cancer in our 
cohort of p16-Leiden germline mutation carriers. No significant association with pancreatic 
cancer was found for any of the seven SNPs. 
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TABLE 2. Association of seven selected SNPs with pancreatic cancer in this study





























0.43 0.39 1.18 (0.74-1.89) 0.49
* SNP reference (major / minor allele), chromosome location, gene
DISCUSSION
In this case-control study, we analysed seven pancreatic cancer-associated SNPs in a 
distinctively homogeneous cohort of 185 CDKN2A germline mutation carriers. That is, 
all cases with (n=50) and all controls without (n=135) pancreatic cancer carry the same 
p16-Leiden germline mutation. We hypothesized that (a subset of) these SNPs would be 
associated with an increased pancreatic cancer risk in these individuals, and that genetic 
modifiers would explain, at least partially, the variability in the occurrence of pancreatic 
cancer in p16-Leiden families. However, in our cohort, no significant association was found 
between the occurrence of pancreatic cancer and any of the seven SNPs.  
Currently, research on genetic modifiers in CDKN2A mutation carriers is mainly focused on 
identifying low-risk variants that influence melanoma risk.9,10 To date, the MC1R gene, which 
is known to have a role in the skin pigmentation process, is the most important modifier 
gene identified so far.11,12 Penetrance of CDKN2A mutations regarding melanoma risk is 




encouraging results from previous studies, it can be expected that genetic variants could 
also be identified in CDKN2A mutation carriers which influence pancreatic cancer risk. It is 
however unlikely that these variants will be the same as those which influence melanoma 
risk, as Wu et al demonstrated.13 Other genetic variants should thus be considered when 
studying the risk of pancreatic cancer in CDKN2A mutation carriers. Yang et al made a 
first attempt at this by sequencing the PALB2 gene in a small cohort of CDKN2A mutation 
carrying families with pancreatic cancer.14 The PALB2 gene (OMIM #610355) is one of the 
relatively few known high-risk pancreatic cancer susceptibility genes associated with 
familial pancreatic cancer to date.15 However, no pathogenic mutations were identified in 
their study and also no association was found between SNPs in the PALB2 gene and the 
occurrence of pancreatic cancer.
The strength of this study is that our cohort of p16-Leiden mutation carriers is homogeneous 
regarding the type of mutation, and therefore relatively large in its kind. Yet, in order to 
study modifier effects in a cohort of individuals with a genetically inherited predisposition 
to cancer, a large sample size is important.16 Because the p16-Leiden mutation is a rare 
mutation, an important limitation of this study is that sample size cannot easily be increased. 
Therefore, the lower age limit of the control group was set at 55 years (the mean age of 
pancreatic cancer in the case group). It is possible that individuals in the control group 
will develop pancreatic cancer in the future and this could have influenced the results. 
Possibly, recalculations in the future, taking into account new clinical follow-up data of 
these individuals, could change the results significantly. 
For this study, we selected seven promising pancreatic cancer-associated SNPs from the 
literature, based on reported odds ratios, p-values and reproducibility. The sample size 
limitation allowed us to test only a restricted number of SNPs and because of the limited 
sample size we chose for those with a relatively high minor allele frequency. Our selection 
of seven SNPs is however only a subset of a much larger set of SNPs associated with 
pancreatic cancer and it is therefore still possible that these other SNPs do play a role in 
the pancreatic cancer risk in p16-Leiden germline mutation carriers (see Lin et al 17 for an 
overview of associated SNPs). It is also possible that other, non-genetic, risk factors play 
a role in the variable pancreatic cancer phenotype. However, we do not have sufficient 
data available of these external risk factors in our studied mutation carriers. One of the 
most important non-genetic risk factors for developing pancreatic cancer is tobacco use, 
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CONCLUSIONS
This study aimed at identifying genetic modifiers that influence pancreatic cancer risk in 
a homogeneous cohort of Dutch p16-Leiden germline mutation carriers. Despite the fact 
that no significant association could be found for the seven tested pancreatic cancer-
associated SNPs, it is still possible that these or other genetic modifiers play a significant 
role in the individual pancreatic cancer risk in these individuals. The search for genetic 
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Pancreatic ductal adenocarcinoma (PDAC) surveillance programs are currently offered to 
high-risk individuals aiming to detect precursor lesions or PDAC at an early stage. We 
assessed differences in frequency and behaviour of precursor lesions and PDAC between 
two high-risk groups.
EXPERIMENTAL DESIGN
Individuals with a p16-Leiden germline mutation (n=116; median age 54 years) and 
individuals from familial pancreatic cancer (FPC) families (n=125; median age 47 years) 
were offered annual surveillance by magnetic resonance imaging (MRI) and magnetic 
resonance cholangiopancreatography (MRCP) with or without endoscopic ultrasound (EUS) 
for a median surveillance period of 34 months (0-127 months) or 36 months (0-110 months), 
respectively. Detailed information was collected on pancreatic cystic lesions detected on 
MRCP and precursor lesions in surgical specimens of patients who underwent pancreatic 
surgery.
RESULTS
Cystic lesions were more common in the FPC cohort (42% versus 16% in p16-Leiden 
cohort), while PDAC was more common in the p16-Leiden cohort (7% versus 0.8% in FPC 
cohort). Intraductal papillary mucinous neoplasm (IPMN) was a common finding in surgical 
specimens of FPC-individuals, and was only found in two patients of the p16-Leiden cohort. 
In the p16-Leiden cohort, a substantial proportion of cystic lesions showed growth or 
malignant transformation during follow-up whereas in FPC-individuals most cystic lesions 
remain stable.
CONCLUSION
In p16-Leiden mutation carriers, cystic lesions have a higher malignant potential than in 
FPC-individuals. Based on these findings, a more intensive surveillance program may be 





Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer death in the 
western world. It is one of the most lethal cancers with an incidence rate almost equaling 
the mortality rate and an overall 5-year survival of approximately 5%.1,2 There has been no 
improvement in prognosis in the last decades. However, longer survival has been reported 
for patients with early stage tumors.3 Probably, the only way to detect PDAC at an early 
stage and to improve the prognosis is by surveillance of asymptomatic individuals. Such 
a surveillance program should ideally focus on the detection of known precursor lesions, 
that is, intraductal papillary mucinous neoplasms (IPMNs) and pancreatic intraepithelial 
neoplasias (PanINs).4,5 Because of the low incidence rate of PDAC, surveillance for this 
cancer would not be appropriate in the general population. However, in high-risk groups, 
i.e. individuals with an inherited predisposition to PDAC, screening could be valuable in 
improving the prognosis. 
Approximately 3-5% of PDAC cases are associated with an inherited predisposition.6,7 
Individuals with certain tumor syndromes, such as familial atypical multiple mole melanoma 
(FAMMM), Peutz-Jeghers syndrome (PJS) and hereditary breast cancer (BRCA2 mutation 
carriers), have a marked increase in risk of developing PDAC.8 In FAMMM syndrome, which 
is associated with a mutation in the CDKN2A (or p16) gene, individuals are at increased risk 
of developing melanoma of the skin. FAMMM members with the Dutch founder mutation, a 
19-base pair deletion of exon 2 of the CDKN2A gene (p16-Leiden), have a 15-20% lifetime 
risk of developing PDAC.9 
When there is no proven tumor syndrome, but apparent familial clustering of PDAC, the 
condition is referred to as familial pancreatic cancer (FPC), which represents the largest 
proportion of hereditary PDAC. By definition, there should be at least two first degree 
relatives with PDAC to fulfill the criteria for FPC. The risk of developing PDAC increases 
with the number of family members affected. Individuals with two affected first degree 
relatives have a 6.4-fold increased risk, and the risk increases to 32-fold in case of three 
or more first degree relatives affected.10  
Several studies on screening for PDAC in high-risk individuals, predominantly FPC, have 
been published during the last decade.11-22 Various screening modalities have been used 
in these studies, but the optimal strategy for surveillance in high-risk groups remains 
undetermined. Endoscopic ultrasonography (EUS) is able to detect small solid tumors, but 
it is an invasive procedure. Magnetic resonance imaging (MRI) and magnetic resonance 
cholangiopancreatography (MRCP) are appropriate for detecting small cystic lesions, but 
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are less sensitive in detecting small solid tumors.23,24
In studies focusing on FPC, a high frequency of precursor lesions have been described, 
but an overall low rate of PDAC. 11-14,17-21 On the other hand, screened individuals with the 
p16-Leiden mutation are reported to have a much lower frequency of precursor lesions but 
a high rate of PDAC.22 Therefore, the question arises whether there is a different role of 
precursor lesions in the development of PDAC in the various high-risk groups.
In the present study, we evaluated screening data from a large p16-Leiden cohort and 
a large FPC cohort from the Leiden University Medical Center and the German FaPaCa 
registry, respectively. The aims were to compare the frequency of precursor lesions and 
PDAC between these two cohorts, to compare the features and natural course of precursor 
lesions, and to discuss possible implications for the surveillance protocol.
PATIENTS AND METHODS
SURVEILLANCE GROUP
Individuals at risk (IAR) from two different registries were included in this study. The current 
study is a retrospective analysis of two ongoing prospective surveillance studies. A subset 
of these have been published earlier and were updated for this study.17,22 Individuals with a 
p16-Leiden germline mutation were referred from the Clinical Genetics Department to the 
Department of Gastroenterology and Hepatology of the Leiden University Medical Center 
in The Netherlands to participate in a surveillance program. Individuals from FPC families 
were recruited via the FaPaCa registry, a German national case collection for FPC families 
which is coordinated by the Philipps-University of Marburg in Germany. The diagnosis of 
FPC was based on the presence of two or more first degree relatives with a confirmed 
diagnosis of PDAC. Also, individuals with a BRCA2 or a PALB2 mutation and familial 
clustering of PDAC (primary tumor burden in family) were included in the FPC cohort. 
Individuals with two first degree relatives with PDAC were classified as moderate risk (5- to 
10-fold), individuals with three or more first degree relatives with PDAC or with a BRCA2 
or PALB2 mutation were classified as high risk (>10-fold). Both inclusion procedures and 
criteria were previously described for the two cohorts.17,22 The ongoing surveillance studies 
in Leiden and Marburg were approved by the Ethics Committee of the Leiden University 
Medical Center and the Phillips-University of Marburg, respectively. For the current study, 
evaluation was from January 2000 to August 2011 at Leiden University Medical Center and 





The surveillance program that was used for the FaPaCa FPC-families consisted of both MRI/
MRCP and EUS. In the p16-Leiden families, MRI/MRCP and optionally EUS was performed. 
However, for this study, only the results of the MRI/MRCP were used for comparison. IARs 
without any MRI/MRCP accomplished were excluded. MRI/MRCP was performed yearly in 
both centers. In case of an abnormal finding, either close follow-up with MRI/MRCP and 
EUS or surgery was advised by a multidisciplinary team. Detailed information regarding 
follow-up and MRI-technique were previously described for both groups.17,22 MRIs were 
evaluated by specialized radiologists at the centers in Marburg and Leiden. All abnormal 
MRIs from the p16-Leiden cohort were revised by the radiologist from Marburg (J.T.H.). 
CYSTIC LESIONS
Cystic lesions were defined as radiologically detected cystic lesions including those 
originating from the pancreatic ducts. For the current study, cystic lesions were subdivided 
into (1) main duct type (MD) lesions, (2) branch duct type (BD) lesions with a clear connection 
to the main duct on imaging and (3) other cystic lesions with uncertain connection to 
pancreatic ducts. Cystic lesions were further classified as multicystic single lesions 
consisting of multiple small cysts, single or multiple unicystic lesions. 
INDICATION FOR SURGERY
In the event of a pathological finding in the pancreas by the imaging modalities, the findings 
were reviewed by an interdisciplinary board consisting of geneticists, psychooncologists, 
surgeons and gastroenterologists at both sides. Criteria to recommend surgery included 
cystic lesions >3 cm, cystic lesions of any size with a substantial solid component, cystic 
lesions with irregular boundaries in IAR with a strong family history (e.g. three or more 
affected first degree relatives), significant change in size and morphology during follow up, 
positive or highly-suspicious EUS fine needle aspiration cytology or patients preference.
HISTOLOGY
For both cohorts, pancreatic surgical specimens were investigated by pathologists at 
each centre and reassessed by a single experienced pathologist (G. K), with a special 
expertise in pancreatic pathology. All available sections were reviewed and particular 
attention was given to the slides showing tumorous/cystic alterations and duct changes 
(average number per specimen/case: 4 (range 3–6). In the sections (range 3–4) containing 
nontumorous/noncystic tissue all PanINs were recorded and their numbers listed in tables 
4-6. PanINs were classified by their grade of dysplasia in low (1) moderate (2) or high (3). 
IPMNs were subtyped as gastric, intestinal, oncocytic or pancreatobiliary type with low 
grade, moderate or high grade dysplasia.4,25,26
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STATISTICAL ANALYSIS
Descriptive statistics were compiled for both groups. Categorical features were compared 
using χ2 analysis. Continues variables were compared using the independent samples t test 
or, when indicated, the Mann-Whitney test. A P value of <0.05 was considered significant. 
Statistical analyses were performed using SPSS 17.0 (SPSS Inc, Chicago, IL). 
RESULTS
PATIENT CHARACTERISTICS
A total of 116 IAR with a p16-Leiden germline mutation and 125 IAR from FPC families 
were available for evaluation and included in this study (table 1). In the FPC cohort, 66 
individuals were classified as moderate risk and 59 individuals as high risk. In the high-risk 
group, 9 individuals (7%) had a known mutation (6x PALB2, 3x BRCA2). Median age at start 
screening was 54 years for the p16-Leiden cohort (range 38-72 years) and 47 years for 
the FPC cohort (range 27-73 years). The median time under surveillance was 34 months 
for the p16-Leiden cohort (range 0-127 months) and 36 months for the FPC cohort (range 
0-110 months). A total of 507 MRIs were performed in the p16-Leiden cohort (mean 4.4 per 
individual) and 457 in the FPC cohort (mean 3.7 per individual). All abnormal MRI’s from 
both cohorts were confirmed by one experienced radiologist (J.T.H.). 
TABLE 1. Patient characteristics of the two cohorts
Median age at start 
screening (range)
Gender m:f Median time under 
surveillance [mo] (range)
Total MRI (pp)
♦ FPC (n=125) 47 (27-73) 54:71 36 (0-110) 457 (3.7)
♦ p16-Leiden (n=116) 54 (38-72) 50:66 34 (0-127) 507 (4.4)
pp = per person (mean), n = number
CYSTIC LESIONS AND PDAC DETECTED BY MRI
Cystic lesions were present in 18 of 116 individuals with the p16-Leiden germline mutation 
(16%). In the FPC cohort, 52 of 125 individuals had cystic lesions (42%, p<0.001) (table 2). In 
the p16-Leiden cohort, PDAC was diagnosed in 8 of 116 individuals (7%). In the FPC cohort, 
only 1 of 125 individuals was diagnosed with PDAC (0.8%, p=0.013). 
Four of the eight PDAC cases (50%) in the p16-Leiden cohort were prevalent cases 




during follow-up). The patient with PDAC in the FPC cohort was a high-risk FPC-patient and 
PDAC was detected during follow-up. 
TABLE 2. Frequency of radiologically detected cystic lesions and of PDAC
Cystic lesions (%)* PDAC (%) Operation (%)
♦ FPC (n=125) 52 (42) 1 (0.8) 12 (10)
♦ p16-Leiden (n=116) 18 (16) 8 (7) 7 (6)
n = number
* Numbers represent the number of individuals with one or more radiologically detected cystic lesions 
of the pancreas
FEATURES AND NATURAL COURSE OF CYSTIC LESIONS
IAR with cystic lesions in the FPC cohort were significantly younger than in the p16-Leiden 
cohort (54 vs. 60 years, p=0.026) (table 3). In both cohorts, most IAR had cystic lesions not 
located in the main duct (89% in p16-Leiden, 98% in FPC), but in the p16-Leiden cohort, 
significantly more cystic lesions were located in the main duct compared to the FPC cohort 
(p=0.020). In both cohorts, most individuals had single unicystic or multiple unicystic lesions, 
only a few had multicystic lesions. All lesions were comparable in size between the two 
cohorts. Unicystic lesions were mostly small (mean size 3-6 mm). In the FPC cohort, one 
high-risk individual had a relatively large unicystic lesion (31 mm) at baseline screening, 
which was located in the main duct (the only main duct ectasia in the FPC cohort). This 
patient is scheduled for resection as recommended by the consensus guidelines due to 
the high risk of malignancy inherent to main duct lesions.27 The distribution of cystic lesions 
over the pancreas in the two cohorts is shown in table 3. Cystic lesions were significantly 
more often located in the corpus of the pancreas in the p16-Leiden mutation carriers than 
in the FPC-cohort. In the FPC cohort, only three of 52 (6%) individuals had a cystic lesion 
detected after the first screening round (incident), which was significantly less than in the 
p16-Leiden cohort (56%, p<0.001). 
In the p16-Leiden cohort, thirteen of 18 (72%) individuals had follow-up of their cystic 
lesions (mean duration of follow-up: 2.5 years). Three individuals (23%) with follow-up MRIs 
showed progression, i.e. growth of a cystic lesion or PDAC-development. The individual 
with growth of the cystic lesion had a multicystic lesion with a diameter of 15 mm. During six 
years of follow-up there was no change in size, but one year later the diameter of the lesion 
increased to 17 mm. The two other individuals with progression at follow-up developed 
PDAC at the site of the cystic lesion. One of these individuals had two multicystic lesions 
(14.2 mm and 12 mm) and developed a 20 mm cancer detected by MRI one year later. 
The second patient had a small solitary lesion and irregular duct and developed a 10 mm 
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cancer detected by MRI five months later. The two other incident cases of PDAC in the 
p16-Leiden cohort did not have a cystic lesion detected on previous MRI. One individual 
developed a 15 mm cancer 12 months after a normal 
TABLE 3. Features and course of cystic lesions on radiology 
p16-Leiden FPC p-value
No. of patients (%) 18 (16) 52 (42)
Mean age at detection (range) 60 (50-72) 54 (31-71) 0.026
Localization Main duct 3 1 0.020
Other than main duct* 16 51 ns
Detection Prevalent 9 49 <0.001
Incident 10 3 <0.001
Appearance Multicystic 5 7 ns
Multiple unicystic 9 21 ns
Single unicystic 7 26 ns
Mean size (range) Multicystic 14 mm (11-18) 11 mm (6-18) ns
Multiple unicystic 4 mm (2-14) 5 mm (1-10) ns
Single unicystic 3 mm (2-4) 6 mm (2-31) ns
Site of pancreas Head 10 18 ns
Corpus 13 23 0.041
Tail 9 27 ns
Proc. Uncinatus 1 - ns
Follow-up No. of patients 13 33 ns
Mean follow-up (range) 2.5 years (0.25-8) 3.8 years (1-7) 0.027
Growth of lesion 1 3 -
Development of PDAC† 2 1 -
Numbers represent the number of individuals. Since an individual is able to have more than one lesion, 
overlap may exist 
ns = not significant 
* includes branch duct cystic lesions with clear connection to the main duct and cystic lesion with 
uncertain connection to pancreatic ducts 
† at the same site of the cystic lesion(s)
MRI; the other individual developed a 40 mm cancer 28 months after a normal MRI. Thus, 
of the four incident PDAC cases, two had one or more cystic lesions detected on previous 
MRI.
A comparable number of individuals in the FPC cohort had follow-up of their cystic lesions 
(33/52=63%, p=0.500). Mean follow-up of these lesions was however significantly longer 
(mean duration of follow-up: 3.8 years, Mann-Whitney test: p=0.027). Only four individuals 




of a lesion, of which one was a multicystic lesion and two were unicystic lesions. Growth 
was slow in all three cases. One individual developed PDAC in the pancreatic head two 
years after the first and only MRI. This MRI showed multiple tiny unicystic lesions in the 
whole pancreas, the largest located in the head with a diameter of 5 mm. The proportion 
of individuals with progression of their cystic lesions was higher in the p16-Leiden cohort 
(23%) than in the FPC cohort (12%) .
HISTOLOGIC FINDINGS IN SURGICAL SPECIMENs
In the p16-Leiden cohort, seven cases underwent surgery, of which six had PDACs (table 
4). Three of these cases had single low grade PanIN lesions (PanIN1 and 2) adjacent to 
the carcinoma. One case (table 4, case A), with the smallest PDAC of the series, showed 
a small gastric type BD-IPMN with low- to high-grade dysplasia, and another case (table 4, 
case G) showed multifocal PanIN1 and 2 disease combined with peripheral foci of lobular 
fibrosis and small gastric-type BD-IPMNs in the subtotal pancreatectomy specimen. The 
surgical specimens of four additional PDACs from symptomatic patients with a p16-Leiden 
germline mutation diagnosed in the same time period at the Leiden University Medical 
Center, were histologically reviewed (table 5). In two cases, the PDAC was accompanied 
by few low grade PanIN lesions. One of the two cases had in addition a PanIN3 lesion. 
IPMNs were not found in these cases. In total, five of the 10 operated PDAC cases (50%) 
(table 4 and table 5) revealed PanIN lesions and 1 of 10 had IPMNs in the surrounding 
tissue. Only one case (table 4, case G) in the screened p16-Leiden cohort was operated 
because of growth of a cystic lesion on MRI. This patient who was already previously 
mentioned showed multifocal PanIN-disease but no infiltrating PDAC (as discussed earlier). 
TABLE 4. p16-Leiden cohort: histologic findings in surgical specimens
Histologic characteristics
Age Tumor diagnosis Precursor lesions in the peritumorous tissue (n)
A 62 Ductal adenocarcinoma G1 BD-IPMN; PanIN1 (1)
B 49 Ductal adenocarcinoma G1 -
C 47 Ductal adenocarcinoma G3 Few PanIN1-2 (2)
D 72 Ductal adenocarcinoma G1 -
E 58 Ductal adenocarcinoma G1 -
F 57 Ductal adenocarcinoma G1 Few PanIN1 (3)
G 62 No PDAC. Multifocal PanIN1-2; BD-IPMN n/a
G = grade, n/a = not applicable, n = number of lesions
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TABLE 5. p16-Leiden: histologic findings in surgical specimens of additional (symptomatic) PDAC 
cases, not screened
Histologic characteristics
Age Tumor diagnosis Precursor lesions in the peritumorous tissue (n)
A 38 Ductal adenocarcinoma G2 Few PanIN1 (3)
B 58 Ductal adenocarcinoma G2 -
C 40 Ductal adenocarcinoma G1 -
D 47 Ductal adenocarcinoma G3 PanIN1, 3 (2)
G = grade, n = number of lesions
In the FPC cohort, one of the twelve cases that underwent pancreatic resection had PDAC 
(table 6). Five cases had small BD-IPMN lesions. Three cases had one or more PanIN3 
lesions as highest grade, of which two were found in combination with a BD-IPMN. Two 
cases had one or more PanIN2 lesions as highest grade, of which again one occurred in 
association with a BD-IPMN. One case had only PanIN1 lesions, one case had in addition to 
a PanIN1 lesion a serous cystadenoma (SCA) and two cases only had a SCA. 
DISCUSSION
In this study we compared a FPC cohort with a p16-Leiden cohort to evaluate the role 
of precursor lesions in the early detection of PDAC in these two high-risk groups. We 
demonstrated a significant difference in recognition of precursor lesions and PDAC 
between the two groups. Cystic lesions were more common in the FPC cohort (42% vs. 
16%), while the incidence of PDAC was ten times higher in the p16-Leiden cohort (7% vs. 
0.8%). Interestingly, on histologic examination of resected pancreas specimens, the FPC 
cohort showed both PanIN lesions as well as IPMN lesions, whereas patients in the p16-
Leiden cohort revealed mainly a few low-grade PanIN lesions. In the p16-Leiden cohort, a 
substantial proportion of cystic lesions showed growth or malignant transformation during 
follow-up whereas in the FPC cohort most cystic lesions were stable. These findings 





TABLE 6. FPC cohort: histologic findings in surgical specimens
Histologic characteristics
Age Risk group† PDAC PanIN IPMN other
1 42 Moderate SCA
2 58 Moderate PanIN1-2 (multifocal*) BD-IPMN, gastric type
3 61 Moderate SCA
4 64 Moderate PanIN1-3 (multifocal) BD-IPMN, gastric type (multiple) 
5 54 Moderate PanIN1-2
6 51 High PanIN1-3 (multifocal)
7 53 High PanIN1 BD-IPMN, gastric type microscopic)
8 54 High PanIN1
9 52 High yes
10 61 High PanIN1 SCA
11 69 High PanIN1-3 (multifocal) BD-IPMN, gastric type (multiple)
12 70 High PanIN1-2 (multifocal) BD-IPMN, gastric type
† Moderate risk = two first degree relatives with PDAC, High risk = three or more first degree relatives 
with PDAC, or with a BRCA2 or PALB2 germline mutation
* multifocal indicates more than 3 PanIN lesions
To date, a number of studies focused on screening for PDAC has been published, 
predominantly concerning individuals from FPC families.11-14,17-21 Overall, in these studies 
both PanIN lesions and IPMN lesions were detected in FPC-individuals, but there was an 
overall low incidence of PDAC (<1%). To date, there is only one screening study that solely 
looked at a large FAMMM/p16-Leiden cohort.22 It showed a high incidence of PDAC (9%) 
and revealed no confirmed IPMN lesions. Other studies that included FAMMM patients 
in their screening program also did not report confirmed IPMN lesions.15,16,20 IPMNs were 
lacking in the pancreas of genetically engineered mice with K-RAS and p16 germline 
mutations.28 Taken together these data show that the results of the current study are in line 
with previous screening investigations on FPC and p16-Leiden.
What is the role of cystic lesions in the development of PDAC? De Jong et al studied the 
prevalence of cystic lesions in the pancreas in the general population and demonstrated 
that 2.4% of almost 3000 asymptomatic individuals who had a screening abdominal MRI 
had a pancreatic cyst of any kind, but only 8% of these cysts (0.2% of total) communicated 
with the pancreatic duct, which can be considered a cystic duct lesion.29 Our current study 
demonstrated a frequency of cystic lesions in the FPC and p16-Leiden cohort of 42% and 
16%, respectively, of which the majority probably originate from pancreatic ducts. Thus, 
the rate of cystic lesions in high-risk groups compared to the general population is much 
higher, which suggests an association between these lesions and the development of 
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PDAC. However, in the study by De Jong et al, no MRCP was performed and the MRI was 
not directed to imaging of the pancreas, so the difference could be overestimated. 
In the development of PDAC, usually only PanIN2-3 or IPMN are considered relevant 
lesions. Andea et al compared tumor free pancreatic tissue from pancreas specimens with 
PDAC with that of entirely nonneoplastic pancreatic tissue.30 A substantial proportion (28%) 
of normal pancreas specimens harbored low-grade PanIN (PanIN1 and 2) lesions but no 
PanIN3 lesions whereas the latter lesions were detected in more than half (58%) of pancreas 
specimens with PDAC, an observation which suggests the pathological significance of 
these lesions. Shi et al found, in their comparison of specimens from FPC associated 
PDACs with sporadic PDACs, that IPMNs are common lesions in FPC-individuals. In the 
FPC series, 33% of the individuals had IPMNs (20% high-grade), whereas the surrounding 
tissue of sporadic PDACs only harbored IPMNs in 6% of cases (none high-grade).31 
In our p16-Leiden cohort, including the four PDAC cases not under surveillance, three of 
10 PDAC cases (30%) had a few associated PanIN1 lesions, whereas in the FPC cohort, six 
of 12 patients (50%) had PanIN2-3 lesions that were not associated with a PDAC. In the 
FPC cohort, five of the 12 patients (42%) had BD-IPMNs of gastric type. These lesions were 
only seen twice in our p16-Leiden cohort, but in both patients the findings resembled the 
precursor pattern observed in FPC cohort. These results suggest that PanINs and BD-
IPMNs of gastric type play an important role in the FPC phenotype, but have much less 
significance for the p16-Leiden phenotype. Our study also showed that in the p16-Leiden 
cohort some PDACs developed without evidence for the presence of precursor lesions.
A common finding in our FPC cohort was serous cystadenoma (SCA), confirmed in three 
cases. SCAs were not observed in p16-families. The screening studies in FPC families 
by Canto et al 13 and Ludwig et al 19 also reported serous cystadenomas and a serous 
microcystic adenoma, all variants of serous cystic neoplasms (SCN), which are considered 
rare benign lesions 32. The relatively high frequency of SCAs in FPC might be explained by 
selection bias as FPC patients underwent surgery because of suspicion of an IPMN. 
Overall, our findings and the findings reported in the literature suggest an important role 
of precursor lesions in the carcinogenesis of PDAC in different high-risk groups which 
justifies the goal of screening, i.e. to identify these precursor lesions. 
The current study has some limitations. First of all it is a retrospective analysis of the 
presence of precursor lesions and PDAC in two high-risk groups. However, the data were 
retrieved from two ongoing prospective surveillance studies. Secondly, there are some 




of the FPC group at the start of surveillance is seven years younger than the age of the 
p16-Leiden group. Because the frequency of cystic lesions was higher in the FPC group, 
we would expect that the differences would be even larger if the age distribution in the 
two groups was similar. However, because the mean age at diagnosis of PDAC in FPC is in 
the mid-60s and the mean age at the start of the surveillance of the FPC cohort was only 
47 years, it is likely that the incidence of PDAC will increase over the coming decades. 
The difference in frequency of PDACs might thus become smaller, although the incidence 
of PDAC in other cohorts consisting of participants that enrolled in their mid-50s was also 
low (<1%). In the present study we compared only the outcome of the MRI/MRCP between 
the two cohorts. A possible source of bias is the fact that in the FPC cohort also EUS was 
used in the surveillance protocol whereas only MRI/MRCP was applied in the p16-Leiden 
cohort. The use of EUS in the FPC-cohort could have increased the detection of cystic 
lesions. However, because the sensitivity of MRCP for detection of such lesions is higher 
compared to EUS, we don’t think that adding EUS to the FPC-protocol had a major effect 
on the results.
The results of our current study could have implications for the current screening protocol. 
In FPC, the incidence of PDAC is low (0.8%) and almost all lesions (88%) detected by 
screening are stable at follow-up (or only slowly growing). This would suggest a relatively 
low malignant potential of precursor lesions in the setting of FPC. Because of these findings, 
it could be argued that it is safe to screen young FPC-individuals (e.g. <55 years) without 
evidence of precursor lesions with larger intervals between examinations, for instance 
once every two years and those with lesions at shorter intervals. In p16-Leiden, however, 
we demonstrated a high incidence of PDAC and a probably high malignant potential of 
precursor lesions. A more intensive surveillance program with MRI/MRCP as well as EUS is 
probably needed for the timely detection of early stage tumors or precursor lesions. 
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Up to 10% of patients with pancreatic ductal adenocarcinoma (PDAC) have either a 
positive family history for pancreatic cancer (Familial Pancreatic Cancer), or an underlying 
germline mutation in specific genes (e.g. CDKN2A, BRCA2) associated with hereditary 
tumour syndromes. Guidelines have recently been established for the surveillance and 
management of individuals with a high risk for PDAC, but no recommendations were 
provided regarding the extent of surgery, that is partial or total pancreatectomy, in cases 
with a small screen-detected PDAC. This is an important issue because it seems very 
likely that a hereditary background increases the risk for a second primary cancer of the 
pancreas. Here we describe two high-risk individuals who developed a second primary 
cancer after a partial pancreatectomy of an early-stage cancer. Based on these cases, 






Despite medical progress and improved diagnostic and surgical procedures, pancreatic 
ductal adenocarcinoma (PDAC) remains one of the most lethal cancers and is currently 
the fourth leading cause of cancer-related death in the western world. Only a minority 
of patients are diagnosed at an early stage of the disease.1 Pancreatic surveillance of 
asymptomatic high-risk individuals could potentially increase the proportion of patients 
with early-stage PDAC and thus improve overall survival. A well-established group of 
individuals at high risk are those with an inherited predisposition for the disease. About 
5-10% of PDAC cases have either a positive family history for pancreatic cancer, a condition 
referred to as Familial Pancreatic Cancer (FPC), or an underlying germline mutation in 
specific genes associated with certain tumour syndromes that also predispose to PDAC.2 
Tumour syndromes that are relatively frequently associated with PDAC include Familial 
Atypical Multiple Mole Melanoma (FAMMM) syndrome caused by a mutation in the CDKN2A 
gene and hereditary breast cancer caused by a mutation in the BRCA2 gene in particular.2 
A number of studies have described pancreatic surveillance in high-risk individuals, using 
screening tools such as endoscopic ultrasonography (EUS) and magnetic resonance 
imaging (MRI) combined with magnetic resonance cholangiopancreatography (MRCP).3 
At an international multidisciplinary consensus meeting in 2011 on the surveillance and 
management of individuals at high risk for PDAC, indications for surgery of these individuals 
were addressed, but no recommendations were given regarding the extent of surgery, that 
is, partial or total pancreatectomy, in patients with a screen-detected PDAC.3 This is an 
important issue because it seems very likely that a hereditary background increases the 
risk for a second primary cancer of the pancreas.
Here we describe two high-risk individuals who developed a second primary cancer after 
a partial pancreatectomy of an early-stage cancer. Based on these cases we discuss the 
pros and cons of a total pancreatectomy.
CASES
Patient 1 is a 62-year-old female with the Dutch ‘p16-Leiden’ founder mutation in the CDKN2A 
gene (c.225_243del19; RefSeq NM_000077.4) and a medical history of melanoma at age 
56. This patient was enrolled in the pancreatic surveillance program at Leiden University 
Medical Center in 2008. The first MRI showed a lesion in the head-corpus region of the 
pancreas, suspicious for an adenocarcinoma. The lesion was confirmed by CT scanning, 
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with no signs of distant metastases. A partial pancreaticoduodenectomy was performed. 
Histopathologic examination showed a well-differentiated (grade 1) adenocarcinoma of 5 
mm, surrounded by PanIN1 lesions and an IPMN lesion. The resection margins were free 
of tumour and seven lymph nodes were unaffected (T1N0M0, UICC stage IA). A KRAS 
hotspot mutation in codon 12 was detected in the tumour (c.35G>T). This patient continued 
pancreatic surveillance. After 4 years and 6 months, a solitary lesion of 7 mm was found 
in the corpus-tail region with EUS. Cytological examination of an EUS-guided fine-needle 
aspirate showed atypical cells compatible with adenocarcinoma. Of note, no KRAS 
mutation was detected in these cells. CT scanning confirmed the presence of the lesion 
without evidence for distant metastases. A completion pancreatectomy with splenectomy 
was performed and histopathologic examination showed one small duct suspicious for 
adenocarcinoma surrounded by multifocal PanIN1-3 lesions. The resection margins of the 
specimen were free of tumour and 13 lymph nodes were unaffected (T1N0M0, stage IA). 
Fifteen months after completion pancreatectomy, the patient is alive with no evidence of 
disease.
Patient 2 is a 46-year-old female with a germline mutation in the BRCA2 gene and three 
affected relatives with PDAC. In 1984, she developed a painless icterus; CT scanning 
and endoscopic retrograde cholangiopancreatography (ERCP) revealed a tumour in the 
pancreatic head. A partial pancreaticoduodenectomy was performed. Histopathologic 
examination showed a moderately differentiated (grade 2) adenocarcinoma of 22 mm. 
The resection margins were free of tumour and none of 14 lymph nodes were affected 
(T2N0M0, stage IB). In 1987, 2 years and 9 months later, the tumour marker CA 19.9 
increased to 190 U/mL (normal <39 U/ml) and CT scanning revealed a tumour in the tail 
of the pancreas. A resection of the remnant pancreas was performed and histopathologic 
examination showed a poorly differentiated (grade 3) adenocarcinoma of 20 mm. The 
resection margins and eight lymph nodes were free of tumour (T2N0M0, stage IB). At 
the last follow-up, 28 years after completion pancreatectomy, the (currently 76-year-old) 
patient is alive with no evidence of PDAC.
DISCUSSION
This is the first report of the development of a second primary PDAC after partial 
resection of a first pancreatic tumour in patients with a genetically increased risk for the 
development of PDAC. The first patient carried a CDKN2A mutation and the second patient 
had a mutation in BRCA2; both gene defects are associated with the development of 




apparently sporadic PDAC cases has been previously described 4, but this is a very rare 
event, which is probably due to the poor survival of these patients. 
The cases presented here raise a number of questions, the first of which is: did these patients 
actually develop a second primary or was the second tumour simply a local recurrence 
of the original tumour? Arguments that would support a second primary tumour rather 
than a local recurrence include: (1) a long interval between diagnoses of the tumours, (2) a 
location of the second tumour in another part of the pancreas (distant from resection lines), 
(3) differences in the pathology of the tumours, (4) different KRAS mutations in the tumours, 
and (5) both first and second tumours are early-stage without evidence for metastatic 
disease. The two cases comply with most of these criteria: (1) intervals between diagnoses 
were 4 years and 6 months in case 1 and 2 years and 9 months in case 2; (2) the location 
of the second tumour was distant from the resection lines in both cases; (3) in patient 2, 
the first tumour was a moderately differentiated (grade 2) adenocarcinoma, whereas the 
second tumour was a poorly differentiated (grade 3) adenocarcinoma; (4) in patient 1, the 
KRAS hotspot mutation detected in the first tumour was not detected in the cells obtained 
by cytology from the second tumour, suggesting a different aetiology; (5) in both cases, 
the first and second cancer were early-stage cancers (T1-2N0M0). Taken together, these 
findings suggest that these tumours are most likely second primary tumours.
A second important question is: what is the risk, in a patient with a genetic predisposition, 
of developing a second primary cancer after resection of a first PDAC? A previous study on 
surveillance outcomes for Dutch carriers of a p16-Leiden mutation reported that, while the 
program substantially increased the proportion of patients with resectable tumours, very 
few patients had a long survival.5 This was echoed in the German surveillance program, 
where patients with a longer survival following resection of PDAC were also very rare.6 
The observation of a second tumour in these ‘rare’ (n=2) patients therefore suggests that 
a genetic predisposition contributes a substantial risk of developing a second primary 
tumour if the patient survives the first tumour. Moreover, the development of a second 
cancer within a relatively short follow-up time (2 to 4 years after the first tumour) also 
indicates substantial risk. 
What are the implications of our findings for the surgical management of high-risk patients? 
Should we offer total pancreatectomy (TP) to all patients with a genetic predisposition 
and an early-stage cancer? A well-known disadvantage of TP is the development of 
‘brittle’ diabetes which is associated with substantial morbidity. However, recent studies all 
concluded that TP is safe, with acceptable mortality and morbidity.7,8 Studies that compared 
the perioperative mortality and morbidity of TP with partial pancreatectomy (PP, mostly 
73
5
LIMITED RESECTION OF PANCREATIC CANCER IN HIGH-RISK PATIENTS CAN RESULT IN A SECOND PRIMARY
pancreaticoduodenectomy [PD]) produced more conflicting results (see table).9-15 Some 
studies reported no significant difference in mortality and morbidity between TP and PD, 
whereas others reported a 1.5-3 fold increased risk of mortality and a (lesser) increased 
morbidity risk. Interestingly, two recent studies assessed quality of life (QoL) in TP cases 
compared with matched PD cases.8,10 These studies demonstrated that QoL following TP 
is acceptable and similar to that reported for PD. Moreover, while brittle diabetes has a 
negative impact on QoL after TP, the level of impact is comparable to that of diabetes 
following PP or due to other causes. This conclusion was supported by another study that 
assessed QoL (without comparisons) in TP cases.7 In light of these recent studies, the best 
approach may be to openly discuss the various advantages and disadvantages of TP with 
high-risk patients with early-stage PDAC and come to a decision together.
In conclusion, we describe two high-risk patients who developed a second primary PDAC 
two to four years after a partial pancreatic resection of an early-stage PDAC. In view of the 
acceptable perioperative mortality and morbidity risk of TP and an improvement of quality 
of life after TP in recent years, this type of surgery should be seriously considered in 
high-risk patients with an early-stage (screen-detected) tumour.
TABLE. Perioperative outcome of total pancreatectomy (TP) versus partial pancreatectomy (PP)





Schmidt et al 9 TP n=33 6 n.s. 36 n.s.
PD n=28 7 54
Muller et al 10 TP n=87 6 n.s. 31 n.s.
PD n=87 3 23
McPhee et al 11 TP n=1,399 8.3 0.0002 n/a n/a
PD n=27,289 6.6 n/a
Reddy et al 12 Period 1970-2007
TP n=100 8 0.0007 69 <0.0001
PD n=1,286 1.5 38.6
Subanalysis of period 2000-2007
0.17 No significant changeTP n=53 1.9
PD n=? 1.2
Nathan et al 13 TP n=376 8.6 0.09 n/a n/a
PP n=3,645 6.3 n/a
Simons et al 14 TP n=5,966 OR 2.90 <0.0001 OR 1.29 0.0025
PD n=56,207 Ref Ref
Bhayani et al 15 TP n=198 6.1 0.02 38 0.02
PD n=6,314 3.1 30
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Pancreatic cancer (PC) surveillance is currently offered to individuals with a genetic 
predisposition to PC, but routinely used radiological screening modalities are not entirely 
reliable in detecting early-stage PC or its precursor lesions. We recently identified 
a discriminating PC biomarker signature in a sporadic patient cohort. In this study, we 
investigated if protein profiling can accurately distinguish PC from non-PC in a pancreatic 
surveillance cohort of genetically predisposed individuals.
METHODS
Serum samples of 66 individuals with a CDKN2A germline mutation who participated 
in the pancreatic surveillance program (5 cases, 61 controls) were obtained following a 
standardized protocol. After sample clean-up, peptide and protein profiles were obtained 
on an ultrahigh resolution MALDI-FTICR mass spectrometry (MS) platform. A discriminant 
score for each sample was calculated with a previously designed prediction rule, and 
the median discriminant scores of cases and controls were compared. Individuals with 
precursor lesions of PC (n=4) and individuals with a recent diagnosis of melanoma (n=4) 
were also separately considered.
RESULTS
Cases had a higher median discriminant score than controls (0.26 vs 0.016; p=0.001). The 
only individual with pathologically confirmed precursor lesions of PC could also be clearly 
distinguished from controls, and having a (recent) medical history of melanoma did not 
influence the protein signatures.
CONCLUSIONS
Peptide and protein signatures are able to accurately distinguish PC cases from controls 
in a pancreatic surveillance setting. MS-based protein profiling therefore seems to be 
a promising candidate for implementation in the pancreatic surveillance program as an 





Pancreatic cancer (PC) is one of the most lethal cancers with a 5-year survival rate of only 
5%.1 The first clinical symptoms generally appear relatively late when the tumour is already 
in an advanced stage. To improve prognosis, PC has to be detected at an earlier stage in 
which curative surgical resection is still possible. Therefore, in the last decade, pancreatic 
surveillance programs for high-risk individuals have been set up, aimed at detecting 
early-stage PC or relevant precursor lesions in individuals with a genetic predisposition 
to PC.2 
At the Leiden University Medical Center (LUMC), such a pancreatic surveillance program 
was initiated in the year 2000 for individuals with a CDKN2A germline mutation.3 These 
individuals have a familial predisposition for developing cutaneous melanoma, a condition 
known as Familial Atypical Multiple Mole Melanoma (FAMMM) syndrome, but also a 15-
20% lifetime risk for developing PC.4 Because many individuals with a specific Dutch 
founder mutation in the CDKN2A gene (a 19bp deletion known as p16-Leiden) are living 
in the vicinity of Leiden, a relatively large cohort of these patients is under pancreatic 
surveillance in the LUMC. The surveillance program consists of annual abdominal 
magnetic resonance imaging (MRI and MRCP) and optionally endoscopic ultrasound 
(EUS). Although these screening modalities are generally able to detect early-stage PC or 
relevant precursor lesions of PC, the diagnostic yield of surveillance programs using these 
modalities varies greatly and only a subset of patients with a screen-detected PC have an 
early-stage  cancer.2,5 Therefore, there is a need to improve the current pancreatic 
surveillance program. 
One way to improve PC surveillance programs is to use serum biomarkers as an additional 
non-invasive screening modality.6-9 These biomarkers have to discriminate cancer patients 
from non-cancer patients or even patients with precursor lesions of PC. Currently, only the 
mucin-associated carbohydrate antigen CA 19-9 is routinely used, but has not proven to be 
an adequate biomarker for detecting early-stage PC.10 Many studies have been published 
on novel individual biomarkers for the early detection of PC, but none of them have been 
implemented in daily practice so far.11,12 
In our center, a discriminating PC biomarker signature was recently identified by following 
a serum peptide and protein profiling strategy based on a combination of automated 
single-step sample clean-up and matrix-assisted laser desorption/ionization mass 
spectrometry (MALDI-MS).13,14 The most detailed protein signatures were obtained using 
an ultrahigh resolution MALDI Fourier transform ion cyclotron resonance (FTICR) MS 
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platform that provided case-control classifications with a sensitivity and specificity both 
well above 85%.15 A discriminating prediction rule was validated for this classification. The 
methodology used in our previous studies is graphically displayed in figure 1 (left-hand 
side). Based on these encouraging results it was concluded that such protein signatures 
are a promising candidate for implementation in the current pancreatic surveillance 
program as an additional screening modality. The aim of the current study is therefore to 
determine whether ultrahigh resolution protein profiling (using MALDI-FTICR-MS) in serum 
can accurately distinguish individuals with PC from non-PC in a novel cohort of CDKN2A 
mutation carriers enrolled in the pancreatic surveillance program, using the previously 
designed and validated prediction rule for the classification of individual samples (figure 
1, right-hand side). 
 
FIGURE 1: Serum peptide and protein profiling strategy, aiming for patient classification based on 
matrix-assisted laser desorption/ionization (MALDI) Fourier transform ion cyclotron resonance 
(FTICR) mass spectrometry. 
Various peptide and protein signatures have been reported based on a single-step sample clean-
up procedure using a combination of a carrier (depicted in the inner shell) with capture material 
(depicted in the middle shell), and a mass spectrometer (depicted in the outer shell). Previously, our 
group has reported signatures for PC based on weak-cation exchange (WCX) with MALDI time-of-
flight (TOF) [Velstra et al. 2013], and reversed-phase (RP) C18 with MALDI-TOF [Velstra et al. 2015]. In 
the current study an ultrahigh resolution RPC18-MALDI-FTICR signature is used that was obtained in 
a case-control calibration and validation design (left-hand side) [Nicolardi et al. 2015]. Serum samples 






PATIENT COHORT AND BLOOD SAMPLING
Individuals with a CDKN2A germline mutation who participate in the pancreatic surveillance 
program at the Leiden University Medical Center were eligible for inclusion. A complete 
medical history was obtained at the start of surveillance, including a medical history of 
melanoma or other cancers. Subsequently, annual MRI and MRCP with optionally EUS 
was performed and in case of an abnormal finding, either close follow-up with MRI/MRCP 
and EUS or surgery was advised by a multidisciplinary team, as previously described.3 
Any cancer occurring in follow up was registered. Cases were defined as having a 
pathologically confirmed diagnosis of PC. Controls were not diagnosed with PC, and 
included individuals with relevant precursor lesions of PC. These were defined as either 
pathologically proven precursor lesions (intraductal papillary mucinous neoplasm (IPMN) 
and pancreatic intraepithelial neoplasia (PanIN) 16), or radiological cystic lesions ≥ 5 mm 
suspicious for IPMN. 
Serum samples from the cases with PC were obtained prior to surgery. Serum samples 
from the controls without PC were obtained during their annual surveillance visit at 
the outpatient gastroenterology clinic. Only one sample was collected per individual. 
Samples were collected over a time period ranging from April 2008 until January 2015. 
Additional serum samples of CDKN2A mutation carriers with PC who did not participate 
in the surveillance program were available through an on-going research project of the 
Department of Surgery, in which serum samples of all patients with PC are obtained prior to 
surgery. Samples were collected and processed following a standardized high-throughput 
clean-up protocol as previously described.17,18 Informed consent was obtained from all 
individuals, and the study was approved by the Ethics Committee of the Leiden University 
Medical Center (#P03.147).
SAMPLE PROCESSING AND MALDI-FTICR MASS SPECTROMETRY 
PEPTIDE PROFILING
The isolation of peptides and protein from serum was performed using a fully automated, 
high-throughput protocol based on solid-phase extraction (SPE) with RPC18-funtionalized 
magnetic beads, as previously described.15,18 Subsequently, MALDI-profiles were obtained 
on a MALDI-FTICR platform that allows mass analysis of serum peptides and proteins with 
isotopic resolution up to 15,000 Da. A detailed description of this approach and workflow, 
as well as the subsequent data processing, was previously described by Nicolardi et al.15 
For this study, only so-called low-mass (LM) data (i.e., up to m/z-value 4000) was used for 
statistical analysis. The serum samples were blindly analysed. 
83
6
APPLICATION OF A SERUM PROTEIN SIGNATURE FOR PANCREATIC CANCER TO SEPARATE CASES FROM CONTROLS IN A 
PANCREATIC SURVEILLANCE COHORT
STATISTICAL ANALYSIS
Our group previously designed a prediction rule to classify a serum sample as either case 
or control using logistic regression ridge shrinkage (LRRS) analysis.15,19 By applying the 
same prediction rule to the LM data acquired in this study, a “discriminant score” was 
calculated for each sample. Samples were grouped according to their known disease 
status and the median discriminant scores per group were compared using a Mann-
Whitney-Wilcoxon test. Individuals with precursor lesions and individuals with a recent 
diagnosis of melanoma were also separately considered.
RESULTS
PATIENTS
A total of 66 individuals (42 females, 64%) were included in the study. Sixty-one individuals 
had a molecularly proven CDKN2A germline mutation, of which 60 had the p16-Leiden 
mutation (c.225_243del19; RefSeq NM_000077.4). One individual carried the c.67G>C 
mutation, which is also associated with PC [not published data]. The remaining 5 individuals 
had a medical history of melanoma (or PC, #4 table 2), and a close relative with a proven 
CDKN2A germline mutation, which makes them highly likely of being a carrier. Patient 
characteristics are shown in table 1. Five individuals (all female) had PC, with a mean age 
of 54 years (range 39-62 years). Two of five cases had a medical history of melanoma, but 
no other cancers occurred in the case group. The remaining 61 individuals (37 females, 
61%) had no PC. The mean age of the control group was 53 years (range 42-72 years). 
Thirty-eight controls had a medical history of melanoma, and a few other cancers occurred 
in the control group (see table 1). One individual in the control group had a melanoma 1 
month prior to serum sampling (#2 table 3), and one individual had a melanoma 1 month 
after serum sampling. Two other individuals had cancer ≤12 months before or after serum 
sampling (both melanoma; 12 months prior and 9 months after). These melanomas were 
non-metastatic.
Detailed information about the case group is shown in table 2. Three cases were 
participating in the surveillance program, of which two were diagnosed with PC at the first 
screening round (prevalent) and one was diagnosed on a subsequent screening round 
(incident). This latter individual (#1, table 2) had a normal MRI two years earlier but missed 
her MRI a year later. She was diagnosed with a 3.6 cm tumour in the subsequent year. Two 
of five cases were not participating in the surveillance program, and had their serum drawn 




TABLE 1. Patient characteristics
Diagnosis No. of 
Patients
Age (range) M:F Medical History of 
Melanoma 
(of which multiple)
Medical History of Other 
Cancers 
(No. of Individuals) *
PC 5 54 (39-62) 0:5 2 (1) None
No PC 61 53 (42-74) 24:37 38 (12) SCC of larynx (1) † 
SCC of mouth (1) † 
SCC of skin (1) 
BCC of skin (3) 
Phyllodes sarcoma of breast (1)
With precursor 
lesions
4/61 54 (45-63) 2:2 3 (1) None
Total 66 53 (39-74) 24:42 40 (13) As above
SCC = Squamous Cell Carcinoma, BCC = Basal Cell Carcinoma
* None of these cancers occurred within a year prior to serum sampling
† These cancers occurred synchronously in one individual
TABLE 2. Tumour Characteristics of Cases with PC











1 57 F - Surveillance, 
incident
Tail 3.6 T2N0M0 
(Stage IB)
2
2 62 F Me 56 yrs Surveillance, 
prevalent
Head-corpus 0.5 T1N0M0 
(Stage IA)
1
3 62 F Me 31 yrs (2x) Symptomatic Head 5.0 T3N1M0 
(Stage IIB)
2





5 47 F - Surveillance, 
prevalent




Four individuals in the control group had relevant precursor lesions of PC, of which detailed 
information is shown in table 3. All four individuals had cystic lesions ≥ 5 mm suspicious 
for IPMN, but only one individual had a surgical resection due to growth of the lesion. 
Pathological examination of the resected pancreas of this patient confirmed the presence 
of an IPMN lesion, as well as multifocal PanIN1-2 lesions.
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TABLE 3. Precursor Lesions of PC in the Control Group
Age M/F Medical History of 
Cancer
Findings Pancreatic Surveillance Surgical 
Intervention
Pathology
1 63 F - Multicystic lesion of 15 mm in 
head-corpus region, stable for 6 years 
and growth to 17 mm in the 7th year. 
Suspicious for BD-IPMN. 
Two cystic lesions (8 mm, head and 5 







2 59 M >15 Me from age 
27, most recent at 
age 59
Multicystic lesion of 7 mm in proc. 
uncinatus, suspicious for BD-IPMN, 




3 45 F Me 42 yrs Cystic lesion of 7 mm and multicystic 
lesion of 7 mm in head region, both 





4 49 M Me 44 yrs Cystic lesion of 13 mm in corpus-tail 





Me = Melanoma, BD-IPMN = Branch duct intraductal papillary mucinous neoplasm, PanIN = Pancreatic 
intraepithelial neoplasia
Statistical classification of serum profiles
High-quality MALDI-FTICR data was obtained from all samples and therefore all samples 
were suitable for further statistical analysis. In figure 2, boxplots of the calculated 
discriminant scores for cases (n=5) and controls (n=61) are shown. Boxplots of the data 
from our previous study are displayed in figure 2 as well. Cases from our previous study 
had a noticeable higher score than cases from the current study, as can be seen in figure 
2. This can probably be explained by the fact that more cases in our previous study had 
metastatic (lymph nodes positive or distant) disease, i.e. stage IIB or higher (83% compared 
to 60% in the current study). As was shown in our previous study, a more advanced tumour 
stage is associated with a higher discriminant score. The difference could further be 
caused by a systematic re-calibration effect. Nonetheless, the boxplots show that cases 
with PC are accurately distinguished from controls without PC in the new surveillance 
data. The median discriminant score for cases is 0.26 and for controls 0.016, which differs 





FIGURE 2.        FIGURE 3.
FIGURE 2: Boxplots of the discriminant scores for cases and controls of the current study and of 
our previous study
The boxplots on the left represent the data of the current study. For comparison, boxplots of the 
data from our previous study [Nicolardi et al. 2015] are displayed on the right. The generally higher 
discriminant scores of cases in the previous study compared to cases in the current study can 
probably be explained by the fact that more cases in our previous study had metastatic (lymph nodes 
positive or distant) disease, i.e. stage IIB or higher (83% compared to 60% in the current study). A more 
advanced tumour stage is associated with a higher discriminant score. A systematic re-calibration 
effect could further explain the difference.
O = Outliers
FIGURE 3: Scatter plot of the discriminant scores of the current study; individuals with precursor 
lesions are separated from controls
This figure shows all the individual discriminant scores of the 66 included individuals, subdivided in 
cases (n=5), controls (n=57) and individuals with precursor lesions (n=4).
* Individual #1 (table 3); discriminant score of 0.34, † Individual #2 (table 3); discriminant score of 0.08
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Scores of individuals with precursor lesions of PC are separately shown in figure 3. The 
only individual with pathologically proven precursor lesions of PC (#1 in table 3, * in 
figure 3) had a relatively high score of 0.34, well above the median score of controls and 
comparable with the scores of the cases. The individual with precursor lesions as well as 
a melanoma 1 month prior to serum sampling (#2 in table 3, † in figure 3) had a score of 
0.08 and scored above the 75th percentile of the median score of the control group. The 
other two individuals with (radiological) precursor lesions had a score below the median 
of the control group. Apart from individual #2 (table 3), there were three other individuals 
with a melanoma diagnosed shorty before or after serum sampling. These individuals had 
a score near or well below the median score of the control group. 
DISCUSSION
In this study, we analysed biomarker profiles in a pancreatic surveillance cohort of CDKN2A 
mutation carriers with and without PC using the same methodology as in our earlier work. 
By applying the previously designed prediction rule for the classification of serum samples, 
cases with PC could be accurately distinguished from controls without PC. Also, individuals 
with suspicious precursor lesions of PC might be distinguished from controls, and having a 
(medical history of) melanoma probably does not influence the protein signatures. Protein 
profiling therefore has potential to be included in the pancreatic surveillance program, 
where it, as an addition to current screening methods, can aid in the decision whether a 
patient will need surgery or not.
Different biomarkers have been extensively studied in sporadic patient cohorts over 
the last decades,12,20,21 but this is the first study to investigate the role of biomarkers in a 
pancreatic surveillance cohort of genetically predisposed individuals. Recent studies from 
the University of Marburg did however investigate biomarkers in familial PC (FPC) individuals 
with PC or relevant precursor lesions of PC in a non-surveillance setting.22,23 Interestingly, 
the (few) individuals with pathologically confirmed high-grade precursor lesions (PanIN2-3) 
in their studies had significantly elevated serum biomarker levels prior to surgery and 
the levels dropped to the normal range after surgery. FPC individuals having relevant 
precursor lesions of PC could thus accurately be distinguished from healthy controls using 
their proposed biomarker sets, and the authors argued that biomarkers may be suitable for 
the early detection of precursor lesions of PC in high-risk individuals.
Indeed, a major goal of screening is the detection of precursor lesions of PC,2 and their 




carriers in the surveillance program had possible precursor lesions (ductectasias) on 
radiology.3 Potjer et al reported an even higher number (16%), and concluded that precursor 
lesions might have a high malignant potential in CDKN2A carriers, compared to precursor 
lesions in FPC individuals.24 In order to be implemented in a pancreatic surveillance cohort, 
it is therefore important that potential serum biomarkers not only distinguish non-cancer 
patients from cancer patients, but also from patients with relevant precursor lesions of PC. 
In this study, there was only one patient with histologically confirmed precursor lesions 
(IPMN and PanIN1-2), and as mentioned those precursor lesions, especially the IPMN, might 
have a relatively high malignant potential because the patient was a CDKN2A mutation 
carrier. This patient had a protein signature comparable to those with PC. The other three 
patients with less suspicious precursor lesions on radiology had a normal to near-normal 
protein profile. Therefore, it seems likely that patients with substantial precursor lesions 
might be accurately distinguished from healthy CDKN2A carriers using serum protein 
profiling, although numbers are too small to make definite conclusions. 
A second requirement for biomarkers to be implemented in a pancreatic surveillance 
cohort of high-risk individuals, especially CDKN2A carriers, is that the signatures are not 
disturbed by the occurrence of other types of cancer. The FAMMM syndrome (due to a 
CDKN2A germline mutation) is mainly characterized by a very high risk (70%) of developing 
cutaneous melanoma, and 62% of the carriers in this study indeed had a medical history of 
melanoma. Having a medical history of melanoma did not influence the protein signatures 
in general, as cases could still accurately be distinguished from controls in this cohort. 
Also, the four controls with a recent diagnosis of melanoma did not evidently diverge from 
the other control patients. Only the individual with both a recent diagnosis of melanoma 
and radiological precursor lesions had a slightly higher discriminant score than the other 
controls, but that could be caused by the presence of precursor lesions as argued above. 
In addition to the high risk of developing melanoma and PC, CDKN2A mutation carriers 
also have a higher risk of developing head and neck squamous cell carcinoma, which 
emphasises that FAMMM syndrome is a true tumour syndrome.25,26 It is therefore also 
important to know if these cancers influence the protein signatures, but that could not be 
investigated in the current study due to the fact that there was no recent diagnosis of this 
type of cancer in the study group. There was only one individual in this cohort with two 
synchronous tumours of the larynx and mouth 4 years prior to serum sampling, without 
recurrence after treatment and a very low discriminant score.
The most important limitation of this study is sample size. More individuals with PC and, 
preferably, histologically confirmed high-grade precursor lesions are needed to investigate 
if these individuals definitely can be distinguished from healthy CDKN2A individuals. These 
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patients are however very rare and it would take years to collect only a few more patients. 
Also, more patients with other tumours than PC at or around the time of serum sampling 
are needed in order to investigate if those tumours intervene with the protein signatures. A 
second limitation is that we did not collect samples after surgical treatment, and therefore 
we could not investigate if the high discriminant scores declined after surgery. Future 
implementation of protein profiling in the surveillance program, with standardized yearly 
serum sampling, including post-surgery sampling, will ensure more patients with different 
types of cancer or precursor lesions of PC.
Since current screening strategies for PC are not entirely reliable for detecting early-stage 
PC or its (high-grade) precursor lesions, there is a strong need to improve the pancreatic 
surveillance program. As is shown in this preliminary study, protein profiling seems a 
very promising method to be included as an additional non-invasive screening modality. 
Previously, similar MS-based profiling studies in our group provided promising results with 
regard to peptide and protein signatures for the early detection of breast cancer and 
colorectal cancer,18,27 and thus protein profiling seems suitable for cancer surveillance in 
general. 
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Several factors have been reported that influence the probability of a germline CDKN2A 
mutation in a melanoma family. Our goal was to create a scoring system to estimate this 
probability, based on a set of clinical features present in the patient and his or her family. 
METHODS
Five clinical features and their association with CDKN2A mutations were investigated in 
a training cohort of 1227 Dutch melanoma families (13.7% with CDKN2A mutation) using 
multivariate logistic regression. Predefined features included number of family members 
with melanoma and with multiple primary melanomas, median age at diagnosis and 
presence of pancreatic cancer or upper airway cancer in a family member. Based on 
these five features, a scoring system (CDKN2A Mutation (CM)-Score) was developed and 
subsequently validated in a combined Swedish and Dutch familial melanoma cohort (n=421 
families; 9.0% with CDKN2A mutation).
RESULTS
All five features were significantly associated (p<0.05) with a CDKN2A mutation. At a 
CM-Score of 16 out of 49 possible points, the threshold of 10% mutation probability is 
approximated (9.9%; 95% CI 9.8-10.1). This probability further increased to >90% for families 
with ≥36 points. A CM-Score under 16 points was associated with a low mutation probability 
(≤4%). CM-Score performed well in both the training cohort (AUC 0.89; 95% CI 0.86-0.92) 
and the external validation cohort (AUC 0.94; 95% CI 0.90-0.98).
CONCLUSION
We developed a practical scoring system to predict CDKN2A mutation status among 
melanoma-prone families. We suggest that CDKN2A analysis should be recommended to 





Since its identification in 1994,1 the CDKN2A gene (MIM 600160) has remained the major 
high-risk susceptibility gene for cutaneous melanoma. Germline mutations are present in 
approximately 10-40% of familial cases.2 Carriers of a germline mutation in the CDKN2A 
gene have an increased risk for developing melanoma, with a penetrance of up to 70% 
at 80 years of age, and 40% of carriers develop multiple primary cutaneous melanomas.3 
Furthermore, mutation carriers have an increased risk for other types of malignancies, 
the most important of which is pancreatic cancer.4 Due to the high risk of melanomas and 
other types of cancer and the advantages of regular surveillance in improving prognosis 
and survival,5,6 it is important to identify families that carry a CDKN2A germline mutation. 
However, the probability of a CDKN2A mutation strongly depends both on the clinical 
characteristics of a family and personal (dermatological) and environmental factors such 
as skin type and the amount of sun exposure. Thus, CDKN2A mutation analysis might not 
be indicated in some lower-risk melanoma families. 
The Netherlands and Sweden both have a high incidence of melanoma (age-standardized 
rate 19.4 and 18.0 per 100.000, respectively7) and specific founder mutations in the 
CDKN2A gene are the predominant cause of familial melanoma in these countries. In the 
Netherlands, the 19-base pair deletion termed p16-Leiden (c.225_243del, p.Ala76Cysfs*64; 
RefSeq NM_000077.4) not only confers an increased risk for melanoma but also for tumors 
of the pancreas and upper airway tract (larynx, pharynx, oral cavity), and to a lesser extent 
tumors of the lungs and digestive tract.8-10 Carriers of the Swedish founder mutation 
(c.335_337dup, p.Arg112dup; RefSeq NM_000077.4) also show an increased risk for these 
tumors.11,12 Although it is recognized that the risk-spectrum for non-melanoma cancers 
differs among carriers of different mutations in the CDKN2A gene, pancreatic and upper 
airway tract cancers have repeatedly been reported in a variety of carrier populations.4,13-17 
Over the past decade, research groups from Europe, the United States and Australia have 
attempted to identify clinical features that are associated with germline CDKN2A mutations 
in melanoma families.18-24 Studied features included (1) number of melanoma patients in a 
family, (2) number of patients with multiple primary melanomas in a family, (3) median age 
at diagnosis of melanoma and (4) presence of pancreatic cancer in a family. The most 
significant associations reported in these studies were the presence of more than two 
melanoma cases in a family, an early age of onset, and having at least one family member 
with multiple primary melanomas and/or pancreatic cancer. Based on a literature review 
from 2009, it was suggested that melanoma patients from areas with a moderate to high 
incidence of melanoma are candidates for genetic testing of CDKN2A if they have at 
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least three primary melanomas, or when there are at least two additional diagnoses of 
melanoma and/or pancreatic cancer among close (first or second-degree) family members 
(“rule of threes”).25 The authors argued that these families have an estimated 10% or greater 
probability of carrying a germline CDKN2A mutation, which is a commonly used threshold 
in clinical practice for gene sequencing in hereditary cancer.26-28
The goal of this study was to create a scoring system for clinicians to estimate the probability 
of a germline CDKN2A mutation based on a set of clinical features present in the patient 
and his or her family. Using a training cohort of Dutch melanoma families, we therefore 
analysed the association of four previously reported clinical features that are associated 
with a CDKN2A mutation, and investigated the association with upper airway cancer as an 
additional feature. A combined cohort of Swedish and Dutch melanoma families was used 
for external validation of the scoring system.
PATIENTS AND METHODS
TRAINING COHORT
The training cohort included all cutaneous melanoma index patients and their families 
in the Netherlands referred for CDKN2A mutation analysis between 1998 and 2015. 
According to current Dutch referral guidelines, CDKN2A mutation analysis is indicated if 
one of the following criteria is met: a family with 1) two first-degree relatives with melanoma, 
2) two first or second-degree relatives with melanoma and one first or second-degree 
relative with pancreatic cancer, 3) three or more primary melanomas in one individual, 
4) an individual with juvenile melanoma (< 18 years), or 5) an individual with a history of 
both melanoma and pancreatic cancer. At the Department of Clinical Genetics at Leiden 
University Medical Centre, the Laboratory for Diagnostic Genome Analysis (LDGA) has 
been the primary sequencing facility for CDKN2A in the Netherlands since 1998, and 
receives diagnostic requests from across the Netherlands. Essential pedigree information 
was gathered for the families and added to the Leiden Familial Melanoma Database. These 
data included the number of first and second-degree family members (of each other) with 
cutaneous melanoma (invasive or in situ), whether these patients had single or multiple 
primary melanomas (MPM), the age of each melanoma patient at first diagnosis and the 
number of family members with pancreatic cancer (PC) and upper airway cancer (UAC), i.e. 
cancer of larynx, pharynx or oral cavity. We restricted our analysis of these latter tumours 
to the first and second-degree relatives of the index patient and the first-degree relatives 
of melanoma patients. We relied on the referring clinical geneticists for complete pedigree 




and others). We included all information on cancer diagnoses, also those unconfirmed 
by the clinical geneticist, since index patient reports of melanomas in family members 
have a high known level of accuracy (true positive predictive value 77-87%).29 We imputed 
the age of melanoma diagnosis for family members where the age at diagnosis was not 
reported in the pedigree (n=320 individuals from 212 families [61 with CDKN2A mutation]). 
Imputation was based on median age at diagnosis in CDKN2A mutation families (40 
years) and sporadic (non-CDKN2A) patients (55 years), as reported by van der Rhee et 
al.30 When the patient was younger than this age or was deceased prior to this age at 
time of CDKN2A analysis in the family, that specific age was used for imputation. Families 
without a CDKN2A mutation were excluded from the study if CDKN2A analysis was only 
performed in a non-affected family member (n=84). Families in which CDKN2A sequencing 
was unsuccessful were also excluded (n=4). The Leiden University Medical Centre Ethics 
Committee issued a declaration of no objection (#C14.064) regarding the creation of the 
Leiden Familial Melanoma Database.
VALIDATION COHORT
The greater portion of the validation cohort in this study consisted of members of 
melanoma-prone families from Sweden.31 Families were identified by questioning newly-
diagnosed melanoma patients about their familial melanoma history. Melanoma families 
were defined as kindreds with at least two relatives (first, second or third-degree) with 
histologically or clinically verified melanoma. Since 1995, germline CDKN2A mutation 
analysis is offered to members of these families after informed consent is obtained. The 
study was approved by Research Ethical Review Boards at Lund University and Karolinska 
Institute in Stockholm, the sites where the genetic tests were performed. In Stockholm, 
patients with multiple primary melanomas (regardless of family history) are also invited to 
undergo germline CDKN2A mutation analysis. In 2012, a study was performed to broaden 
understanding of the identified familial melanoma kindreds and of multiple primary 
melanoma patients through linkage to Swedish national registries.11,12,32,33 Further linkage to 
the Swedish Cancer Registry (established in 1958 with register completeness estimated to 
be 96%)34 provided data on all registered cancers in the CDKN2A genotyped individuals 
and their first and second-degree relatives. 
Additional Dutch melanoma families were recruited at the Department of Dermatology, 
Leiden University Medical Centre, according to the inclusion criteria of the GenoMEL study 
(http://www.genomel.org/). After providing written informed consent, melanoma patients 
were asked about their familial melanoma history. A melanoma family was defined by the 
presence of three or more cases with histologically-confirmed melanoma, or two cases 
with histologically-confirmed melanoma in first-degree relatives.
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DNA ANALYSIS
In the Dutch cohorts (both training and validation), DNA was extracted from whole blood 
samples of index patients and was used for sequencing of all coding exons of CDKN2A (1α, 
1β, 2 and 3), including exon/intron boundaries. To detect larger deletions or duplications, 
multiplex ligation-dependent probe amplification (MPLA) was performed. In the early years 
of CDKN2A diagnostics, analysis was limited to a mutation-specific PCR for the detection of 
the p16-Leiden mutation. However, only a very small subset of CDKN2A wild type families 
in the training cohort were analysed in this manner (n=32). In an additional 89 families from 
the training cohort, exon 1β was not sequenced. For the Swedish cohort, procedures used 
for PCR of all CDKN2A exons and direct sequencing of PCR products has been described 
previously.11 Presence of a CDKN2A mutation was defined as having either a pathogenic 
or likely pathogenic variant in the CDKN2A gene (class 4 or 5 variant)35 or an unclassified 
variant (class 3) shown to be located on a pathogenic CDKN2A haplotype. Classification 
of these variants was based on (previously reported) co-segregation with disease, strong 
evidence of impaired protein function, and in some families, shared pathogenic haplotypes.
STATISTICAL ANALYSIS 
Five clinical features were predefined and used for analysis: the number of first and 
second-degree family members (including the index patient) with (1) melanoma and (2) 
multiple primary melanomas (MPM), (3) the median age at diagnosis of (first) melanoma in 
the family and the presence of (4) pancreatic cancer (PC) and (5) upper airway cancer (UAC) 
in a family. Median age at diagnosis was divided into three age groups (<30 years, 30-50 
years and ≥50 years). A univariate analysis was performed to independently evaluate these 
features and a multivariate logistic regression model was used to assess the association 
between all five features and the presence of a germline CDKN2A mutation. The formula 
of the logistic regression model is P(robability)=eL/(1+eL) where L= constant + β1*C1 (number 
of family members with melanoma [1=0, 2=1, 3=2, ≥4=3]) + β2*C2 (number of family members 
with MPM [0=0, 1=1, ≥2=2]) + β3*C3 (median age at primary diagnosis [≥50=0, <50=1]) + β4*C4 
(presence of PC [No=0, Yes=1]) + β5*C5 (presence of UAC [No=0, Yes=1]), and where β is 
the feature-specific β-coefficient. All statistical analyses were carried out in SPSS (version 
23.0). 
DEVELOPMENT OF A SCORING SYSTEM: CM-SCORE 
The β-coefficients derived from the multivariate analysis were converted to points for each 
feature using the formula Points=(Cx*βC)/B (as described by Sullivan et al,36 where Cx is the 
feature-specific numeral from the logistic regression formula, βC is the β-coefficient and B 
is the fixed multiplier or constant [defined 0.22]). The total number of points was calculated 




the number of families with successive point totals (for instance, there were 6 families with 
21 points (33% mutation) and 37 families with 22 points (16% mutation)), the cohort was 
subsequently split into eight point-groups. This grouping would ensure a more accurate 
calculation of the observed mutation frequencies per group with narrower confidence 
intervals. For each of these groups, the observed mutation frequencies, the mean of the 
predicted probabilities and their 95% confidence intervals were calculated. The scoring 
system, CM- (CDKN2A Mutation) Score, was subsequently applied to the validation cohort, 
with the families split into the same point-groups as in the training cohort. The observed 
mutation frequencies and their 95% confidence intervals were again calculated for each 
group. The performance of the scoring system was assessed for both the training cohort 
and the validation cohort with the Hosmer-Lemeshow goodness of fit test (calibration) and 
Receiver Operator Characteristic (ROC) curve analysis with calculation of the Area Under 
the Curve (AUC) (discrimination). The slope of the calibration line was estimated with linear 
regression. The proposed cut-off value in CM-Score for performing CDKN2A analysis was 
determined as the score that corresponds to a predicted mutation probability of ~10%.26-28
RESULTS
TRAINING COHORT
A total of 1227 families were included in the study, 168 of which had a (likely) pathogenic variant 
in the CDKN2A gene (13.7%). The p16-Leiden founder mutation was present in 77% of these 
families (n=130) (supplementary table S1). Most of the families had two or more members with 
melanoma (853 families; 70%) and included 503 two-case families, 233 three-case families 
and 117 families with four or more melanoma cases. In 654 (77%) of these multiple-case families, 
at least one additional clinical feature was present (i.e. median age <50 years or presence of 
MPM, PC or UAC in the family, see supplementary table S2). In the 374 single-case families, 
207 families (55%) had at least two other clinical features and 150 families (40%) had one other 
clinical feature. The majority of melanomas in the training cohort were confirmed by histology 
reports (76%). Pancreatic cancer and upper airway cancer diagnoses were less frequently 
confirmed by the referring clinical geneticist (both 43%). 
UNIVARIATE AND MULTIVARIATE ANALYSIS
Having at least three family members with melanoma was significantly associated with the 
presence of a CDKN2A mutation in the univariate analysis (table 1). A median age of under 
50 years and one or more cases with multiple melanomas in a family were also significantly 
associated with a CDKN2A mutation. Age under 30 years at time of diagnosis did not result 
in a higher odds ratio than age 30 to 50 years (OR 5.1 [95% CI 2.5-10.4] versus OR 7.1 [95% 
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CI 4.1-12.3], respectively). A significantly increased risk for a CDKN2A mutation was seen in 
families in which pancreatic cancer and upper airway cancer co-occurred with melanoma; 
a mutation was present in 33% of the families with one or more pancreatic cancer patients 
and 46% of the families with one or more upper airway cancer patients. 
TABLE 1. Univariate analysis showing the independent association between each clinical feature 







OR* 95% CI P-Value
No. of family members with melanoma†
1 374 346 28 (7.5%) 1.0 - -
2 503 461 42 (8.3%) 1.1 0.7-1.9 0.641
3 233 194 39 (16.7%) 2.5 1.5-4.2 <0.001
≥4 117 58 59 (50.4%) 12.6 7.4-21.3 <0.001
No. of family members with MPM†
0 749 697 52 (6.9%) 1.0 - -
1 406 329 77 (19.0%) 3.1 2.2-4.6 <0.001
≥2 72 33 39 (54.2%) 15.8 9.2-27.3 <0.001
Median age at primary diagnosis
≥50 years 437 422 15 (3.4%) 1.0 - -
30-50 years 666 532 134 (20.1%) 7.1 4.1-12.3 <0.001
<30 years 124 105 19 (15.3%) 5.1 2.5-10.4 <0.001
Presence of pancreatic cancer¥
No 956 877 79 (8.3%) 1.0 - -
Yes 271 182 89 (32.8%) 5.4 3.9-7.6 <0.001
Presence of upper airway cancer¥
No 1117 999 118 (10.6%) 1.0 - -
Yes 110 60 50 (45.5%) 7.1 4.6-10.7 <0.001
MPM = multiple primary melanomas, OR = odds ratio, CI = confidence interval
* The variable with the smallest risk was defined as baseline with an odds ratio of 1.0, and odds ratios for the 
other variables were calculated against this baseline value. 
† First and second-degree relatives of each other; including the index patient
¥ First and second-degree relatives of the index patient and first-degree relatives of melanoma patients
In a multivariate logistic regression model, the five features investigated in the univariate 
model remained significantly associated with a mutation (table 2). Since in the univariate 
analysis age under 30 years was not a stronger predictor than age 30 to 50 years, these 
age groups were combined into one group (age <50 years) for the multivariate analysis. 




16.0]) and for presence of pancreatic or upper airway cancer in a family (OR 7.5; [95% 
CI 4.8-11.7] and OR 6.0 [95% CI 3.4-10.5], respectively), but these features had only two 
possible outcomes (<50 or ≥50 years, Yes or No), whereas the other melanoma-specific 
features had three or four possible outcomes and increasing odds ratios for each step. 
TABLE 2. Multivariate logistic regression model showing the association between all five clinical 
features combined and a germline CDKN2A mutation
Clinical feature β-coefficient OR 95% CI P-Value
No. of family members with melanoma (1, 2, 3, ≥4) 0.871 2.4 1.9-3.0 <0.001
No. of family members with MPM (0, 1, ≥2) 1.096 3.0 2.2-4.1 <0.001
Median age at primary diagnosis (≥50, <50) 2.142 8.5 4.5-16.0 <0.001
Presence of pancreatic cancer (No, Yes) 2.013 7.5 4.8-11.7 <0.001
Presence of upper airway cancer (No, Yes) 1.790 6.0 3.4-10.5 <0.001
MPM = multiple primary melanomas, OR = odds ratio, CI = confidence interval
The formula of the logistic regression model:
P= eL / (1+ eL ) where L= -6.220 + 0.871 x C1 (no. of family members with melanoma [1=0, 2=1, 3=2, ≥4=3]) + 
1.096 x C2 (no. of family members with MPM [0=0, 1=1, ≥2=2]) + 2.142 x C3 (median age at primary diagnosis 
[≥50=0, <50=1]) + 2.013 x C4 (presence of pancreatic cancer [No=0, Yes=1]) + 1.790 x C5 (presence of upper 
airway cancer [No=0, Yes=1])
CM-SCORE
The points assigned to each clinical feature are shown in table 3. The predicted mutation 
probabilities and observed mutation frequencies per point-group are shown in table 4. 
Below a total of 16 of 49 possible points, the predicted mutation probability is low (≤4.0%). 
Between 16 and 19 points, the predicted mutation probability is 9.9% and substantially 
increases in subsequent point-groups (20-23 points: 20.9%, 24-27 points: 34.7%, 28-31 
points: 52.1%, 32-35 points: 71.4%, ≥36 points: 90.7%). 
The concordance between observed and predicted mutation probabilities (calibration) is 
graphically displayed in figure 1A. The slope of the calibration line (1.03) indicates a good 
calibration, and the Hosmer-Lemeshow test (p=0.925) provided no evidence of a poor fit. 
Figure 2A shows the ROC curve analysis. The AUC is 0.89 (95% CI 0.86-0.92, p< 0.001), 
which indicates that the model has a good ability to discriminate between families with and 
without a CDKN2A mutation. The threshold of 10% predicted probability is approximated 
at the cut-off value of 16 points in CM-Score, with a sensitivity of 90.5% (95% CI 84.7-94.2) 
and a specificity of 68.0% (95% CI 65.1-70.8). The majority of families (n=736; 60%) had a 
CM-Score of less than 16 points. 
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TABLE 3. Scoring system (CM-Score) based on the multivariate logistic regression model
Features Points









Median age at primary diagnosis
≥50 years 0
<50 years 10
Presence of pancreatic cancer¥ 
No 0
Yes 9
Presence of upper airway cancer¥
No 0
Yes 8
MPM = multiple primary melanomas
† First and second-degree relatives of each other; including the index patient
¥ First and second-degree relatives of the index patient and first-degree relatives of melanoma patients
TABLE 4. Point totals from CM-Score with the corresponding mean predicted mutation 
probabilities and the observed mutation frequencies in the training and validation cohorts.
CM-Score Predicted mutation probability Observed mutation frequency
 Training cohort (n=1227) Validation cohort (n=421)
Points Prob. (%) 95% CI Freq. % 95% CI Freq. % 95% CI
≤11 1.0 0.9-1.0 4 / 383 1.0 0.4-2.7 0 / 159 0 0.0-2.4
12 – 15 4.0 3.9-4.1 12 / 353 3.4 2.0-5.9 4 / 166 2.4 0.9-6.0
16 – 19 9.9 9.8-10.1 26 / 203 12.8 8.9-18.1 4 / 38 10.5 4.2-24.1
20 – 23 20.9 20.4-21.4 18 / 99 18.2 11.8-26.9 1 / 17 5.9 1.1-27.0
24 – 27 34.7 33.1-36.3 23 / 75 30.7 21.4-41.8 4 / 12 33.3 13.8-60.9
28 – 31 52.1 49.4-54.7 16 / 32 50.0 33.6-66.4 4 / 6 66.7 30.0-90.3
32 – 35 71.4 69.6-73.1 30 / 40 75.0 59.8-85.8 5 / 7 71.4 35.9-91.8
≥36 90.7 89.0-92.4 39 / 42 92.9 81.0-97.5 16 / 16 100 80.6-100.0
The predicted mutation probability for each point-group is the mean of the predicted probabilities of the point 
totals in that group in the training cohort. The corresponding 95% confidence interval is estimated using the 
standard error of the mean.




EXTERNAL VALIDATION OF THE SCORING SYSTEM
The validation cohort consisted of a total of 421 families (403 from Sweden; 18 from the 
Netherlands), of which 38 had a (likely) pathogenic variant in the CDKN2A gene (9.0%). 
Most of these families (n=30; 79%) carried the Swedish founder mutation p.Arg112dup 
and two Dutch families carried the p16-Leiden founder mutation (supplementary table S3). 
The majority were multiple-case families (294 families; 70%) and included 232 two-case 
families, 37 three-case families and 25 families with four or more cases. All melanomas in 
the validation cohort were histologically confirmed. Pancreatic cancer was present in 29 
families (28 histologically confirmed; 72% CDKN2A mutation) and upper airway cancer in 
24 families (23 histologically confirmed; 63% CDKN2A mutation). 
The observed mutation frequencies per point-group in the validation cohort are shown in 
table 4. The performance of CM-Score in the validation cohort is displayed in figures 1B 
and 2B. The slope of the calibration line is 1.14 with a non-significant Hosmer-Lemeshow 
test (p=0.615). The AUC is 0.94 (95% CI 0.90-0.98, p<0.001), indicating good performance 
of CM-Score in the validation cohort. The sensitivity and specificity at the cut-off value of 
16 points is 89.5% (95% CI 74.3-96.6) and 83.8% (95% CI 79.6-87.3), respectively. Similar 
to the training cohort, the majority of families in the validation cohort (n=325; 77%) had a 
CM-Score of less than 16 points.
   1A. Training cohort     1B. Validation cohort
FIGURE 1. Calibration of CM-Score
The calibration line (red) is a linear regression line that shows the relation between observed mutation 
frequency and predicted mutation probability in the training cohort (A) and the validation cohort (B). 
The dashed line is the reference line of perfect calibration. The 95% confidence intervals of the 
observed mutation frequencies per point-group are displayed by the vertical lines.
HL-test = Hosmer-Lemeshow test
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  2A. Training cohort     2B. Validation cohort
FIGURE 2. Discriminative ability of CM-Score
Receiver Operator Characteristic (ROC) curve analysis of the training cohort (A) and the validation 
cohort (B).Point total was used as the test variable and mutation status was used as the state variable. 
Comparable results were obtained when the calculated predicted probability was used as test 
variable. 
AUC = Area Under the Curve
DISCUSSION
This study in a large Dutch training cohort of 1227 melanoma families confirmed the 
importance of four previously established clinical features that are associated with the 
presence of a germline CDKN2A mutation in a melanoma patient. Furthermore, a fifth 
feature, the presence of upper airway cancer in the family, could be validated. Based on 
these clinical features and their odds ratios in our multivariate logistic regression model, 
we developed the CM-Score system to predict CDKN2A mutation probability, which 
performed very well in a combined Swedish and Dutch external validation cohort (AUC 
0.94). At a cut-off value of 16 out of 49 points, the predicted probability approximates 
the commonly used 10% predicted probability threshold for germline gene sequencing in 
hereditary cancer, with a sensitivity of 89% and a specificity of 84% in the validation cohort. 
This cut-off value is also clinically relevant, since the majority of families in the training 
and validation cohorts scored less than 16 points (60% and 77%, respectively), a threshold 
below which the probability of a mutation decreases substantially (≤4%). Use of CM-Score 




relevant in countries where resources for genetic testing are limited. Conversely, in 
families with a high CM-Score and therefore high mutation probability, genetic testing is 
even more urgent. A scoring system should, however, always only complement the clinical 
judgment of the clinical geneticist requesting DNA diagnostics (for instance taking into 
account family size, age of family members, whether a patient has a certain combination of 
different malignancies and the availability of reliable medical information).
Risk models involving melanoma37 and CDKN2A mutation probability23,24 have been 
described previously. Niendorf et al incorporated the features (1) number of primary 
proband melanomas, (2) number of primary melanomas in the family and (3) age in a 
logistic regression model they named MELPREDICT.23 The AUC was 0.881 in the training 
set (n=116 families) and 0.803 in the external validation set (n=143 families). A computerized 
optimization of this model, renamed MelaPRO, was published in 2010, and outperformed 
the former model with an AUC of 0.86 in a validation set of 167 families.24 MelaPRO includes 
the same clinical (familial) features as MELPREDICT, but also takes into account regional 
melanoma incidence rates and the geographical penetrance of CDKN2A. In contrast, while 
our CM-Score was trained and validated using families of Northern European descent, its 
strength lies in its simple, non-computerized scoring system that incorporates five features 
(including the presence of pancreatic cancer and upper airway cancer in a family), and 
despite this simplicity shows a superior performance in very large sets of melanoma-prone 
families. 
The guidelines for CDKN2A mutation testing proposed by Leachman et al in 200925 were 
recently updated.38 In view of the recent reports of non-CDKN2A melanoma syndromes, 
such as those related to germline mutations in BAP139 (MIM 603089), POT140 (MIM 
606478) and MITF41 (MIM 156845), the authors propose tailored multi-gene panel testing 
in melanoma families instead of CDKN2A mutation testing alone. The 2009 criteria for 
genetic testing were converted into a points system, with points awarded for cancers that 
occur in so-called melanoma-dominant syndromes and melanoma-subordinate syndromes 
(where melanoma is not the predominant cancer type, such as in hereditary breast and 
ovarian cancer). Based on these points, the clinical geneticist can subsequently select the 
appropriate gene panel(s) to be tested in a family. In the selection and genetic assessment 
of melanoma families, this is a rather different approach to the one we propose in the 
current study. Firstly, CM-Score is designed for families where melanoma is the predominant 
cancer type. Secondly, since CDKN2A is still by far the major susceptibility gene in familial 
melanoma, we based the selection of families for genetic assessment on the probability 
of specifically detecting a CDKN2A mutation in these families. Because other melanoma-
dominant syndromes (such as those related to BAP1, POT1, CDK4 and MITF) are very 
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rare compared to CDKN2A-related familial melanoma (each gene contributing <1%),42 we 
hypothesize that the calculated mutation probability from CM-Score largely reflects the joint 
probability of detecting a germline CDKN2A mutation and other rare melanoma-dominant 
mutations. However, it should be noted that some tumors that are not part of CM-Score 
are highly specific to non-CDKN2A melanoma syndromes, especially BAP1-related tumors 
such as uveal melanoma and mesothelioma.43,44 BAP1 germline analysis should therefore 
be specifically offered when these tumors co-occur with cutaneous melanoma in a family, 
either together with CDKN2A or as part of a multi-gene panel test. It is not within the scope 
of this study to elaborate on the choice between multi-gene panel testing and CDKN2A 
mutation testing alone in melanoma-prone families. Although multi-gene panel testing 
increases the detection rate of cancer-predisposing germline mutations, there is also an 
elevated risk of identifying a variant of unknown significance in one of the genes and 
therefore increasing the uncertainty for a family regarding their genetic risk. The chance of 
this happening increases as more genes are included in a panel or when multiple panels 
are considered. Pros and cons of multi-gene panel testing should therefore always be 
carefully discussed with the patient.
Strengths of our study include relatively large and homogeneous cohorts and the broad 
analysis of five clinical features, including one more recently described feature (i.e. 
upper airway cancer). However, because the scoring system is based on populations 
with a high melanoma incidence, it is possible that it will underestimate the probability 
of finding a CDKN2A mutation in lower melanoma incidence areas such as Southern 
(Mediterranean) Europe or overestimate the probability in extreme incidence areas such 
as Australia. Additional validation in other geographical areas would therefore be valuable. 
Another limitation of our study is information bias. In the training cohort we had to rely on 
information supplied by the referring clinical geneticists and not all melanoma diagnoses 
were therefore histologically confirmed (76%). However, since the reporting of additional 
melanomas in family members by the index patient is known to be highly accurate, this 
factor is unlikely to have influenced the results.29 Unfortunately, only 43% of all pancreatic 
tumors and 43% of all upper airway tumors were confirmed. Nevertheless, all melanomas 
and other cancers in the validation cohort were verified since the majority of diagnoses 
were derived from the Swedish Cancer registry. 
In conclusion, we have developed and validated a non-computerized and clinically easy-
to-use scoring system that shows high utility in predicting the probability of a germline 
CDKN2A mutation in melanoma-prone families from Northern Europe. The scoring system 
is based on clinical information on melanoma diagnoses in the patient´s family, and 




trained and validated in large sets of Northern European families, we suggest that the 
system should be further validated in other regions as well. In view of the 10% mutation 
probability threshold, we suggest that CDKN2A analysis should be recommended to 
families with a CM-Score of ≥16 points. 
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SUPPLEMENTARY TABLE S1. Spectrum of (likely) pathogenic CDKN2A variants and variants of 






amino acid change No. of families
5’ UTR c.-34 G>T p.? None 4
Exon 1β‡ c.193+1G>A None p.? 5
c.193G>C None p.Gly65Arg 4
Exon 1α c.47T>G p.Leu16Arg None 2§
c.67G>C p.Gly23Arg None 8§
c.71G>C p.Arg24Pro None 2
c.131_132insAA p.Tyr44* None 1
c.143C>A p.Pro48Gln None 1
Exon 2 c.151-2A>G p.? p.? 1
c.159G>A p.Met53Ile p.Asp68Asn 2
c.203C>T p.Ala68Val p.Arg82Arg 2§
c.225_243del† p.Ala76Cysfs*64 p.Arg90Valfs*76 130
c.301G>T p.Gly101Trp p.Arg115Leu 2
c.352G>A p.Ala118Thr p.Gly132Asp 3§
Exon 
1+2+3
Deletion 155 kb of CDKN2A, 
CDKN2B and MTAP
Whole gene deletion Whole gene deletion 1
Total 168
¥ RefSeq NM_000077.4 isoform p16INK4a
‡ RefSeq NM_058195.3 isoform p14ARF
† p16-Leiden. Dutch founder mutation
§ located on pathogenic haplotype
115
7
CM-SCORE: A VALIDATED SCORING SYSTEM TO PREDICT CDKN2A GERMLINE MUTATIONS IN MELANOMA FAMILIES FROM 
NORTHERN EUROPE















5 + + + + +  18  18
4 + + + + - 42
+ + + - + 15
+ + - + + 1
+ - + + + 5
- + + + + 4   67
3 + + + - - 129
+ + - + - 17
+ + - - + 4
+ - + + - 30
+ - + - + 22
+ - - + + 4
- + + + - 23
- + + - + 6
- + - + + 0
- - + + + 8  243
2 + + - - - 69
+ - + - - 260
+ - - + - 32
+ - - - + 6
- + + - - 92
- + - + - 9
- + - - + 3
- - + + - 51
- - + - + 9
- - - + + 2  533
1 + - - - - 199
- + - - - 46
- - + - - 76
- - - + - 25
- - - - + 3  349
0 - - - - - 17    17
Total  1227




SUPPLEMENTARY TABLE S3. Spectrum of (likely) pathogenic CDKN2A variants in Swedish and 





amino acid change No. of families
Exon 1α c.83dup p.Arg29Alafs*15 None 1
c.134G>T p.Gly45Val None 1
c.143C>T p.Pro48Leu None 1
Exon 2 c.179_202del p.Ala60_Gly67del p.Gly75_Arg82del 1
c.225_243del† p.Ala76Cysfs*64 p.Arg90Valfs*76 2
c.241C>T p.Pro81Ser p.Thr95Ile 1
c.335_337dup‡ p.Arg112dup p.Ser127dup 30 
c.353C>T p.Ala118Val None (p.Gly132Gly) 1
Total 38
¥ RefSeq NM_000077.4 isoform p16INK4a
† p16-Leiden. Dutch founder mutation
‡ Swedish founder mutation
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Germline mutations in the major melanoma susceptibility gene CDKN2A explain genetic 
predisposition in only 10-40% of melanoma-prone families. In this study we comprehensively 
characterized 488 melanoma cases from 451 non-CDKN2A/CDK4 families for mutations in 
30 established and candidate melanoma susceptibility genes using a custom-designed 
targeted gene panel approach. We identified (likely) pathogenic variants in established 
melanoma susceptibility genes in 18 families (n=3 BAP1, n=15 MITF p.E318K; diagnostic 
yield 4.0%). Among the three identified BAP1-families, there were no reported diagnoses 
of uveal melanoma or malignant mesothelioma. We additionally identified two potentially 
deleterious missense variants in the telomere maintenance genes ACD and TERF2IP, but 
none in the POT1 gene. MC1R risk variants were strongly enriched in our familial melanoma 
cohort compared to healthy controls (R variants: OR 3.67, 95% CI 2.88-4.68, p<0.001). 
Several variants of interest were also identified in candidate melanoma susceptibility 
genes, in particular rare (pathogenic) variants in the albinism gene OCA2 were repeatedly 
found. We conclude that multi-gene panel testing for familial melanoma is appropriate 
considering the additional 4% diagnostic yield in non-CDKN2A/CDK4 families. Our study 





Cutaneous melanoma is the most aggressive type of common skin cancers and incidence 
has been increasing worldwide over the past decades.1 With an age-standardized rate of 
19.4 per 100.000, the Netherlands is among the countries with the highest incidence rates 
in the world, comparable to incidence rates in the northernmost European (Scandinavian) 
countries.2 Well-established personal and environmental risk factors for melanoma include a 
fair skin type, having (many) atypical nevi, a high level of ultraviolet radiation exposure, and a 
history of sunburns in childhood.3 A family history for the disease is also a significant risk factor 
and suggests a shared genetic predisposition among family members. This familial clustering 
occurs in approximately 5-10% of melanoma cases, and is referred to as familial melanoma.4
The major high-risk susceptibility gene for familial melanoma is CDKN2A and germline 
mutations are identified in 10-40% of familial cases.5,6 In the Netherlands, a specific 
founder mutation in CDKN2A, known as p16-Leiden (c.225_243del, p.A76Cfs*64; RefSeq 
NM_000077.4), is the most frequent cause of familial melanoma (~80% of CDKNA 
mutations). Carriers of this mutation show not only a markedly increased risk for (multiple) 
cutaneous melanomas, but also for other cancers, especially pancreatic cancer and 
cancers of the upper respiratory tract (larynx, pharynx, oral cavity).7,8 CDKN2A is an unusual 
gene in that it encodes two distinct proteins, p16INK4a and the alternatively spliced 
p14ARF, both of which are tumour-suppressors that act in two distinct pathways. The 
p16-retinoblastoma(Rb)-pathway controls cell-cycle G1-phase exit, while the p14ARF-p53 
pathway induces cell cycle arrest or apoptosis.9 Despite the major role of these pathways 
in melanoma susceptibility, only one other gene in the p16-retinoblastoma(Rb)-pathway, 
the CDK4 gene, has been shown to be associated with familial melanoma, and only a small 
number of families with germline mutations in this gene have been identified to date.10 
However, new melanoma susceptibility pathways have emerged in recent years.5,6 Several 
high-penetrance genes involved in telomere lengthening (TERT) or telomere maintenance 
(Shelterin complex: POT1, ACD, TERF2IP) have been identified, and mutations in these genes 
each account for approximately 1% of familial melanoma predisposition.11-13 Furthermore, 
germline mutations in the BRCA1-associated protein (BAP1) gene cause a specific cancer 
predisposition syndrome mainly characterized by an increased susceptibility for uveal 
melanoma and malignant mesothelioma, but also including cutaneous melanoma, renal 
cancer, basal cell carcinoma and characteristic skin lesions called atypical Spitz tumours 
(AST) or melanocytic BAP1–mutated atypical intradermal tumours (MBAIT).14 The MITF 
gene is a medium-penetrance melanoma susceptibility gene and shows incomplete co-
segregation with the phenotype. MITF is a basic-helix-loop-helix-leucine zipper transcription 
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factor that has a key function in melanocyte homeostasis. Loss-of-function mutations in this 
gene cause auditory-pigmentary syndromes, such as Waardenburg syndrome type 2A (MIM 
#193510). However, a specific missense variant (c.952G>A, p.E318K; RefSeq NM_000248.3) 
located in a small-ubiquitin-like modifier (SUMO) consensus site impairs the SUMOylation 
of MITF, which results in a gain-of-function increase in MITF transcriptional activity. Carriers 
of this variant have an approximately three- to fourfold increased risk for melanoma and 
are more likely to develop multiple primary melanomas.15 Several other cancers (renal 
cancer, pancreatic cancer) have also been reported in carriers of this variant.16,17 In addition 
to these known high- and medium-penetrance melanoma susceptibility genes, there are 
several well-established (common) variants in the lower-penetrance MC1R gene that are 
associated with an increased risk for melanoma in the general population. MC1R encodes 
the receptor for 𝛼-melanocyte stimulating hormone (𝛼-MSH), which plays an important 
role in skin pigmentation. Variants in MC1R that are most strongly associated with red 
hair color (RHC) confer an approximately twofold increased risk for melanoma (R variants), 
while other variants (r variants) show a weaker association with RHC (non-RHC) and confer 
a much smaller increase in risk for melanoma.18 It has also been shown that both R and 
r variants in MC1R act as modifiers of melanoma risk in families with a CDKN2A germline 
mutation.19 Furthermore, mutations in other cancer susceptibility genes have been recently 
reported in melanoma families in studies using mainly Whole Exome Sequencing (WES) 
technologies,20-22 but the exact role of these and other candidate melanoma susceptibility 
genes in the familial setting remains unclear and requires further evaluation.
Although Dutch melanoma families are well characterized for CDKN2A and CDK4 
mutations,23 no large scale investigation has yet been performed to identify (potential) 
deleterious variants in other established or candidate melanoma susceptibility genes. 
In the current study, we therefore sequenced a comprehensive panel of 30 (candidate) 
melanoma susceptibility genes in a large cohort of Dutch melanoma-prone families 
without a known CDKN2A or CDK4 mutation. Our goal was to determine the frequency of 
pathogenic variants in established melanoma susceptibility genes and to investigate the 
role of a broad range of candidate susceptibility genes in familial melanoma.
PATIENTS AND METHODS
PATIENT COHORT
Both cutaneous melanoma (CM) and uveal melanoma (UM) patients were eligible for inclusion 
in the study if they had at least one other relative (up to third-degree) with CM and/or UM, and 




or CDK4. Diagnostic sequencing of these two genes was performed at the Laboratory for 
Diagnostic Genome Analysis (LDGA) at the Department of Clinical Genetics of the Leiden 
University Medical Centre (LUMC), which has served as the primary sequencing facility for 
CDKN2A and CDK4 in the Netherlands since 1998. In a small minority of referred families, 
the CDKN2A gene was only partly sequenced and/or the CDK4 gene was not sequenced. 
Both genes were included in our research gene panel in order to exclude the presence of 
pathogenic variants in these genes. The study was approved by the LUMC Ethics Committee 
(#P15.341) and informed consent was obtained from all included individuals. 
We initially selected 500 patients from 460 families for inclusion in the study. After critical 
re-evaluation of these families, 11 samples were excluded from the analysis based on failure 
to meet above mentioned inclusion criteria. In one of these samples, a pathogenic variant 
in the 5‘UTR region of CDKN2A (c.-34G>T) was identified. Another sample was excluded 
because sequencing was unsuccessful. In total, 488 samples from 451 families remained 
for analysis (table 1). Most families had a proband with CM (n=446) and the majority of 
these probands had at least one other relative with CM (n=442 families; n=478 samples). 
This ‘familial CM’ subgroup included 208 two-case families (83% of which consisted of 
first-degree relatives), 182 three-case families and 52 families with four or more melanoma 
cases. An additional four probands with CM had one or more relatives with UM, but no 
CM. The remaining five families had a proband with UM and one or more relatives with UM 
and/or CM. A control cohort consisted of a total of 449 adult individuals sequenced at the 
LUMC for a non-melanoma, non-oncogenic indication (MODY; MIM #606391). MODY is an 
autosomal dominant form of diabetes mellitus which manifests in young adults. 
TABLE 1. Characteristics of the cohort
Proband history Family history No. of families No. of samples 
Cutaneous melanoma 
(CM)




4+ 52 62  
Total 446 483
Uveal melanoma (UM) Total no. of UM cases in familyb
1 2 2
2 3 3  
Total 5 5
Total 451 488
a Uveal melanoma was present in all four single-case families (one additional sample included), six two-case 
families, one three-case family and six families with four or more cases 
b Cutaneous melanoma was present in both single-case families and in one two-case family
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GENE SELECTION AND SEQUENCING 
A total of 30 genes were selected by a multidisciplinary expert team (TP, RvD, NG, FH, 
NvdS; July 2016) and incorporated into a custom-designed targeted gene panel. This 
included nine established melanoma susceptibility genes and an additional 21 candidate 
genes identified in previous studies (table 2). Sequencing of all coding exons, including 
exon-intron boundaries, was performed on the Illumina HiSeq4000 platform to yield 150 
basepair, paired-end reads. Targets were captured using a custom-designed, gene panel-
specific Agilent SureSelect XT Clearseq enrichment kit and sequenced using the 200 ng 
XT protocol. Capture, enrichment and sequencing were performed at the GenomeScan 
sequencing facility in Leiden (https://www.genomescan.nl/). Subsequent data analysis was 
performed using our in-house developed set-up for diagnostic next generation sequence 
(NGS) analysis. In brief, FastQ sequence data was analyzed using an in-house developed 
and stringent post-sequencing annotation pipeline (using BWA-GATK-VEP). 
Only variants that occurred with a minor allele frequency (MAF) of less than 5% in the 1000 
Genomes variant database were collected and annotated. Subsequent variant filtering and 
analysis was performed using a second in-house developed variant analysis tool called 
LOVDplus. Only variants that had an optimal Genotype Quality (GQ) score of 99 (range 
0-99) were considered for further interpretation. The obtained sequencing data had an 
average depth of >1000 (>99% at least 30x) with horizontal coverage >99%, and were 
aligned to human reference genome build GRCh37. Variants with an alternate read ratio of 
<0.2 were excluded. 
VARIANT SELECTION AND INTERPRETATION
We used Alamut® Visual (V.2.9.0, Interactive Biosoftware, Rouen, France) as an in silico 
tool for interpretation of the variants. In the primary filtering step, we selected exonic 
variants and intronic variants up to 10 nucleotides from the exon-intron junction with a MAF 
of less than 0.01 in the Exome Aggregation Consortium (ExAC; http://exac.broadinstitute.
org/) and Genome of the Netherlands (GoNL; http://nlgenome.nl) public variant databases. 
Synonymous variants without a possible effect on splicing were excluded. The functional 
effect of missense variants was predicted by the in silico tools SIFT (http://sift.jcvi.org/), Align 
GVGD (http://agvgd.hci.utah.edu/), PolyPhen-2 (http://genetics.bwh.harvard.edu/pph2/) and 
the CADD score (http://cadd.gs.washington.edu/). A further selection of variants of interest 
(secondary filtering) was based on the following criteria: 1) known pathogenic variants in 
literature, 2) truncating variants, 3) missense variants with a CADD score >15 and at least 
two out of three in silico protein prediction tools predicting a possible functional effect, 4) 
in-frame indels, and 5) variants that likely affect splicing (predicted by SpliceSiteFinder-like, 




TABLE 2. List of genes included in the panel
  Gene Full Name Alt. 
Name
MIM no. Refs.
Established melanoma susceptibility genes
High to medium penetrance:
Reviewed in: 
Aoude et al.,5
Read et al.6 
CDKN2A Cyclin-Dependent Kinase Inhibitor 2A 600160
CDK4 Cyclin-Dependent Kinase 4  123829
BAP1 BRCA1-Associated Protein 1 603089
POT1 Protection of Telomeres 1 606478
ACD Adrenocortical Dysplasia Homolog TPP1 609377
TERF2IP TERF2-Interacting Protein RAP1 605061
TERT Telomerase Reverse Transcriptase 187270
MITF Microphthalmia-Associated Transcription Factor 156845
Low to medium penetrance:
MC1R Melanocortin 1 receptor 155555
Shelterin complex candidate genes
TERF1 Telomeric Repeat-Binding Factor 1 TRF1 600951
Aoude et al.12TERF2 Telomeric Repeat-Binding Factor 2 TRF2 602027
TINF2 TERF1-Interacting Nuclear Factor 2 TIN2 604319
Candidate genes from WES/WGS and GWA studies
BRIP1 BRCA1-Interacting Protein 1 605882 Tuominen et al.22
RAD51B RAD51 Paralog B RAD51L1 602948 Wadt et al.21
POLE DNA Polymerase Epsilon 174762 Aoude et al.20
NEK2 NIMA-Related Kinase 2 604043 -
NEK4 NIMA-Related Kinase 4 601959 -
NEK10 NIMA-Related Kinase 10 - -
NEK11 NIMA-Related Kinase 11 609779 -
DOT1L DOT1-Like Histone Lysine Methyltransferase 607375 -
PARP1 Poly (ADP-Ribose) Polymerase 1 173870 -
CENPS Centromere Protein S APITD1 609130 -
CREB3L1 CAMP Responsive Element Binding Protein 3 Like 1 616215 -
MLLT6 Mixed-Lineage Leukemia, 
Translocated to, 6
600328 -
ERCC3 ERCC Excision Repair 3 133510 -
CBLB Cbl Proto-Oncogene B 604491 -
Other candidate genes 
PTEN Phosphatase and Tensin Homolog 601728 Bubien et al.48
RASEF RAS and EF-Hand Domains-Containing Protein 611344 Maat et al.49
POLH DNA Polymerase Eta 603968 Di Lucca et al. 50
OCA2 OCA2 Melanosomal Transmembrane Protein 611409 Hawkes et al. 45
MIM = Mendelian Inheritance in Man (http://www.omim.org)
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Analysis of the POLE gene was confined to variants in the exonuclease domain (exon 
9-14),20 while analysis of CDK4, TERT, MITF and MC1R was restricted to specific variants 
known to be associated with an increased melanoma risk. This included the p.R24H and 
p.R24C variants in CDK4,10 the c.-57T>G promoter variant in TERT,13 the p.E318K variant 
in MITF,15 and the R and r variants in MC1R.18 Co-segregation analysis of the detected 
variants was possible for families in which more than one case was included in the study. 
Finally, all variants of interest were evaluated using a recently published in silico prediction 
tool, UMD-predictor (http://umd-predictor.eu/). This tool uses a combinatorial approach to 
predict pathogenicity of coding single nucleotide variants by pooling information at the 
nucleotide level, the protein level and at the mRNA level, and has an exceptionally good 
reported performance.24
RESULTS
In our cohort of 488 samples (451 families), a total of 171 variants passed our primary filtering 
criteria (see supplementary table S1). These included 151 exonic variants, of which eight 
were truncating (four frameshift, four nonsense), 138 missense, three in-frame indels, and 
two synonymous variants with a possible effect on splicing. The remaining 20 variants 
were intronic. Of the 171 variants, 44 were novel (not reported in the reference databases 
ExAC and GoNL), 41 were extremely rare (MAF<0.0001), 29 were very rare (MAF<0.001), 
and the remaining 57 variants were rare (MAF<0.01). Subsequent filtering resulted in 60 
variants of interest in 20 genes (tables 3-5). These selected variants were only detected 
in probands with CM and in none of the probands with UM. The MC1R risk variants were 
separately analyzed (table 6).
VARIANTS OF INTEREST IN ESTABLISHED MELANOMA SUSCEPTIBILITY GENES AND 
SHELTERIN COMPLEX GENES 
We detected two novel splice variants and one novel truncating variant in the BAP1 gene 
in three probands (0.7% of families) (table 3). The c.122+1G>T, p.? and c.1730-1G>A, p.? 
variants are both located in a canonical splice site and are predicted to inactivate the splice 
donor site of intron 3 and splice acceptor site of intron 13, respectively, likely resulting in 
a prematurely truncated protein. The c.1936_1937insTT, p.(Y646Ffs*10) frameshift variant 
is also predicted to cause a truncated protein due to a premature stop codon. All three 
families had multiple members with CM (see supplementary figure S1). In two families, 
possible BAP1-associated nevi (Spitz nevi) were reported in first-degree relatives, and in 





No other BAP1-specific tumours, such as UM, malignant mesothelioma or renal cell 
carcinoma, were reported in these families. Interestingly, in the proband who carried the 
BAP1 c.122+1G>T, p.? variant we also identified a novel nonsense variant in the BRIP1 gene 
(c.894C>A, p.(C298*)). Ovarian cancer was not reported in this family. 
The MITF p.E318K risk variant was detected in a total of fifteen probands (3.3%), a frequency 
more than twice that of the Dutch reference population (MAF 0.015; GoNL: 0.007) (table 3). 
All MITF p.E318K families had at least two members with CM (‘familial CM’; seven two-case 
families, six three-case families, and two families with four or more cases). The median age 
of probands at melanoma diagnosis was 41 years (range 27-74). One proband had multiple 
primary melanomas, a feature also present in two additional families. Renal cancer and 
pancreatic cancer were present in two families and in one family, respectively.
In the three shelterin complex subunits that have been reported as high-penetrance 
melanoma susceptibility genes (POT1, ACD, TERF2IP), we identified two potentially 
deleterious variants (table 3). A rare missense variant in the ACD gene (c.871A>G, p.(T291A)), 
detected in a proband from a two-case family, is located in the POT1 binding domain in which 
previously reported pathogenic variants seem to cluster.12 A very rare missense variant in 
the TERF2IP gene (c.398G>A, p.(R133Q)), located in the MyB DNA binding domain, was 
detected in a proband of another two-case family. These variants had a CADD score >20 
and were predicted to be damaging by at least two in silico tools, although UMD-predictor 
classified both variants as polymorphisms. Remarkably, we did not detect any potentially 
deleterious variants in the POT1 gene. In the other shelterin complex subunit genes TERF1, 
TERF2 and TINF2, we identified eight potentially deleterious variants (six missense, two 
in-frame dups) (table 3). These included a novel variant in the ACD/TERF2 binding motif 
domain of the TINF2 gene (c.38G>T, p.(R13L)) and two extremely rare variants in the TERF1 
gene (c.1193A>G, p.(Y398C); MyB DNA binding domain) and the TERF2 gene (c.794G>A, 
p.(R265H)). An in-frame duplication in the TERF1 gene (c.186_188dup, p.(E62dup); telomeric 
 repeat binding factor homology domain) was shared among two third-degree relatives 
with CM in one family, but as this is a common variant in Asian and African populations 
(MAF ~2% in ExAC) it is unlikely to be pathogenic. None of the patients in our cohort carried 
the known melanoma susceptibly variant in the TERT promoter region (c.-57T>G). 
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Gene Variant Type Allele count MAF (AN=976) MAF in ExACa / GoNL CADD SIFT Align GVGDb PolyPhen-2c UMD-Predictor FD CoSe
Established melanoma susceptibility genes
ACD c.871A>G, p.(Thr291Ala) missense 1 0.0010025 0.0012/0.001 23.2 delet. C55 prob. damaging polymorphism Y
BAP1 c.122+1G>T, p.? splicing 1 0.0010025 -/- Y
BAP1 c.1730-1G>A, p.? splicing 1 0.0010025 -/- Y
BAP1 c.1936_1937insTT, p.(Tyr646Phefs*10) frameshift 1 0.0010025 -/- Y
MITF c.952G>A, p.(Glu318Lys) missense 15 0.015369 0.0025/0.007 27.9 tol. C0 prob. damaging prob. polymorphism Y
TERF2IP c.398G>A, p.(Arg133Gln) missense 1 0.0010025 0.00022/- 23.4 delet. C35 benign polymorphism Y
Shelterin complex candidate genes
TERF1 c.186_188dup, p.(Glu62dup) in-frame
duplication
2 0.002049 0.0005/-d Y Y
TERF1 c.212_217dup, p.(Glu71_Ala72dup) in-frame
duplication
1 0.0010025 0.00014/- Y
TERF1 c.1193A>G, p.(Tyr398Cys) missense 1 0.0010025 0.000009/- 24.7 delet. C25 prob. damaging pathogenic Y
TERF2 c.56A>G, p.(Asp19Gly) missense 1 0.0010025 0.00012/- 16.35 delet. C0 pos. damaging n.a. N
TERF2 c.794G>A, p.(Arg265His) missense 1 0.0010025 0.000027/- 28.3 delet. C0 pos. damaging prob. polymorphism N
TERF2 c.1492G>A, p.(Glu498Lys) missense 4 0.004098 0.0022/0.003 34 delet. C55 pos. damaging prob. polymorphism Y
TINF2 c.38G>T, p.(Arg13Leu) missense 1 0.0010025 -/- 27 delet. C0 prob. damaging pathogenic Y
TINF2 c.734C>A, p.(Ser245Tyr) missense 3 0.003074 0.00073/- 22.7 delet. C15 benign polymorphism N
TABLE 3. Selected variants of interest in established melanoma susceptibility genes and shelterin 
complex candidate genes
Gene reference sequences: ACD: NM_001082486.1, BAP1: NM_004656.3, MITF: NM_000248.3, TERF2IP: 
NM_018975.3, TERF1: NM_017489.2, TERF2: NM_005652.4, TINF2: NM_001099274.1 
AN = allele number, MAF = minor allele frequency, CADD = Combined Annotation Dependent Depletion, FD 
= in known functional domain, CoS = co-segregation with melanoma in one or more families, Y = yes, N = no, 
delet = deleterious, pos = possibly, prob = probably
a In European (Non-Finnish) population
b Possible classifications in Align GVGD are C0, C15, C25, C35, C45, C55 and C65. Variants in class C0 have 
the least probability of being pathogenic, variants in class C65 have the highest probability of being pathogen-
ic. See also http://agvgd.hci.utah.edu/classifiers.php 
c HumVar trained PolyPhen-2 model used for prediction
d Common variant (MAF>1%) in one or more non-European populations




Gene Variant Type Allele count MAF (AN=976) MAF in ExACa / GoNL CADD SIFT Align GVGDb PolyPhen-2c UMD-Predictor FD CoSe
Established melanoma susceptibility genes
ACD c.871A>G, p.(Thr291Ala) missense 1 0.0010025 0.0012/0.001 23.2 delet. C55 prob. damaging polymorphism Y
BAP1 c.122+1G>T, p.? splicing 1 0.0010025 -/- Y
BAP1 c.1730-1G>A, p.? splicing 1 0.0010025 -/- Y
BAP1 c.1936_1937insTT, p.(Tyr646Phefs*10) frameshift 1 0.0010025 -/- Y
MITF c.952G>A, p.(Glu318Lys) missense 15 0.015369 0.0025/0.007 27.9 tol. C0 prob. damaging prob. polymorphism Y
TERF2IP c.398G>A, p.(Arg133Gln) missense 1 0.0010025 0.00022/- 23.4 delet. C35 benign polymorphism Y
Shelterin complex candidate genes
TERF1 c.186_188dup, p.(Glu62dup) in-frame
duplication
2 0.002049 0.0005/-d Y Y
TERF1 c.212_217dup, p.(Glu71_Ala72dup) in-frame
duplication
1 0.0010025 0.00014/- Y
TERF1 c.1193A>G, p.(Tyr398Cys) missense 1 0.0010025 0.000009/- 24.7 delet. C25 prob. damaging pathogenic Y
TERF2 c.56A>G, p.(Asp19Gly) missense 1 0.0010025 0.00012/- 16.35 delet. C0 pos. damaging n.a. N
TERF2 c.794G>A, p.(Arg265His) missense 1 0.0010025 0.000027/- 28.3 delet. C0 pos. damaging prob. polymorphism N
TERF2 c.1492G>A, p.(Glu498Lys) missense 4 0.004098 0.0022/0.003 34 delet. C55 pos. damaging prob. polymorphism Y
TINF2 c.38G>T, p.(Arg13Leu) missense 1 0.0010025 -/- 27 delet. C0 prob. damaging pathogenic Y
TINF2 c.734C>A, p.(Ser245Tyr) missense 3 0.003074 0.00073/- 22.7 delet. C15 benign polymorphism N
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Gene Variant Type Allele count MAF (AN=976) MAF in ExACa / GoNL CADD SIFT Align GVGDb PolyPhen-2c UMD-Predictor FD CoSe
BRIP1 c.517C>T, p.(Arg173Cys) missense 9 0.009221 0.0047/0.004 27.6 delet. C55 prob. damaging pathogenic Y
BRIP1 c.790C>T, p.(Arg264Trp) missense 1 0.0010025 0.0012/0.003 32 delet. C0 prob. damaging pathogenic Y
BRIP1 c.894C>A, p.(Cys298*) nonsense 1 0.0010025 -/- 36 pathogenic Y
BRIP1 c.1198G>T, p.(Asp400Tyr) missense 2 0.002049 0.000027/- 33 delet. C35 prob. damaging pathogenic Y
BRIP1 c.1255C>T, p.(Arg419Trp) missense 1 0.0010025 0.00046/0.001 33 delet. C35 prob. damaging pathogenic Y N
BRIP1 c.2069G>A, p.(Gly690Glu) missense 1 0.0010025 -/- 32 delet. C65 prob. damaging pathogenic Y
BRIP1 c.2582C>G, p.(Ser861Cys) missense 1 0.0010025 0.000027/- 28.5 delet. C65 prob. damaging pathogenic Y
BRIP1 c.2593C>T, p.(Arg865Trp) missense 1 0.0010025 0.000027/- 34 delet. C25 prob. damaging pathogenic Y N
POLE c.861T>A, p.(Asp287Glu) missense 9 0.009221 0.0017/0.004 25.7 delet. C35 prob. damaging pathogenic Y
POLE c.893A>G, p.(Tyr298Cys) missense 1 0.0010025 -/- 28.3 delet. C65 prob. damaging pathogenic Y
POLE c.1230G>A, p.(Trp410*) nonsense 1 0.0010025 -/- 38 pathogenic Y N
OCA2 c.163del, p.(Ala55Leufs*47)f frameshift 1 0.0010025 0.000019/- N
OCA2 c.796C>T, p.(Arg266Trp) missense 1 0.0010025 0.0018/0.003d 18.24 delet. C0 pos. damaging prob. polymorphism N
OCA2 c.1255C>T, p.(Arg419Trp)f missense 1 0.0010025 0.00011/- 32 delet. C0 prob. damaging pathogenic Y
OCA2 c.1261C>T, p.(Arg421Trp) missense 1 0.0010025 0.000065/- 28 delet. C0 prob. damaging pathogenic Y N
OCA2 c.1327G>A, p.(Val443Ile)f missense 18 0.018443 0.0051/0.008 34 tol. C0 prob. damaging polymorphism Y N
OCA2 c.1441G>A, p.(Ala481Thr)f missense 1 0.0010025 0.0026/0.001d 27.6 tol. C0 pos. damaging prob. polymorphism Y
OCA2 c.1465A>G, p.(Asn489Asp)f missense 7 0.007172 0.0007/0.003 28.2 delet. C0 prob. damaging pathogenic Y Y
OCA2 c.1592A>G, p.(Tyr531Cys) missense 1 0.0010025 0.00011/0.001 25.3 delet. C0 prob. damaging pathogenic Y
OCA2 c.2037G>C, p.(Trp679Cys)f missense 1 0.0010025 0.00015/- 34 delet. C0 prob. damaging pathogenic Y
TABLE 4. Selected variants of interest in candidate melanoma susceptibility genes BRIP1, POLE 
and OCA2
Gene reference sequences: BRIP1: NM_032043.2, POLE: NM_006231.2, OCA2: NM_000275.2
AN = allele number, MAF = minor allele frequency, CADD = Combined Annotation Dependent Depletion, 
FD = in known functional domain, CoS = co-segregation with melanoma in one or more families, Y = yes, N = 
no, delet = deleterious, pos = possibly, prob = probably
a In European (Non-Finnish) population
b Possible classifications in Align GVGD are C0, C15, C25, C35, C45, C55 and C65. Variants in class C0 have 
the least probability of being pathogenic, variants in class C65 have the highest probability of being pathogen-
ic. See also http://agvgd.hci.utah.edu/classifiers.php 
c HumVar trained PolyPhen-2 model used for prediction
d Common variant (MAF>1%) in one or more non-European populations
e Co-segregation analyses of variants with melanoma phenotype: BRIP1 p.R419W: 1/2, BRIP1 p.R865W: 1/2, 
OCA2 p.R421W: 1/2, OCA2 p.V443I: 1/2 (two families), OCA2 p.N489D: 3/3 (one family), POLE p.W410*: 1/2




Gene Variant Type Allele count MAF (AN=976) MAF in ExACa / GoNL CADD SIFT Align GVGDb PolyPhen-2c UMD-Predictor FD CoSe
BRIP1 c.517C>T, p.(Arg173Cys) missense 9 0.009221 0.0047/0.004 27.6 delet. C55 prob. damaging pathogenic Y
BRIP1 c.790C>T, p.(Arg264Trp) missense 1 0.0010025 0.0012/0.003 32 delet. C0 prob. damaging pathogenic Y
BRIP1 c.894C>A, p.(Cys298*) nonsense 1 0.0010025 -/- 36 pathogenic Y
BRIP1 c.1198G>T, p.(Asp400Tyr) missense 2 0.002049 0.000027/- 33 delet. C35 prob. damaging pathogenic Y
BRIP1 c.1255C>T, p.(Arg419Trp) missense 1 0.0010025 0.00046/0.001 33 delet. C35 prob. damaging pathogenic Y N
BRIP1 c.2069G>A, p.(Gly690Glu) missense 1 0.0010025 -/- 32 delet. C65 prob. damaging pathogenic Y
BRIP1 c.2582C>G, p.(Ser861Cys) missense 1 0.0010025 0.000027/- 28.5 delet. C65 prob. damaging pathogenic Y
BRIP1 c.2593C>T, p.(Arg865Trp) missense 1 0.0010025 0.000027/- 34 delet. C25 prob. damaging pathogenic Y N
POLE c.861T>A, p.(Asp287Glu) missense 9 0.009221 0.0017/0.004 25.7 delet. C35 prob. damaging pathogenic Y
POLE c.893A>G, p.(Tyr298Cys) missense 1 0.0010025 -/- 28.3 delet. C65 prob. damaging pathogenic Y
POLE c.1230G>A, p.(Trp410*) nonsense 1 0.0010025 -/- 38 pathogenic Y N
OCA2 c.163del, p.(Ala55Leufs*47)f frameshift 1 0.0010025 0.000019/- N
OCA2 c.796C>T, p.(Arg266Trp) missense 1 0.0010025 0.0018/0.003d 18.24 delet. C0 pos. damaging prob. polymorphism N
OCA2 c.1255C>T, p.(Arg419Trp)f missense 1 0.0010025 0.00011/- 32 delet. C0 prob. damaging pathogenic Y
OCA2 c.1261C>T, p.(Arg421Trp) missense 1 0.0010025 0.000065/- 28 delet. C0 prob. damaging pathogenic Y N
OCA2 c.1327G>A, p.(Val443Ile)f missense 18 0.018443 0.0051/0.008 34 tol. C0 prob. damaging polymorphism Y N
OCA2 c.1441G>A, p.(Ala481Thr)f missense 1 0.0010025 0.0026/0.001d 27.6 tol. C0 pos. damaging prob. polymorphism Y
OCA2 c.1465A>G, p.(Asn489Asp)f missense 7 0.007172 0.0007/0.003 28.2 delet. C0 prob. damaging pathogenic Y Y
OCA2 c.1592A>G, p.(Tyr531Cys) missense 1 0.0010025 0.00011/0.001 25.3 delet. C0 prob. damaging pathogenic Y
OCA2 c.2037G>C, p.(Trp679Cys)f missense 1 0.0010025 0.00015/- 34 delet. C0 prob. damaging pathogenic Y
131
8
MULTI-GENE PANEL SEQUENCING OF ESTABLISHED AND CANDIDATE MELANOMA SUSCEPTIBILITY GENES IN A LARGE COHORT 
OF DUTCH NON-CDKN2A/CDK4 MELANOMA FAMILIES
Gene Variant Type Allele count MAF (AN=976) MAF in ExACa / GoNL CADD SIFT Align GVGDb PolyPhen-2c UMD-Predictor FD CoSe
CBLB c.770A>T, p.(His257Leu) missense 1 0.0010025 -/- 33 delet. C0 prob. damaging pathogenic Y
CBLB c.1402C>G, p.(Arg468Gly) missense 1 0.0010025 0.000018/- 23.6 delet. C0 pos. damaging pathogenic Y
ERCC3 c.496G>A, p.(Val166Ile) missense 1 0.0010025 -/- 24.6 delet. C25 benign prob. polymorphism Y
ERCC3 c.847C>T, p.(Arg283Cys) missense 5 0.005123 0.0014/0.002 34 delet. C65 benign pathogenic Y N
ERCC3 c.1421dup, p.(Asp474Glufs*2) frameshift 1 0.0010025 0.00014/- Y
ERCC3 c.1776T>G, p.(Ile592Met) missense 1 0.0010025 -/- 24.9 delet. C0 prob. damaging prob. pathogenic Y
ERCC3 c.2111C>T, p.(Ser704Leu) missense 2 0.002049 0.0022/0.001 24 delet. C15 benign pathogenic N N
MLLT6 c.655C>T, p.(Arg219Trp) missense 1 0.0010025 0.000064/- 25.2 delet. C15 pos. damaging pathogenic N
MLLT6 c.2195A>C, p.(Glu732Ala) missense 1 0.0010025 -/- 24.6 delet. C0 prob. damaging pathogenic Y
MLLT6 c.2755G>A, p.(Gly919Arg) missense 1 0.0010025 -/- 26.2 delet. C0 pos. damaging pathogenic N
NEK2 c.97-2A>G splicing 1 0.0010025 0.00029/- Y
NEK2 c.137A>G, p.(Glu46Gly) missense 1 0.0010025 -/- 28 delet. C0 prob. damaging pathogenic Y N
NEK2 c.952C>T, p.(Arg318*) nonsense 1 0.0010025 0.000018/- 39 pathogenic Y





1 0.0010025 0.0011/0.002 N
NEK4 c.2093+1G>C splicing 1 0.0010025 -/- N
NEK10 c.1094G>A, p.(Arg365Gln) missense 7 0.007172 0.0094/0.009 25.2 delet. C0 pos. damaging polymorphism N Y
NEK11 c.127G>C, p.(Val43Leu) missense 2 0.002049 0.00016/-d 27.5 delet. C25 pos. damaging prob. polymorphism Y
PARP1 c.1814C>T, p.(Pro605Leu) missense 1 0.0010025 0.000036/- 22.6 delet. C15 benign pathogenic Y
PARP1 c.2656G>A, p.(Val886Met) missense 1 0.0010025 0.000027/- 32 delet. C0 prob. damaging pathogenic Y
POLH c.626G>T, p.(Gly209Val) missense 2 0.002049 0.0032/0.003d 28.1 delet. C15 prob. damaging prob. polymorphism Y
POLH c.890G>A, p.(Trp297*) nonsense 1 0.0010025 -/- 40 pathogenic Y Yf
RASEF c.157C>T, p.(Arg53Trp) missense 1 0.0010025 0.000049/- 28.4 delet. C0 prob. damaging prob. pathogenic Y
RASEF c.1049_1050del,
p.(His350Argfs*3)
frameshift 1 0.0010025 0.000063/- Y
RASEF c.2078A>G, p.(Asp693Gly) missense 1 0.0010025 0.000018/- 32 delet. C0 pos. damaging pathogenic Y
RASEF c.2207A>T, p.(Asn736Ile) missense 1 0.0010025 0.000027/- 27.4 delet. C0 pos. damaging pathogenic Y
TABLE 5. Selected variants of interest in candidate melanoma susceptibility genes (excluding 
BRIP1, POLE and OCA2)
Gene reference sequences: CBLB: NM_170662.4, ERCC3: NM_000122.1, MLLT6: NM_005937.3, NEK2: 
NM_002497.3, NEK4: NM_003157.5, NEK10: NM_152534.4, NEK11: NM_024800.4, PARP1: NM_001618.3, POLH: 
NM_006502.2, RASEF: NM_152573.3
AN = allele number, MAF = minor allele frequency, CADD = Combined Annotation Dependent Depletion, FD 
= in known functional domain, CoS = co-segregation with melanoma in one or more families, Y = yes, N = no, 
delet = deleterious, pos = possibly, prob = probably
a In European (Non-Finnish) population
b Possible classifications in Align GVGD are C0, C15, C25, C35, C45, C55 and C65. Variants in class C0 have 
the least probability of being pathogenic, variants in class C65 have the highest probability of being pathogen-
ic. See also http://agvgd.hci.utah.edu/classifiers.php 
c HumVar trained PolyPhen-2 model used for prediction




Gene Variant Type Allele count MAF (AN=976) MAF in ExACa / GoNL CADD SIFT Align GVGDb PolyPhen-2c UMD-Predictor FD CoSe
CBLB c.770A>T, p.(His257Leu) missense 1 0.0010025 -/- 33 delet. C0 prob. damaging pathogenic Y
CBLB c.1402C>G, p.(Arg468Gly) missense 1 0.0010025 0.000018/- 23.6 delet. C0 pos. damaging pathogenic Y
ERCC3 c.496G>A, p.(Val166Ile) missense 1 0.0010025 -/- 24.6 delet. C25 benign prob. polymorphism Y
ERCC3 c.847C>T, p.(Arg283Cys) missense 5 0.005123 0.0014/0.002 34 delet. C65 benign pathogenic Y N
ERCC3 c.1421dup, p.(Asp474Glufs*2) frameshift 1 0.0010025 0.00014/- Y
ERCC3 c.1776T>G, p.(Ile592Met) missense 1 0.0010025 -/- 24.9 delet. C0 prob. damaging prob. pathogenic Y
ERCC3 c.2111C>T, p.(Ser704Leu) missense 2 0.002049 0.0022/0.001 24 delet. C15 benign pathogenic N N
MLLT6 c.655C>T, p.(Arg219Trp) missense 1 0.0010025 0.000064/- 25.2 delet. C15 pos. damaging pathogenic N
MLLT6 c.2195A>C, p.(Glu732Ala) missense 1 0.0010025 -/- 24.6 delet. C0 prob. damaging pathogenic Y
MLLT6 c.2755G>A, p.(Gly919Arg) missense 1 0.0010025 -/- 26.2 delet. C0 pos. damaging pathogenic N
NEK2 c.97-2A>G splicing 1 0.0010025 0.00029/- Y
NEK2 c.137A>G, p.(Glu46Gly) missense 1 0.0010025 -/- 28 delet. C0 prob. damaging pathogenic Y N
NEK2 c.952C>T, p.(Arg318*) nonsense 1 0.0010025 0.000018/- 39 pathogenic Y





1 0.0010025 0.0011/0.002 N
NEK4 c.2093+1G>C splicing 1 0.0010025 -/- N
NEK10 c.1094G>A, p.(Arg365Gln) missense 7 0.007172 0.0094/0.009 25.2 delet. C0 pos. damaging polymorphism N Y
NEK11 c.127G>C, p.(Val43Leu) missense 2 0.002049 0.00016/-d 27.5 delet. C25 pos. damaging prob. polymorphism Y
PARP1 c.1814C>T, p.(Pro605Leu) missense 1 0.0010025 0.000036/- 22.6 delet. C15 benign pathogenic Y
PARP1 c.2656G>A, p.(Val886Met) missense 1 0.0010025 0.000027/- 32 delet. C0 prob. damaging pathogenic Y
POLH c.626G>T, p.(Gly209Val) missense 2 0.002049 0.0032/0.003d 28.1 delet. C15 prob. damaging prob. polymorphism Y
POLH c.890G>A, p.(Trp297*) nonsense 1 0.0010025 -/- 40 pathogenic Y Yf
RASEF c.157C>T, p.(Arg53Trp) missense 1 0.0010025 0.000049/- 28.4 delet. C0 prob. damaging prob. pathogenic Y
RASEF c.1049_1050del,
p.(His350Argfs*3)
frameshift 1 0.0010025 0.000063/- Y
RASEF c.2078A>G, p.(Asp693Gly) missense 1 0.0010025 0.000018/- 32 delet. C0 pos. damaging pathogenic Y
RASEF c.2207A>T, p.(Asn736Ile) missense 1 0.0010025 0.000027/- 27.4 delet. C0 pos. damaging pathogenic Y
e Co-segregation analyses of variants with melanoma phenotype: ERCC3 p.R283C: 1/2 (one family), ERCC3 
p.S704L: 1/2 (one family), NEK2 p.E46G: 1/2, NEK10 p.R365Q: 2/2 (one family)
f The proband with the POLH p.W297* variant had a father with the recessively inherited disease xeroderma 
pigmentosum (MIM #278750) and he is therefore highly likely to have carried this variant as well
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Since we were particularly interested in the frequency of MC1R risk variants in familial CM 
cases, we only analyzed the MC1R gene in the ‘familial CM’ subgroup (n=478 individuals). 
In this cohort, we observed a substantial enrichment of R variants compared to controls 
(OR 3.67, 95% CI 2.88-4.68, p<0.001) (table 6). The frequency of p.D84E was most strikingly 
increased in our cohort (OR 5.66, 95% CI 1.88-17.06, p=0.001), followed by p.R160W (OR 
3.82, 95% CI 2.72-5.37, p<0.001) and p.R151C (OR 3.78, 95% CI 2.68-5.34, p<0.001). Although 
less prominent, r variants were also enriched in familial CM cases (any r variant: OR 1.53, 
95% CI 1.22-1.91, p<0.001).
TABLE 6. Association of MC1R risk variants with familial cutaneous melanoma
familial CM cohorta 
(AN=956)
control cohorta 
(AN=898) OR 95% CI p valueb
No. of individuals 478 449  
Reference sequencec 388 549 Ref. Ref. Ref.
All R variants 0.342 0.140 3.67 2.88 – 4.68 <0.001
c.252C>A, p.D84E 0.017 0.004 5.66 1.88 – 17.06 0.001
c.425G>A, p.R142H 0.008 0.008 1.62 0.58 – 4.50 0.431
c.451C>T, p.R151C 0.145 0.058 3.78 2.68 – 5.34 <0.001
c.478C>T, p.R160W 0.150 0.059 3.82 2.72 – 5.37 <0.001
c.880G>C, p.D294H 0.022 0.011 2.79 1.38 – 6.38 0.005
All r variants 0.252 0.248 1.53 1.22 – 1.91 <0.001
c.178G>T, p.V60L 0.105 0.104 1.52 1.12 – 2.08 0.008
c.274G>A, p.V92M 0.082 0.081 1.51 1.07 – 2.13 0.021
c.464T>C, p.I155T 0.006 0.006 1.70 0.52 – 5.60 0.540
c.488G>A, p.R163Q 0.060 0.058 1.55 1.04 – 2.31 0.032
MC1R reference sequence: NM_002386.3
AN = allele number
a minor allele frequency (MAF)
b using Fisher’s exact test (two-sided)
c number of alleles without any R or r variant
VARIANTS OF INTEREST IN CANDIDATE MELANOMA SUSCEPTIBILITY GENES 
In addition to the novel, truncating variant in the BRIP1 gene (c.894C>A, p.(C298*)) found 
in one of the BAP1-families, an additional seven potentially deleterious missense variants 
were identified in BRIP1 (table 4). This included one novel variant (c.2069G>A, p.(G690E)) 
and two extremely rare variants (c.2582C>G, p.(S861C) and c.2593C>T, p.(R865W)) located 
in the DNA helicase domain and predicted to be damaging by all in silico tools including 
UMD-predictor. However, the latter variant did not co-segregate with the phenotype 




reported to co-segregate in a three-case melanoma family.22 The remaining four variants 
were located in the ATPase/helicase core domain, and included an extremely rare variant 
(c.1198G>T, p.(D400Y)) in two probands and a very rare variant (c.1255C>T, p.(R419W)) in 
one proband. Currently, little is known from literature about the effect of these missense 
variants and no functional testing has been performed.
We further identified two missense variants in the exonuclease domain of the POLE gene: 
one novel variant (c.893A>G, p.(Y298C)) in a single proband and a rare variant (c.861T>A, 
p.(D287E)) in nine other probands (table 4). Both variants were predicted to be damaging 
by all in silico tools including UMD-predictor. In another proband, we identified a novel 
truncating variant in POLE (c.1230G>A, p.(W410*)), but this variant did not co-segregate with 
the phenotype in a two-case family. 
In the OCA2 gene, we identified nine (potentially) deleterious variants, of which six were 
previously reported in patients with the recessively inherited condition oculocutaneous 
albinism type 2 (MIM #203200) (table 4). Two of these established pathogenic variants, 
c.1327G>A, p.(V443I) and c.1465A>G, p.(N489D), were detected in multiple individuals 
(n=17 and 7, respectively) and the frequency of these variants was more than twice that 
found in the Dutch GoNL reference database (MAF: 0.018 and 0.0071; GoNL: 0.008 and 
0.003, respectively). Co-segregation analysis was, however, ambiguous: the c.1465A>G, 
p.(N489D) variant co-segregated with the phenotype in a three-case family (all first-degree 
relatives), but the c.1327G>A, p.(V443I) variant did not co-segregate in two two-case 
families. Interestingly, one proband was homozygous for the c.1327G>A, p.(V443I) variant. 
This proband had a medical history of three primary melanomas from age 57 and a first-
degree relative (sibling) with melanoma. Although the proband was reported to have a fair 
skin type and reddish hair, no other physical signs of albinism were reported. 
Another proband, with a medical history of three primary melanomas from age 48 and a 
first-degree relative (child) with melanoma at age 32, carried two pathogenic variants in 
the OCA2 gene (c.1327G>A, p.(V443I) and c.2037G>C, p.(W679C)). Since physical signs of 
albinism were not reported in the proband, it is possible that these variants are located 
on the same allele, but this could not be confirmed because co-segregation data was 
unavailable. 
In the other included candidate melanoma susceptibility genes, largely derived from whole 
exome/genome sequencing studies by both our own research group and other research 
groups, we detected four truncating variants (in ERCC3, NEK2, POLH, RASEF), two 
canonical splice site variants (in NEK2, NEK4) and several potentially deleterious missense 
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variants (in CBLB, ERCC3, MLLT6, NEK2, NEK4, NEK10, NEK11, PARP1, POLH, RASEF) (table 
5). All of these variants occurred in only one proband and co-segregation data was only 
occasionally available. UMD-predictor classified the majority of these variants as (probably) 
pathogenic. 
DISCUSSION
In this study, we performed multi-gene panel testing of 30 (candidate) melanoma 
susceptibility genes in 451 Dutch melanoma-prone families without a CDKN2A or 
CDK4 mutation. We identified (likely) pathogenic variants in established high- and 
medium-penetrance melanoma susceptibility genes in 4.0% of these families (18/451; n=3 
BAP1, n=15 MITF). In addition, two potentially deleterious missense variants were detected 
in important functional domains of the ACD and TERF2IP genes (0.4%) and, surprisingly, 
none of the 451 families carried a variant of interest in the POT1 gene.
The frequency of BAP1 mutations in our cohort (n=3; 0.7%) is in line with a reported 
frequency of ~1% among melanoma-prone families worldwide.25 BAP1 is a deubiquitinating 
hydrolase that acts as a tumour suppressor and is involved in the regulation of key pathways 
including cell proliferation, cell differentiation, cell survival and the DNA damage response. 
Germline BAP1 mutations have been reported in patients with several types of tumours, 
but particularly in UM and malignant mesothelioma.14 Interestingly, these two major cancers 
were not present in our three families. Although CM itself is relatively common in BAP1 
mutation carriers (13-18%),14,26 BAP1 mutations are rarely reported in CM families without 
these other cancers: a study by Njauw et al27 detected only one BAP1 mutation in 193 CM 
families (0.5%), and a study by Wadt et al28 found no BAP1 mutations in 133 high-risk CM 
patients (of which 94 CM families). By contrast, Gerami et al29 found a BAP1 mutation in a 
single case with multiple primary cutaneous melanomas and a dysplastic nevus phenotype, 
with no family history for either CM or UM or any other BAP1-associated cancers. A recent 
population-based study reported only three loss-of-function BAP1 mutations in CM cases 
(<0.2%), and all these cases had relatives with BAP1-associated cancers, although none had 
UM.30 Our study demonstrates that BAP1 mutations can indeed be detected in some CM 
families without UM or malignant mesothelioma and it is therefore important to incorporate 
the BAP1 gene in a diagnostic (cutaneous) melanoma gene panel test. However, it should 
be noted that basal cell carcinoma and (atypical) Spitz nevi, features also associated with 
BAP1 mutations, were reported in two of the families.




which is amongst the highest frequencies reported in familial non-CDKN2A cases. Only one 
small study from Switzerland reported a higher frequency, 7.7% (2/26), in melanoma-prone 
families.31 A similar frequency, 3.4% (19/558) in familial cases, was found in a study from the 
United States, although it is unclear if these patients were all pre-screened for CDKN2A 
mutations.32 Frequencies in various other cohorts range from 0-3% 16,28,33-35, with the lowest 
frequency (<1%) reported in familial cases from Italy.17,36 In the Netherlands, diagnostic 
testing for the MITF p.E318K risk variant is now included in the default genetic work-up for 
familial CM and all carriers are offered regular dermatologic surveillance (regardless of the 
familial burden for CM). This regular surveillance is recommended because carriers are at 
increased risk for developing subsequent (multiple primary) melanomas 15 that might also 
be fast-growing 35 and/or amelanotic 37, a subtype less easily recognized by the patient 
and/or the dermatologist. Hence, knowledge about MITF p.E318K mutation status can be 
relevant for both the patient and the dermatologist. Surveillance for other cancers such as 
renal- or pancreatic cancer is not (yet) offered because the actual risk for these cancers is 
insufficiently established and surveillance methods are more challenging. 
Germline mutations in the telomere maintenance pathway genes in melanoma families 
have been described in several studies.11-13 The present study demonstrates that mutations 
in these genes are probably very rare in the Dutch familial melanoma population. We 
identified only two potentially deleterious missense variants in ACD and TERF2IP (0.4%) 
and none in POT1 or the promoter region of TERT. In the ACD and TERF2IP genes, both 
nonsense and pathogenic missense variants have been previously reported in familial 
melanoma kindreds.12 Interestingly, the TERF2IP p.(R133Q) variant that we detected in a 
two-case melanoma family was previously reported in a three-case chronic lymphocytic 
leukemia (CLL) family (without melanoma).38 Because the variant co-segregated with only 
two of the cases, the authors concluded that this is a medium-penetrance variant for 
CLL. Leukemia was not reported in relatives of the proband in our cohort. Of the eight 
potentially deleterious missense variants detected in the TERF1, TERF2 and TINF2 genes, 
co-segregation analysis was only possible for one of these variants. There is no additional 
evidence for pathogenicity of these missense variants, and as yet no protein truncating 
variants have been reported in these latter genes. Therefore, their role in melanoma 
susceptibility remains uncertain. 
We identified several variants of interest in the known cancer susceptibility genes BRIP1 and 
POLE, including a nonsense variant in BRIP1. BRIP1 (BRCA1-interacting protein C-terminal 
helicase 1) is a Fanconi anemia group protein and is required for the double-strand break 
repair function of BRCA1. Heterozygous protein truncating variants in BRIP1 have mainly 
been associated with an increased susceptibility for ovarian cancer,39 but there were 
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no diagnoses of ovarian cancer in family members of the proband with the nonsense 
BRIP1 variant in this study. Interestingly, this variant co-occurred with a canonical splice 
site variant in BAP1 in the same proband, the latter presumably being the predominant 
melanoma susceptibility factor in this family. We additionally identified several potentially 
deleterious missense variants in BRIP1, some novel or extremely rare, and most of which 
were predicted to be damaging by all in silico tools used. In a recent study from Sweden, 
an extremely rare missense variant in the DNA helicase domain of BRIP1 was found to co-
segregate in a three-case melanoma family.22 Three missense variants in our cohort were 
located in this same functional domain. Based on these findings, the BRIP1 gene might 
be involved in melanoma susceptibility, but more research is needed to clarify this, in 
particular replication studies in other melanoma cohorts and functional studies to address 
the pathogenicity of missense variants. The POLE gene is a polymerase gene involved in 
DNA repair and replication and is primarily associated with colorectal cancer. It appears 
that only missense variants in the exonuclease domain confer an increased susceptibility 
for cancer through impaired proofreading, which results in tumours with a high mutation 
burden.40 Therefore, we restricted our analysis of variants to this specific exonuclease 
domain and, consequently, all reported variants in POLE are located within this domain. 
Recently, a novel missense variant in the exonuclease domain of POLE was reported in a 
seven-case melanoma family and showed near-complete co-segregation.20 Although we 
were not able to perform co-segregation analysis for the novel missense variant (c.893A>G, 
p.(Y298C)) detected in our cohort, functional analysis of melanoma tissue (mutation burden 
test) might provide more insight. Of note, colorectal cancer was not reported in this family.
Biallelic germline mutations in OCA2 cause oculocutaneous albinism type 2 (MIM 
#203200). OCA2 encodes the P-protein which has multiple functions in the biosynthesis 
of melanin. Loss-of-function of the P-protein results in hypopigmentation of the skin, 
hair and iris and an increased risk for sun-induced skin cancers, in particular basal cell 
carcinoma and squamous cell carcinoma.41 Although melanoma is not known to be 
a common cancer type in patients with OCA2-related albinism, families with multiple 
members with albinism and melanoma have been reported.42 In our cohort, one proband 
with a possible subclinical phenotype of albinism carried a homozygous pathogenic OCA2 
variant. Additionally, we observed an increased frequency of rare heterozygous variants 
in the OCA2 gene, in particular the known pathogenic variants c.1327G>A, p.(V443I) and 
c.1465A>G, p.(N489D).43,44 The association with melanoma predisposition of the c.1327G>A, 
p.(V443I) variant in combination with another OCA2 variant was also studied by Hawkes 
et al45 in one albinism-melanoma family. They concluded that these variants might be 
high-penetrance loci for melanoma in this family (OR 6.5). In a recent study by Goldstein et 




susceptibly genes that were sequenced in 144 melanoma cases from 76 American families. 
Comparable to our study, numerous rare variants in OCA2 were found. The frequency 
of rare variants in other albinism genes (TYR, TYRP1) was also significantly increased in 
the Goldstein study. Interestingly, a nonsense variant in TYR showed near-complete co-
segregation in a large family with six melanoma cases. The precise role of OCA2 (and 
other albinism genes) in melanoma predisposition remains to be determined, but based on 
these findings a medium-penetrance or modifier effect can be hypothesized. The albinism 
genes are therefore good candidates for further investigation. 
There is extensive literature on the association between MC1R R and r variants and 
sporadic melanoma in population-based cohorts.18 In our ‘familial CM’ cases, we observed 
a high frequency of MC1R R variants in particular, a finding comparable to the results of 
a Danish high-risk melanoma cohort.28 This suggests that these common risk variants 
also play a significant role in the familial setting. Since some of the familial occurrence 
of melanoma might be explained by the aggregation of common risk variants in a family, 
we are currently incorporating all MC1R R and r variants in a polygenic risk score (PRS) 
model that also includes approximately 40 other common risk variants derived from large 
melanoma GWAS. PRS models have already been shown to improve risk stratification in 
other familial cancer cohorts, in particular familial breast cancer.47
A major strength of our study is cohort size. With the inclusion of 451 families lacking a 
mutation in the CDKN2A or CDK4 genes, of which 442 families had at least two cases of 
CM, to our knowledge this is the largest melanoma gene panel study to date. Although 
our inclusion criteria were not highly stringent, most families had at least two close 
relatives with melanoma (for instance, 83% of the two-case families consisted of first-
degree relatives). Furthermore, our panel included all eight currently known high- and 
medium-penetrance melanoma susceptibility genes and therefore our reported 4% 
diagnostic yield for these genes (excluding CDKN2A and CDK4) is probably very accurate. 
As a custom-designed targeted gene panel was used, filtering of variants was less 
strict compared to most reported WES studies. It is therefore very unlikely that potential 
pathogenic variants in the selected genes were missed in our study. A limitation is that 
co-segregation analysis of variants was not possible in many families. This was primarily 
due to Ethics Committee restrictions that prohibited us from re-contacting patients 
when variants of uncertain significance (VUS) or variants in non-established genes were 
detected. However, co-segregation analysis of (likely) pathogenic variants in known cancer 
susceptibility genes (BAP1, MITF, BRIP1) is currently being initiated. 
To conclude, we demonstrate that multi-gene panel testing for familial melanoma results in 
139
8
MULTI-GENE PANEL SEQUENCING OF ESTABLISHED AND CANDIDATE MELANOMA SUSCEPTIBILITY GENES IN A LARGE COHORT 
OF DUTCH NON-CDKN2A/CDK4 MELANOMA FAMILIES
an additional 4% diagnostic yield in non-CDKN2A/CDK4 families. The identification of several 
families with pathogenic variants in the BAP1 and MITF genes suggests a significant role of 
these genes in melanoma predisposition and it is therefore important to include these in a 
diagnostic test. Conversely, variants in the telomere maintenance genes, especially POT1, 
seem to be (very) rare in the Dutch population. When including these genes in a panel 
test, one should be aware of identifying variants of uncertain significance, as we did in the 
current study. In view of the relatively high frequency of (potential) pathogenic variants in 
the OCA2 gene in both our own and in a recently published American familial melanoma 
cohort, further elucidation of the role of heterozygous OCA2 variants in melanoma 
predisposition appears to be of particular interest. In the future, candidate susceptibility 
genes such as OCA2 could potentially be added to routine germline diagnostics, given 
sufficient evidence for their pathogenicity in melanoma predisposition. This will in turn 
enhance the diagnostic yield of the panel and improve tumour risk assessment in 
melanoma families.
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67694102 c.280G>A 1 p.(Val94Ile) ms rs149365469 1 0.001025 0.00076 - W M S 12.74 T C0 B
ACD NM_001082486.1
chr16: 
67694044 c.338G>A 1 p.(Arg113Gln) ms rs142507451 3 0.003074 0.0022 0.002 N W S 18.17 T C0 B
ACD NM_001082486.1
chr16: 
67692863 c.871A>G 7 p.(Thr291Ala) ms rs139438549 1 0.001025 0.0012 0.001 M H S 23.2 D C55 D
ACD NM_001082486.1
chr16: 
67691917 c.1436G>A 10 p.(Arg479Lys) ms rs531580930 1 0.001025 0.000099 0.001 N W S 0.006 T C0 B
BAP1 NM_004656.3
chr3: 
52443569 c.122+1G>T - p.? intron - 1 0.001025 - - - - - - - - - +
BAP1 NM_004656.3
chr3: 
52439834 c.878C>T 10 p.(Pro293Leu) ms rs777664260 1 0.001025 0 - M M M 23.8 D C0 B
BAP1 NM_004656.3
chr3: 
52437424 c.1729+8T>C - p.? intron rs150945583 5 0.005123 0.006 0.007 - - - - - - -
BAP1 NM_004656.3
chr3: 







646Phefs*10) fs - 1 0.001025 - - - - - - - - -
BRIP1 NM_032043.2
chr17: 
59924572 c.517C>T 6 p.(Arg173Cys) ms rs4988345 9 0.009221 0.0047 0.004 M H L 27.6 D C55 D
BRIP1 NM_032043.2
chr17: 
59924512 c.577G>A 6 p.(Val193Ile) ms rs4988346 4 0.004098 0.0054 0.007 N W S 0.002 T C0 B
BRIP1 NM_032043.2
chr17: 
59924505 c.584T>C 6 p.(Leu195Pro) ms rs4988347 1 0.001025 0.002 0.002 W W M 4.462 T C0 B
BRIP1 NM_032043.2
chr17: 
59924502 c.587A>G 6 p.(Asn196Ser) ms rs550707862 1 0.001025 0.000018 - W W S 0.003 T C0 B
BRIP1 NM_032043.2
chr17: 
59885956 c.790C>T 7 p.(Arg264Trp) ms rs28997569 1 0.001025 0.0012 0.003 M M M 32 D C0 D
BRIP1 NM_032043.2
chr17: 
59885852 c.894C>A 7 p.(Cys298*) ns - 1 0.001025 - - - - - 36 - - -
BRIP1 NM_032043.2
chr17: 
59876603 c.1198G>T 9 p.(Asp400Tyr) ms rs764711572 2 0.002049 0.000027 - H H L 33 D C35 D
BRIP1 NM_032043.2
chr17: 
59876546 c.1255C>T 9 p.(Arg419Trp) ms rs150624408 1 0.001025 0.00046 0.001 W H M 33 D C35 D
BRIP1 NM_032043.2
chr17: 
59853928 c.1936-5T>A - p.? intron - 1 0.001025 - - - - - - - - -
BRIP1 NM_032043.2
chr17: 
59853790 c.2069G>A 14 p.(Gly690Glu) ms - 1 0.001025 - - H H M 32 D C65 D
BRIP1 NM_032043.2
chr17: 
59821955 c.2098-3T>C - p.? intron - 2 0.002049 - - - - - - - - -
BRIP1 NM_032043.2
chr17: 
59821830 c.2220G>T 15 p.(Gln740His) ms rs45589637 1 0.001025 0.00065 0.001 W M S 25.7 T C0 P
BRIP1 NM_032043.2
chr17: 
59763520 c.2582C>G 19 p.(Ser861Cys) ms rs774415723 1 0.001025 0.000027 - M H M 28.5 D C65 D
BRIP1 NM_032043.2
chr17: 
59763509 c.2593C>T 19 p.(Arg865Trp) ms rs578022079 1 0.001025 0.000027 - W H M 34 D C25 D
CBLB NM_170662.4
chr3: 
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67694102 c.280G>A 1 p.(Val94Ile) ms rs149365469 1 0.001025 0.00076 - W M S 12.74 T C0 B
ACD NM_001082486.1
chr16: 
67694044 c.338G>A 1 p.(Arg113Gln) ms rs142507451 3 0.003074 0.0022 0.002 N W S 18.17 T C0 B
ACD NM_001082486.1
chr16: 
67692863 c.871A>G 7 p.(Thr291Ala) ms rs139438549 1 0.001025 0.0012 0.001 M H S 23.2 D C55 D
ACD NM_001082486.1
chr16: 
67691917 c.1436G>A 10 p.(Arg479Lys) ms rs531580930 1 0.001025 0.000099 0.001 N W S 0.006 T C0 B
BAP1 NM_004656.3
chr3: 
52443569 c.122+1G>T - p.? intron - 1 0.001025 - - - - - - - - - +
BAP1 NM_004656.3
chr3: 
52439834 c.878C>T 10 p.(Pro293Leu) ms rs777664260 1 0.001025 0 - M M M 23.8 D C0 B
BAP1 NM_004656.3
chr3: 
52437424 c.1729+8T>C - p.? intron rs150945583 5 0.005123 0.006 0.007 - - - - - - -
BAP1 NM_004656.3
chr3: 







646Phefs*10) fs - 1 0.001025 - - - - - - - - -
BRIP1 NM_032043.2
chr17: 
59924572 c.517C>T 6 p.(Arg173Cys) ms rs4988345 9 0.009221 0.0047 0.004 M H L 27.6 D C55 D
BRIP1 NM_032043.2
chr17: 
59924512 c.577G>A 6 p.(Val193Ile) ms rs4988346 4 0.004098 0.0054 0.007 N W S 0.002 T C0 B
BRIP1 NM_032043.2
chr17: 
59924505 c.584T>C 6 p.(Leu195Pro) ms rs4988347 1 0.001025 0.002 0.002 W W M 4.462 T C0 B
BRIP1 NM_032043.2
chr17: 
59924502 c.587A>G 6 p.(Asn196Ser) ms rs550707862 1 0.001025 0.000018 - W W S 0.003 T C0 B
BRIP1 NM_032043.2
chr17: 
59885956 c.790C>T 7 p.(Arg264Trp) ms rs28997569 1 0.001025 0.0012 0.003 M M M 32 D C0 D
BRIP1 NM_032043.2
chr17: 
59885852 c.894C>A 7 p.(Cys298*) ns - 1 0.001025 - - - - - 36 - - -
BRIP1 NM_032043.2
chr17: 
59876603 c.1198G>T 9 p.(Asp400Tyr) ms rs764711572 2 0.002049 0.000027 - H H L 33 D C35 D
BRIP1 NM_032043.2
chr17: 
59876546 c.1255C>T 9 p.(Arg419Trp) ms rs150624408 1 0.001025 0.00046 0.001 W H M 33 D C35 D
BRIP1 NM_032043.2
chr17: 
59853928 c.1936-5T>A - p.? intron - 1 0.001025 - - - - - - - - -
BRIP1 NM_032043.2
chr17: 
59853790 c.2069G>A 14 p.(Gly690Glu) ms - 1 0.001025 - - H H M 32 D C65 D
BRIP1 NM_032043.2
chr17: 
59821955 c.2098-3T>C - p.? intron - 2 0.002049 - - - - - - - - -
BRIP1 NM_032043.2
chr17: 
59821830 c.2220G>T 15 p.(Gln740His) ms rs45589637 1 0.001025 0.00065 0.001 W M S 25.7 T C0 P
BRIP1 NM_032043.2
chr17: 
59763520 c.2582C>G 19 p.(Ser861Cys) ms rs774415723 1 0.001025 0.000027 - M H M 28.5 D C65 D
BRIP1 NM_032043.2
chr17: 
59763509 c.2593C>T 19 p.(Arg865Trp) ms rs578022079 1 0.001025 0.000027 - W H M 34 D C25 D
CBLB NM_170662.4
chr3: 
105572408 c.269G>A 3 p.(Ser90Asn) ms - 1 0.001025 0 - M M S 21.2 T C0 B
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105572313 c.364A>G 3 p.(Ile122Val) ms rs748358316 1 0.001025 0 - M H S 13.69 T C0 B ±
CBLB NM_170662.4
chr3: 
105464836 c.770A>T 6 p.(His257Leu) ms - 1 0.001025 - - H H M 33 D C0 D
CBLB NM_170662.4
chr3: 
105438947 c.1351G>A 10 p.(Asp451Asn) ms rs377118360 1 0.001025 0 - H M S 27.7 T C0 D
CBLB NM_170662.4
chr3: 
105438896 c.1402C>G 10 p.(Arg468Gly) ms - 1 0.001025 0.000018 - W M M 23.6 D C0 P
CBLB NM_170662.4
chr3: 
105421032 c.1865G>C 12 p.(Ser622Thr) ms rs41302192 9 0.009221 0.0083 0.007 W W S 5.998 T C0 B
CBLB NM_170662.4
chr3: 
105421025 c.1872T>G 12 p.(Asn624Lys) ms - 1 0.001025 - - W W M 0.007 T C0 B
CBLB NM_170662.4
chr3: 
105400624 c.2240A>T 15 p.(His747Leu) ms rs149189614 2 0.002049 0.000045 - M M M 19.56 T C0 B
CBLB NM_170662.4
chr3: 
105397298 c.2546A>T 17 p.(Gln849Leu) ms - 1 0.001025 0.000018 - M W M 20.7 T C0 B
CENPS NM_199294.2
chr1: 
10494754 c.209+7A>G - p.? intron rs760512781 1 0.001025 0.000046 - - - - - - - -
CENPS NM_199294.2
chr1: 
10502454 c.409G>A 5 p.(Glu137Lys) ms rs146240548 1 0.001025 0.0014 0.002 M M S 10.71 T C0 B
CREB3L1 NM_052854.3
chr11: 
46329489 c.454G>A 3 p.(Ala152Thr) ms rs199951144 1 0.001025 0.0065d 0.006 N M S 3.186 T C0 B
CREB3L1 NM_052854.3
chr11: 
46332586 c.599A>T 5 p.(Asp200Val) ms rs187725533 7 0.007172 0.0059 0.006 M H L 26.9 D C0 B
CREB3L1 NM_052854.3
chr11: 
46337910 c.1105G>A 9 p.(Ala369Thr) ms rs201046043 1 0.001025 0.00033 0.001 W M S 22.7 D C0 B
DOT1L NM_032482.2
chr19: 
2191003 c.265-8G>A - p.? intron rs374436091 4 0.004098 0.00034 0.001 - - - - - - -
DOT1L NM_032482.2
chr19: 
2191226 c.480G>A 5 p.(=) syn - 1 0.001025 0.000018 - N - - - - - - ±
DOT1L NM_032482.2
chr19: 
2210451 c.1058C>G 13 p.(Ala353Gly) ms rs138206172 1 0.001025 0.0024 0.004 M W S 19.18 T C0 B
DOT1L NM_032482.2
chr19: 
2211098 c.1352A>G 15 p.(Asp451Gly) ms rs377185393 1 0.001025 0.00025 0.001 M M M 23.3 T C0 D ±
DOT1L NM_032482.2
chr19: 
2214564 c.1892C>T 19 p.(Ser631Leu) ms rs200661860 1 0.001025 0.00055 0.001 H H L 34 T C0 D
DOT1L NM_032482.2
chr19: 
2216470 c.2114G>C 20 p.(Ser705Thr) ms - 1 0.001025 - - M M S 23 T C0 B
DOT1L NM_032482.2
chr19: 
2216545 c.2189C>T 20 p.(Ser730Leu) ms rs750873331 1 0.001025 0.000027 - M W L 25.9 T C0 B
DOT1L NM_032482.2
chr19: 
2216610 c.2254C>T 20 p.(Pro752Ser) ms rs370203392 1 0.001025 0.000027 - M M M 25.8 T C0 B
DOT1L NM_032482.2
chr19: 
2216658 c.2302G>C 20 p.(Ala768Pro) ms rs758184437 1 0.001025 0.0001 - N W S 22.2 T C0 B
DOT1L NM_032482.2
chr19: 
2217034 c.2489C>T 21 p.(Pro830Leu) ms rs368118931 3 0.003074 0.000018 - W M M 26.4 T C0 B
DOT1L NM_032482.2
chr19: 
2217094 c.2544+5G>A - p.? intron rs202211033 2 0.002049 0.0015 0.003 - - - - - - - ±
DOT1L NM_032482.2
chr19: 
2217786 c.2560G>A 22 p.(Ala854Thr) ms rs201843576 2 0.002049 0.0017 0.004 N W S 3.499 T C0 B
DOT1L NM_032482.2 chr19: 2217801 c.2575G>A 22 p.(Gly859Arg) ms rs753001418 1 0.001025 0.000009973 - M M M 25.8 T C0 P
DOT1L NM_032482.2
chr19: 
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105572313 c.364A>G 3 p.(Ile122Val) ms rs748358316 1 0.001025 0 - M H S 13.69 T C0 B ±
CBLB NM_170662.4
chr3: 
105464836 c.770A>T 6 p.(His257Leu) ms - 1 0.001025 - - H H M 33 D C0 D
CBLB NM_170662.4
chr3: 
105438947 c.1351G>A 10 p.(Asp451Asn) ms rs377118360 1 0.001025 0 - H M S 27.7 T C0 D
CBLB NM_170662.4
chr3: 
105438896 c.1402C>G 10 p.(Arg468Gly) ms - 1 0.001025 0.000018 - W M M 23.6 D C0 P
CBLB NM_170662.4
chr3: 
105421032 c.1865G>C 12 p.(Ser622Thr) ms rs41302192 9 0.009221 0.0083 0.007 W W S 5.998 T C0 B
CBLB NM_170662.4
chr3: 
105421025 c.1872T>G 12 p.(Asn624Lys) ms - 1 0.001025 - - W W M 0.007 T C0 B
CBLB NM_170662.4
chr3: 
105400624 c.2240A>T 15 p.(His747Leu) ms rs149189614 2 0.002049 0.000045 - M M M 19.56 T C0 B
CBLB NM_170662.4
chr3: 
105397298 c.2546A>T 17 p.(Gln849Leu) ms - 1 0.001025 0.000018 - M W M 20.7 T C0 B
CENPS NM_199294.2
chr1: 
10494754 c.209+7A>G - p.? intron rs760512781 1 0.001025 0.000046 - - - - - - - -
CENPS NM_199294.2
chr1: 
10502454 c.409G>A 5 p.(Glu137Lys) ms rs146240548 1 0.001025 0.0014 0.002 M M S 10.71 T C0 B
CREB3L1 NM_052854.3
chr11: 
46329489 c.454G>A 3 p.(Ala152Thr) ms rs199951144 1 0.001025 0.0065d 0.006 N M S 3.186 T C0 B
CREB3L1 NM_052854.3
chr11: 
46332586 c.599A>T 5 p.(Asp200Val) ms rs187725533 7 0.007172 0.0059 0.006 M H L 26.9 D C0 B
CREB3L1 NM_052854.3
chr11: 
46337910 c.1105G>A 9 p.(Ala369Thr) ms rs201046043 1 0.001025 0.00033 0.001 W M S 22.7 D C0 B
DOT1L NM_032482.2
chr19: 
2191003 c.265-8G>A - p.? intron rs374436091 4 0.004098 0.00034 0.001 - - - - - - -
DOT1L NM_032482.2
chr19: 
2191226 c.480G>A 5 p.(=) syn - 1 0.001025 0.000018 - N - - - - - - ±
DOT1L NM_032482.2
chr19: 
2210451 c.1058C>G 13 p.(Ala353Gly) ms rs138206172 1 0.001025 0.0024 0.004 M W S 19.18 T C0 B
DOT1L NM_032482.2
chr19: 
2211098 c.1352A>G 15 p.(Asp451Gly) ms rs377185393 1 0.001025 0.00025 0.001 M M M 23.3 T C0 D ±
DOT1L NM_032482.2
chr19: 
2214564 c.1892C>T 19 p.(Ser631Leu) ms rs200661860 1 0.001025 0.00055 0.001 H H L 34 T C0 D
DOT1L NM_032482.2
chr19: 
2216470 c.2114G>C 20 p.(Ser705Thr) ms - 1 0.001025 - - M M S 23 T C0 B
DOT1L NM_032482.2
chr19: 
2216545 c.2189C>T 20 p.(Ser730Leu) ms rs750873331 1 0.001025 0.000027 - M W L 25.9 T C0 B
DOT1L NM_032482.2
chr19: 
2216610 c.2254C>T 20 p.(Pro752Ser) ms rs370203392 1 0.001025 0.000027 - M M M 25.8 T C0 B
DOT1L NM_032482.2
chr19: 
2216658 c.2302G>C 20 p.(Ala768Pro) ms rs758184437 1 0.001025 0.0001 - N W S 22.2 T C0 B
DOT1L NM_032482.2
chr19: 
2217034 c.2489C>T 21 p.(Pro830Leu) ms rs368118931 3 0.003074 0.000018 - W M M 26.4 T C0 B
DOT1L NM_032482.2
chr19: 
2217094 c.2544+5G>A - p.? intron rs202211033 2 0.002049 0.0015 0.003 - - - - - - - ±
DOT1L NM_032482.2
chr19: 
2217786 c.2560G>A 22 p.(Ala854Thr) ms rs201843576 2 0.002049 0.0017 0.004 N W S 3.499 T C0 B
DOT1L NM_032482.2 chr19: 2217801 c.2575G>A 22 p.(Gly859Arg) ms rs753001418 1 0.001025 0.000009973 - M M M 25.8 T C0 P
DOT1L NM_032482.2
chr19: 
2222325 c.3157G>A 24 p.(Ala1053Thr) ms rs144165419 1 0.001025 0.0018 - N W S 0.136 T C0 B
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2223364 c.3475G>C 25 p.(Asp1159His) ms rs377512955 2 0.002049 0.00022 0.001 H M M 28.9 T C0 D
DOT1L NM_032482.2
chr19: 
2226219 c.3699C>T 27 p.(=) syn rs771189396 1 0.001025 0.00018 - W - - - - - - ±
DOT1L NM_032482.2
chr19: 
2226539 c.4019A>G 27 p.(Lys1340Arg) ms - 1 0.001025 - - W W S 25.2 T C0 D
DOT1L NM_032482.2
chr19: 
2226592 c.4072G>A 27 p.(Gly1358Ser) ms rs376766280 1 0.001025 0.000059 - W W S 8.724 T C0 B
DOT1L NM_032482.2
chr19: 
2226694 c.4174G>A 27 p.(Gly1392Ser) ms rs375002753 1 0.001025 0.00052 0.002 N W S 2.832 T C0 B
DOT1L NM_032482.2
chr19: 
2226728 c.4208C>A 27 p.(Thr1403Asn) ms rs200561588 1 0.001025 0.00024 - N W S 12.39 T C0 B
DOT1L NM_032482.2
chr19: 
2226833 c.4313T>G 27 p.(Leu1438Arg) ms rs371610616 1 0.001025 0.00011 - W W M 11.78 T C0 D
DOT1L NM_032482.2
chr19: 
2226929 c.4409C>T 27 p.(Pro1470Leu) ms - 1 0.001025 - - M W M 25.3 D C0 B
DOT1L NM_032482.2
chr19: 
2226935 c.4415C>G 27 p.(Pro1472Arg) ms - 1 0.001025 - - M W M 23.3 T C0 B
DOT1L NM_032482.2
chr19: 
2227081 c.4561C>T 27 p.(His1521Tyr) ms - 1 0.001025 - - M W M 25.4 T C0 D
ERCC3 NM_000122.1
chr2: 
128047825 c.496G>A 4 p.(Val166Ile) ms - 1 0.001025 - - H H S 24.6 D C25 B
ERCC3 NM_000122.1
chr2: 
128047311 c.611G>A 5 p.(Gly204Glu) ms rs751705179 1 0.001025 0.000009 - M H M 18.35 T C0 B
ERCC3 NM_000122.1
chr2: 
128046416 c.847C>T 7 p.(Arg283Cys) ms rs145201970 5 0.005123 0.0014 0.002 H H L 34 D C65 B
ERCC3 NM_000122.1
chr2: 
128044468 c.1153G>A 8 p.(Asp385Asn) ms - 2 0.002049 - - H H S 21.8 T C0 B
ERCC3 NM_000122.1
chr2: 
128038129 c.1421dup 9 p.(Asp474Glufs*2) fs rs587778281 1 0.001025 0.00014 - - - - - - - -
ERCC3 NM_000122.1
chr2: 
128030492 c.1776T>G 11 p.(Ile592Met) ms - 1 0.001025 - - W H S 24.9 D C0 D
ERCC3 NM_000122.1
chr2: 
128016978 c.2111C>T 14 p.(Ser704Leu) ms rs4150521 2 0.002049 0.0022 0.001 H M L 24 D C15 B
MITF NM_000248.3
chr3: 
70014091 c.952G>A 9 p.(Glu318Lys) ms rs149617956 15 0.015369 0.002527 0.007 H H S 27.9 T C0 D
MLLT6 NM_005937.3
chr17: 
36864133 c.354+8G>A - p.? intron rs113618401 1 0.001025 0.00031d - - - - - - - -
MLLT6 NM_005937.3
chr17: 
36868139 c.592G>A 7 p.(Ala198Thr) ms rs2241012 1 0.001025 0.00001d - N W S 0.011 T C0 B
MLLT6 NM_005937.3
chr17: 
36868202 c.655C>T 7 p.(Arg219Trp) ms rs369771793 1 0.001025 0.000064 - W H M 25.2 D C15 P
MLLT6 NM_005937.3
chr17: 
36869017 c.794C>T 8 p.(Pro265Leu) ms rs754493479 1 0.001025 0.000063 - M M M 25 D C0 B
MLLT6 NM_005937.3
chr17: 
36872024 c.979G>A 9 p.(Ala327Thr) ms rs146278240 9 0.009221 0.0067 0.008 W M S 18.24 D C0 B
MLLT6 NM_005937.3
chr17: 
36872922 c.1339G>T 10 p.(Ala447Ser) ms rs145966494 9 0.009221 0.0069 0.008 N W M 6.782 T C0 B
MLLT6 NM_005937.3
chr17: 
36876664 c.2195A>C 15 p.(Glu732Ala) ms - 1 0.001025 - - M H M 24.6 D C0 D
MLLT6 NM_005937.3
chr17: 
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2223364 c.3475G>C 25 p.(Asp1159His) ms rs377512955 2 0.002049 0.00022 0.001 H M M 28.9 T C0 D
DOT1L NM_032482.2
chr19: 
2226219 c.3699C>T 27 p.(=) syn rs771189396 1 0.001025 0.00018 - W - - - - - - ±
DOT1L NM_032482.2
chr19: 
2226539 c.4019A>G 27 p.(Lys1340Arg) ms - 1 0.001025 - - W W S 25.2 T C0 D
DOT1L NM_032482.2
chr19: 
2226592 c.4072G>A 27 p.(Gly1358Ser) ms rs376766280 1 0.001025 0.000059 - W W S 8.724 T C0 B
DOT1L NM_032482.2
chr19: 
2226694 c.4174G>A 27 p.(Gly1392Ser) ms rs375002753 1 0.001025 0.00052 0.002 N W S 2.832 T C0 B
DOT1L NM_032482.2
chr19: 
2226728 c.4208C>A 27 p.(Thr1403Asn) ms rs200561588 1 0.001025 0.00024 - N W S 12.39 T C0 B
DOT1L NM_032482.2
chr19: 
2226833 c.4313T>G 27 p.(Leu1438Arg) ms rs371610616 1 0.001025 0.00011 - W W M 11.78 T C0 D
DOT1L NM_032482.2
chr19: 
2226929 c.4409C>T 27 p.(Pro1470Leu) ms - 1 0.001025 - - M W M 25.3 D C0 B
DOT1L NM_032482.2
chr19: 
2226935 c.4415C>G 27 p.(Pro1472Arg) ms - 1 0.001025 - - M W M 23.3 T C0 B
DOT1L NM_032482.2
chr19: 
2227081 c.4561C>T 27 p.(His1521Tyr) ms - 1 0.001025 - - M W M 25.4 T C0 D
ERCC3 NM_000122.1
chr2: 
128047825 c.496G>A 4 p.(Val166Ile) ms - 1 0.001025 - - H H S 24.6 D C25 B
ERCC3 NM_000122.1
chr2: 
128047311 c.611G>A 5 p.(Gly204Glu) ms rs751705179 1 0.001025 0.000009 - M H M 18.35 T C0 B
ERCC3 NM_000122.1
chr2: 
128046416 c.847C>T 7 p.(Arg283Cys) ms rs145201970 5 0.005123 0.0014 0.002 H H L 34 D C65 B
ERCC3 NM_000122.1
chr2: 
128044468 c.1153G>A 8 p.(Asp385Asn) ms - 2 0.002049 - - H H S 21.8 T C0 B
ERCC3 NM_000122.1
chr2: 
128038129 c.1421dup 9 p.(Asp474Glufs*2) fs rs587778281 1 0.001025 0.00014 - - - - - - - -
ERCC3 NM_000122.1
chr2: 
128030492 c.1776T>G 11 p.(Ile592Met) ms - 1 0.001025 - - W H S 24.9 D C0 D
ERCC3 NM_000122.1
chr2: 
128016978 c.2111C>T 14 p.(Ser704Leu) ms rs4150521 2 0.002049 0.0022 0.001 H M L 24 D C15 B
MITF NM_000248.3
chr3: 
70014091 c.952G>A 9 p.(Glu318Lys) ms rs149617956 15 0.015369 0.002527 0.007 H H S 27.9 T C0 D
MLLT6 NM_005937.3
chr17: 
36864133 c.354+8G>A - p.? intron rs113618401 1 0.001025 0.00031d - - - - - - - -
MLLT6 NM_005937.3
chr17: 
36868139 c.592G>A 7 p.(Ala198Thr) ms rs2241012 1 0.001025 0.00001d - N W S 0.011 T C0 B
MLLT6 NM_005937.3
chr17: 
36868202 c.655C>T 7 p.(Arg219Trp) ms rs369771793 1 0.001025 0.000064 - W H M 25.2 D C15 P
MLLT6 NM_005937.3
chr17: 
36869017 c.794C>T 8 p.(Pro265Leu) ms rs754493479 1 0.001025 0.000063 - M M M 25 D C0 B
MLLT6 NM_005937.3
chr17: 
36872024 c.979G>A 9 p.(Ala327Thr) ms rs146278240 9 0.009221 0.0067 0.008 W M S 18.24 D C0 B
MLLT6 NM_005937.3
chr17: 
36872922 c.1339G>T 10 p.(Ala447Ser) ms rs145966494 9 0.009221 0.0069 0.008 N W M 6.782 T C0 B
MLLT6 NM_005937.3
chr17: 
36876664 c.2195A>C 15 p.(Glu732Ala) ms - 1 0.001025 - - M H M 24.6 D C0 D
MLLT6 NM_005937.3
chr17: 
36878443 c.2755G>A 17 p.(Gly919Arg) ms - 1 0.001025 - - M H M 26.2 D C0 P
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36881009 c.3020C>T 19 p.(Ala1007Val) ms rs150198262 4 0.004098 0.0021 0.002 M M S 33 D C0 B
NEK2 NM_002497.3
chr1: 
211847857 c.97-2A>G - p.? intron rs201869074 1 0.001025 0.00029 - - - - - - - - +
NEK2 NM_002497.3
chr1: 
211847815 c.137A>G 2 p.(Glu46Gly) ms - 1 0.001025 - - H H M 28 D C0 D
NEK2 NM_002497.3
chr1: 
211842488 c.952C>T 6 p.(Arg318*) ns rs146817802 1 0.001025 0.000018 - - - - 39 - - -
NEK4 NM_003157.5
chr3: 
52800252 c.500T>C 3 p.(Ile167Thr) ms - 1 0.001025 0.000009 - H H M 26.9 D C25 D
NEK4 NM_003157.5
chr3: 
52786252 c.1064A>G 7 p.(Asn355Ser) ms - 1 0.001025 - - N W S 0.001 T C0 B
NEK4 NM_003157.5
chr3: 
52783745 c.1469G>A 8 p.(Arg490Gln) ms rs189287859 2 0.002049 0.00088 - W W S 6.179 T C0 B
NEK4 NM_003157.5
chr3: 
52780883 c.1544G>T 9 p.(Gly515Val) ms - 1 0.001025 - - N W M 11.36 T C0 B ±
NEK4 NM_003157.5
chr3: 
52777417 c.1953_1955del 12 p.(Glu651del) del rs534558039 1 0.001025 0.0011 0.002 W M - - - - -
NEK4 NM_003157.5
chr3: 
52775426 c.2093+1G>C - p.? intron - 1 0.001025 - - - - - - - - - +
NEK10 NM_152534.4
chr3: 
27343261 c.1094G>A 14 p.(Arg365Gln) ms rs75891446 7 0.007172 0.0094 0.009 M M S 25.2 D C0 P
NEK10 NM_152534.4
chr3: 
27233631 c.2394G>T 27 p.(Gln798His) ms rs766212798 2 0.002049 0 - N W S 8.073 T C0 B
NEK10 NM_152534.4
chr3: 
27216236 c.2594C>A 28 p.(Pro865His) ms rs140958685 2 0.002049 0.00065 - W W M 21 D C0 B
NEK10 NM_152534.4
chr3: 
27216215 c.2615A>G 28 p.(Tyr872Cys) ms rs141326474 5 0.005123 0.0016 0.006 W W L 1.542 T C0 B
NEK10 NM_152534.4
chr3: 
27203966 c.2996A>G 32 p.(Asn999Ser) ms - 1 0.001025 0.000018 - W W S 2.977 T C0 B
NEK10 NM_152534.4
chr3: 
27182990 c.3124A>G 34 p.(Ile1042Val) ms rs41487750 3 0.003074 0.0063d 0.004 W W S 13.03 T C0 B
NEK10 NM_152534.4
chr3: 
27161337 c.3275C>T 36 p.(Pro1092Leu) ms rs34545563 1 0.001025 0.000064 - W W M 12.07 T C0 B
NEK11 NM_024800.4
chr3: 
130748679 c.127G>C 3 p.(Val43Leu) ms rs140058289 2 0.002049 0.00016d - H H S 27.5 D C25 P
NEK11 NM_024800.4
chr3: 
130947497 c.1525G>C 15 p.(Glu509Gln) ms - 1 0.001025 0 - W W S 5.17 T C0 B
OCA2 NM_000275.2
chr15: 
28326992 c.29G>A 2 p.(Arg10Gln) ms rs199752361 1 0.001025 0.00051 0.002 W W S 11.75 T C0 B
OCA2 NM_000275.2
chr15: 
28326984 c.37G>A 2 p.(Gly13Ser) ms rs201554429 1 0.001025 0.000038 - W W S 10.86 T C0 B
OCA2 NM_000275.2
chr15: 
28326977 c.44C>G 2 p.(Pro15Arg) ms - 1 0.001025 - - W W M 11.18 T C0 B
OCA2 NM_000275.2
chr15: 
28326858 c.163del 2 p.(Ala55Leufs*47) fs - 1 0.001025 0.000019 - - - - - - - -
OCA2 NM_000275.2
chr15: 
28263599 c.751G>A 7 p.(Val251Met) ms rs147432138 1 0.001025 0.00017d - N W S 4.551 T C0 B
OCA2 NM_000275.2
chr15: 
28263554 c.796C>T 7 p.(Arg266Trp) ms rs33929465 1 0.001025 0.0018d 0.003 W H M 18.24 D C0 P
OCA2 NM_000275.2
chr15: 
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36881009 c.3020C>T 19 p.(Ala1007Val) ms rs150198262 4 0.004098 0.0021 0.002 M M S 33 D C0 B
NEK2 NM_002497.3
chr1: 
211847857 c.97-2A>G - p.? intron rs201869074 1 0.001025 0.00029 - - - - - - - - +
NEK2 NM_002497.3
chr1: 
211847815 c.137A>G 2 p.(Glu46Gly) ms - 1 0.001025 - - H H M 28 D C0 D
NEK2 NM_002497.3
chr1: 
211842488 c.952C>T 6 p.(Arg318*) ns rs146817802 1 0.001025 0.000018 - - - - 39 - - -
NEK4 NM_003157.5
chr3: 
52800252 c.500T>C 3 p.(Ile167Thr) ms - 1 0.001025 0.000009 - H H M 26.9 D C25 D
NEK4 NM_003157.5
chr3: 
52786252 c.1064A>G 7 p.(Asn355Ser) ms - 1 0.001025 - - N W S 0.001 T C0 B
NEK4 NM_003157.5
chr3: 
52783745 c.1469G>A 8 p.(Arg490Gln) ms rs189287859 2 0.002049 0.00088 - W W S 6.179 T C0 B
NEK4 NM_003157.5
chr3: 
52780883 c.1544G>T 9 p.(Gly515Val) ms - 1 0.001025 - - N W M 11.36 T C0 B ±
NEK4 NM_003157.5
chr3: 
52777417 c.1953_1955del 12 p.(Glu651del) del rs534558039 1 0.001025 0.0011 0.002 W M - - - - -
NEK4 NM_003157.5
chr3: 
52775426 c.2093+1G>C - p.? intron - 1 0.001025 - - - - - - - - - +
NEK10 NM_152534.4
chr3: 
27343261 c.1094G>A 14 p.(Arg365Gln) ms rs75891446 7 0.007172 0.0094 0.009 M M S 25.2 D C0 P
NEK10 NM_152534.4
chr3: 
27233631 c.2394G>T 27 p.(Gln798His) ms rs766212798 2 0.002049 0 - N W S 8.073 T C0 B
NEK10 NM_152534.4
chr3: 
27216236 c.2594C>A 28 p.(Pro865His) ms rs140958685 2 0.002049 0.00065 - W W M 21 D C0 B
NEK10 NM_152534.4
chr3: 
27216215 c.2615A>G 28 p.(Tyr872Cys) ms rs141326474 5 0.005123 0.0016 0.006 W W L 1.542 T C0 B
NEK10 NM_152534.4
chr3: 
27203966 c.2996A>G 32 p.(Asn999Ser) ms - 1 0.001025 0.000018 - W W S 2.977 T C0 B
NEK10 NM_152534.4
chr3: 
27182990 c.3124A>G 34 p.(Ile1042Val) ms rs41487750 3 0.003074 0.0063d 0.004 W W S 13.03 T C0 B
NEK10 NM_152534.4
chr3: 
27161337 c.3275C>T 36 p.(Pro1092Leu) ms rs34545563 1 0.001025 0.000064 - W W M 12.07 T C0 B
NEK11 NM_024800.4
chr3: 
130748679 c.127G>C 3 p.(Val43Leu) ms rs140058289 2 0.002049 0.00016d - H H S 27.5 D C25 P
NEK11 NM_024800.4
chr3: 
130947497 c.1525G>C 15 p.(Glu509Gln) ms - 1 0.001025 0 - W W S 5.17 T C0 B
OCA2 NM_000275.2
chr15: 
28326992 c.29G>A 2 p.(Arg10Gln) ms rs199752361 1 0.001025 0.00051 0.002 W W S 11.75 T C0 B
OCA2 NM_000275.2
chr15: 
28326984 c.37G>A 2 p.(Gly13Ser) ms rs201554429 1 0.001025 0.000038 - W W S 10.86 T C0 B
OCA2 NM_000275.2
chr15: 
28326977 c.44C>G 2 p.(Pro15Arg) ms - 1 0.001025 - - W W M 11.18 T C0 B
OCA2 NM_000275.2
chr15: 
28326858 c.163del 2 p.(Ala55Leufs*47) fs - 1 0.001025 0.000019 - - - - - - - -
OCA2 NM_000275.2
chr15: 
28263599 c.751G>A 7 p.(Val251Met) ms rs147432138 1 0.001025 0.00017d - N W S 4.551 T C0 B
OCA2 NM_000275.2
chr15: 
28263554 c.796C>T 7 p.(Arg266Trp) ms rs33929465 1 0.001025 0.0018d 0.003 W H M 18.24 D C0 P
OCA2 NM_000275.2
chr15: 
28261316 c.824C>T 8 p.(Thr275Met) ms rs369750458 1 0.001025 0.000036 - M M M 25.7 T C0 P
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28230319 c.1255C>T 13 p.(Arg419Trp) ms rs143218168 1 0.001025 0.00011 - N H M 32 D C0 D
OCA2 NM_000275.2
chr15: 
28230313 c.1261C>T 13 p.(Arg421Trp) ms rs372899234 1 0.001025 0.000065 - W M M 28 D C0 D
OCA2 NM_000275.2
chr15: 
28230247 c.1327G>A 13 p.(Val443Ile) ms rs121918166 18 0.018443 0.0051 0.008 H H S 34 T C0 D
OCA2 NM_000275.2
chr15: 
28230238 c.1336A>G 13 p.(Met446Val) ms rs140566426 2 0.002049 0.00025 0.001 W M S 1.045 T C0 B
OCA2 NM_000275.2
chr15: 
28228553 c.1441G>A 14 p.(Ala481Thr) ms rs74653330 1 0.001025 0.0026d 0.001 H H S 27.6 T C0 P
OCA2 NM_000275.2
chr15: 
28228529 c.1465A>G 14 p.(Asn489Asp) ms rs121918170 7 0.007172 0.0007 0.003 M H S 28.2 D C0 D
OCA2 NM_000275.2
chr15: 
28211880 c.1592A>G 15 p.(Tyr531Cys) ms rs143699063 1 0.001025 0.00011 0.001 W M L 25.3 D C0 D
OCA2 NM_000275.2
chr15: 
28202728 c.1784+6G>A - p.? intron rs779188429 1 0.001025 0.000019 - - - - - - - -
OCA2 NM_000275.2
chr15: 
28171315 c.2037G>C 19 p.(Trp679Cys) ms rs121918169 1 0.001025 0.00015 - H H L 34 D C0 D
OCA2 NM_000275.2
chr15: 





del - p.? intron - 1 0.001025 - - - - - - - - -
PARP1 NM_001618.3
chr1: 
226578278 c.450G>T 4 p.(Gln150His) ms rs142376976 3 0.003074 0.00051 0.001 W H S 23.4 T C0 D
PARP1 NM_001618.3
chr1: 
226573230 c.986A>G 7 p.(Asn329Ser) ms - 1 0.001025 - - W W S 7.255 T C0 B
PARP1 NM_001618.3
chr1: 
226570767 c.1129C>T 8 p.(Pro377Ser) ms rs2230484 3 0.003074 0.0068 0.004 M H M 13.58 T C0 B
PARP1 NM_001618.3
chr1: 
226570748 c.1148C>A 8 p.(Ser383Tyr) ms rs3219062 9 0.009221 0.0027 0.002 H M L 24.6 D C0 B
PARP1 NM_001618.3
chr1: 
226567661 c.1505C>T 10 p.(Ala502Val) ms rs183533639 3 0.003074 0.00082 - W M S 10.01 T C0 B
PARP1 NM_001618.3
chr1: 
226564936 c.1814C>T 13 p.(Pro605Leu) ms rs369900729 1 0.001025 0.000036 - M M M 22.6 D C15 B
PARP1 NM_001618.3
chr1: 
226564855 c.1895C>T 13 p.(Thr632Met) ms rs138228205 2 0.002049 0.00034 - M M M 26.2 T C0 B
PARP1 NM_001618.3
chr1: 
226552705 c.2656G>A 19 p.(Val886Met) ms rs776746526 1 0.001025 0.000027 - H H S 32 D C0 D
PARP1 NM_001618.3
chr1: 
226549169 c.3037C>A 23 p.(Leu1013Met) ms rs138906127 2 0.002049 0.00095 - W H S 18.79 T C0 B
POLE NM_006231.2
chr12: 
133253180 c.861T>A 9 p.(Asp287Glu) ms rs139075637 9 0.009221 0.0017 0.004 W H S 25.7 D C35 D
POLE NM_006231.2
chr12: 
133253148 c.893A>G 9 p.(Tyr298Cys) ms - 1 0.001025 - - H H L 28.3 D C65 D
POLE NM_006231.2
chr12: 
133250290 c.1230G>A 13 p.(Trp410*) ns - 1 0.001025 - - - - - 38 - - -
POLH NM_006502.2
chr6: 
43550882 c.272+4A>G - p.? intron rs373430329 1 0.001025 0.00041 - - - - - - - - ±
POLH NM_006502.2
chr6: 
43555032 c.296T>C 4 p.(Val99Ala) ms rs750026446 1 0.001025 0.000036 - H H S 27.4 T C0 D
POLH NM_006502.2
chr6: 
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28230319 c.1255C>T 13 p.(Arg419Trp) ms rs143218168 1 0.001025 0.00011 - N H M 32 D C0 D
OCA2 NM_000275.2
chr15: 
28230313 c.1261C>T 13 p.(Arg421Trp) ms rs372899234 1 0.001025 0.000065 - W M M 28 D C0 D
OCA2 NM_000275.2
chr15: 
28230247 c.1327G>A 13 p.(Val443Ile) ms rs121918166 18 0.018443 0.0051 0.008 H H S 34 T C0 D
OCA2 NM_000275.2
chr15: 
28230238 c.1336A>G 13 p.(Met446Val) ms rs140566426 2 0.002049 0.00025 0.001 W M S 1.045 T C0 B
OCA2 NM_000275.2
chr15: 
28228553 c.1441G>A 14 p.(Ala481Thr) ms rs74653330 1 0.001025 0.0026d 0.001 H H S 27.6 T C0 P
OCA2 NM_000275.2
chr15: 
28228529 c.1465A>G 14 p.(Asn489Asp) ms rs121918170 7 0.007172 0.0007 0.003 M H S 28.2 D C0 D
OCA2 NM_000275.2
chr15: 
28211880 c.1592A>G 15 p.(Tyr531Cys) ms rs143699063 1 0.001025 0.00011 0.001 W M L 25.3 D C0 D
OCA2 NM_000275.2
chr15: 
28202728 c.1784+6G>A - p.? intron rs779188429 1 0.001025 0.000019 - - - - - - - -
OCA2 NM_000275.2
chr15: 
28171315 c.2037G>C 19 p.(Trp679Cys) ms rs121918169 1 0.001025 0.00015 - H H L 34 D C0 D
OCA2 NM_000275.2
chr15: 





del - p.? intron - 1 0.001025 - - - - - - - - -
PARP1 NM_001618.3
chr1: 
226578278 c.450G>T 4 p.(Gln150His) ms rs142376976 3 0.003074 0.00051 0.001 W H S 23.4 T C0 D
PARP1 NM_001618.3
chr1: 
226573230 c.986A>G 7 p.(Asn329Ser) ms - 1 0.001025 - - W W S 7.255 T C0 B
PARP1 NM_001618.3
chr1: 
226570767 c.1129C>T 8 p.(Pro377Ser) ms rs2230484 3 0.003074 0.0068 0.004 M H M 13.58 T C0 B
PARP1 NM_001618.3
chr1: 
226570748 c.1148C>A 8 p.(Ser383Tyr) ms rs3219062 9 0.009221 0.0027 0.002 H M L 24.6 D C0 B
PARP1 NM_001618.3
chr1: 
226567661 c.1505C>T 10 p.(Ala502Val) ms rs183533639 3 0.003074 0.00082 - W M S 10.01 T C0 B
PARP1 NM_001618.3
chr1: 
226564936 c.1814C>T 13 p.(Pro605Leu) ms rs369900729 1 0.001025 0.000036 - M M M 22.6 D C15 B
PARP1 NM_001618.3
chr1: 
226564855 c.1895C>T 13 p.(Thr632Met) ms rs138228205 2 0.002049 0.00034 - M M M 26.2 T C0 B
PARP1 NM_001618.3
chr1: 
226552705 c.2656G>A 19 p.(Val886Met) ms rs776746526 1 0.001025 0.000027 - H H S 32 D C0 D
PARP1 NM_001618.3
chr1: 
226549169 c.3037C>A 23 p.(Leu1013Met) ms rs138906127 2 0.002049 0.00095 - W H S 18.79 T C0 B
POLE NM_006231.2
chr12: 
133253180 c.861T>A 9 p.(Asp287Glu) ms rs139075637 9 0.009221 0.0017 0.004 W H S 25.7 D C35 D
POLE NM_006231.2
chr12: 
133253148 c.893A>G 9 p.(Tyr298Cys) ms - 1 0.001025 - - H H L 28.3 D C65 D
POLE NM_006231.2
chr12: 
133250290 c.1230G>A 13 p.(Trp410*) ns - 1 0.001025 - - - - - 38 - - -
POLH NM_006502.2
chr6: 
43550882 c.272+4A>G - p.? intron rs373430329 1 0.001025 0.00041 - - - - - - - - ±
POLH NM_006502.2
chr6: 
43555032 c.296T>C 4 p.(Val99Ala) ms rs750026446 1 0.001025 0.000036 - H H S 27.4 T C0 D
POLH NM_006502.2
chr6: 
43555151 c.415G>A 4 p.(Ala139Thr) ms rs554936509 2 0.002049 - 0.001 M M S 23 T C0 P
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43565568 c.626G>T 5 p.(Gly209Val) ms rs2307456 2 0.002049 0.0032d 0.003 M H M 28.1 D C15 D
POLH NM_006502.2
chr6: 
43572357 c.890G>A 8 p.(Trp297*) ns - 1 0.001025 - - - - - 40 - - -
POLH NM_006502.2
chr6: 
43573062 c.1074+6A>G - p.? intron - 1 0.001025 - - - - - - - - -
POLH NM_006502.2
chr6: 
43581662 c.1510C>T 11 p.(Pro504Ser) ms - 1 0.001025 0.000009 - W M M 0.001 T C0 B
POLH NM_006502.2
chr6: 
43581782 c.1630C>A 11 p.(Leu544Ile) ms - 1 0.001025 - - W M S 9.276 T C0 B
POLH NM_006502.2
chr6: 
43581915 c.1763C>T 11 p.(Ser588Phe) ms - 1 0.001025 - - W M L 17.46 T C0 B
POT1 NM_015450.2
chr7: 
124491972 c.903G>T 11 p.(Gln301His) ms rs116916706 1 0.001025 0.0042 0.003 N H S 15.65 T C0 P
POT1 NM_015450.2
chr7: 





3del - p.? intron rs587780544 1 0.001025 0.0003 - - - - - - - - ±
RAD51B NM_133509.3
chr14: 
68301816 c.218A>G 4 p.(Gln73Arg) ms rs774570772 1 0.001025 0.000018 - W W S 4.787 T C0 B
RAD51B NM_133509.3
chr14: 
68331840 c.436G>A 5 p.(Ala146Thr) ms rs200741476 1 0.001025 0.00027 0.002 H H S 25.3 T C0 P
RAD51B NM_133509.3
chr14: 
68352579 c.453-7C>T - p.? intron rs201722637 1 0.001025 0.0004 0.001 - - - - - - -
RAD51B NM_133509.3
chr14: 
68352672 c.539A>G 6 p.(Tyr180Cys) ms rs28910275 8 0.008197 0.0039d - W M L 18.52 T C0 B
RAD51B NM_133509.3
chr14: 
68353784 c.619G>T 7 p.(Val207Leu) ms rs28908168 4 0.004098 0.0029 0.004 W H S 15.32 D C0 B
RAD51B NM_133509.3
chr14: 
69061228 c.1063G>A 11 p.(Ala355Thr) ms rs61758785 9 0.009221 0.0041 0.004 W W S 7.995 T C0 B
RASEF NM_152573.3
chr9: 





6dup - p.? intron - 1 0.001025 - - - - - - - - -
RASEF NM_152573.3
chr9: 
85622429 c.960-9A>G - p.? intron rs375961814 3 0.003074 0.000027 - - - - - - - - ±
RASEF NM_152573.3
chr9: 
85620394 c.1049_1050del 8 p.(His350Argfs*3) fs rs755447494 1 0.001025 0.000063 - - - - - - - - ±
RASEF NM_152573.3
chr9: 
85619464 c.1151G>A 9 p.(Arg384Lys) ms rs138418572 1 0.001025 0.0005 0.001 H M S 15.71 T C0 B
RASEF NM_152573.3
chr9: 
85613340 c.1745C>A 13 p.(Thr582Asn) ms rs143848788 1 0.001025 0.00017 - M H S 22.6 D C0 B
RASEF NM_152573.3
chr9: 
85605345 c.2078A>G 16 p.(Asp693Gly) ms - 1 0.001025 0.000018 - H H M 32 D C0 P ±
RASEF NM_152573.3
chr9: 
85597608 c.2207A>T 17 p.(Asn736Ile) ms rs762067279 1 0.001025 0.000027 - W M L 27.4 D C0 P
TERF1 NM_017489.2
chr8: 





up) dup rs755588334 1 0.001025 0.00014 - M H - - - - -
TERF1 NM_017489.2
chr8: 
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43565568 c.626G>T 5 p.(Gly209Val) ms rs2307456 2 0.002049 0.0032d 0.003 M H M 28.1 D C15 D
POLH NM_006502.2
chr6: 
43572357 c.890G>A 8 p.(Trp297*) ns - 1 0.001025 - - - - - 40 - - -
POLH NM_006502.2
chr6: 
43573062 c.1074+6A>G - p.? intron - 1 0.001025 - - - - - - - - -
POLH NM_006502.2
chr6: 
43581662 c.1510C>T 11 p.(Pro504Ser) ms - 1 0.001025 0.000009 - W M M 0.001 T C0 B
POLH NM_006502.2
chr6: 
43581782 c.1630C>A 11 p.(Leu544Ile) ms - 1 0.001025 - - W M S 9.276 T C0 B
POLH NM_006502.2
chr6: 
43581915 c.1763C>T 11 p.(Ser588Phe) ms - 1 0.001025 - - W M L 17.46 T C0 B
POT1 NM_015450.2
chr7: 
124491972 c.903G>T 11 p.(Gln301His) ms rs116916706 1 0.001025 0.0042 0.003 N H S 15.65 T C0 P
POT1 NM_015450.2
chr7: 





3del - p.? intron rs587780544 1 0.001025 0.0003 - - - - - - - - ±
RAD51B NM_133509.3
chr14: 
68301816 c.218A>G 4 p.(Gln73Arg) ms rs774570772 1 0.001025 0.000018 - W W S 4.787 T C0 B
RAD51B NM_133509.3
chr14: 
68331840 c.436G>A 5 p.(Ala146Thr) ms rs200741476 1 0.001025 0.00027 0.002 H H S 25.3 T C0 P
RAD51B NM_133509.3
chr14: 
68352579 c.453-7C>T - p.? intron rs201722637 1 0.001025 0.0004 0.001 - - - - - - -
RAD51B NM_133509.3
chr14: 
68352672 c.539A>G 6 p.(Tyr180Cys) ms rs28910275 8 0.008197 0.0039d - W M L 18.52 T C0 B
RAD51B NM_133509.3
chr14: 
68353784 c.619G>T 7 p.(Val207Leu) ms rs28908168 4 0.004098 0.0029 0.004 W H S 15.32 D C0 B
RAD51B NM_133509.3
chr14: 
69061228 c.1063G>A 11 p.(Ala355Thr) ms rs61758785 9 0.009221 0.0041 0.004 W W S 7.995 T C0 B
RASEF NM_152573.3
chr9: 





6dup - p.? intron - 1 0.001025 - - - - - - - - -
RASEF NM_152573.3
chr9: 
85622429 c.960-9A>G - p.? intron rs375961814 3 0.003074 0.000027 - - - - - - - - ±
RASEF NM_152573.3
chr9: 
85620394 c.1049_1050del 8 p.(His350Argfs*3) fs rs755447494 1 0.001025 0.000063 - - - - - - - - ±
RASEF NM_152573.3
chr9: 
85619464 c.1151G>A 9 p.(Arg384Lys) ms rs138418572 1 0.001025 0.0005 0.001 H M S 15.71 T C0 B
RASEF NM_152573.3
chr9: 
85613340 c.1745C>A 13 p.(Thr582Asn) ms rs143848788 1 0.001025 0.00017 - M H S 22.6 D C0 B
RASEF NM_152573.3
chr9: 
85605345 c.2078A>G 16 p.(Asp693Gly) ms - 1 0.001025 0.000018 - H H M 32 D C0 P ±
RASEF NM_152573.3
chr9: 
85597608 c.2207A>T 17 p.(Asn736Ile) ms rs762067279 1 0.001025 0.000027 - W M L 27.4 D C0 P
TERF1 NM_017489.2
chr8: 





up) dup rs755588334 1 0.001025 0.00014 - M H - - - - -
TERF1 NM_017489.2
chr8: 
73939257 c.857A>G 6 p.(Glu286Gly) ms - 1 0.001025 - - W M M 28.4 D C0 B
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73958245 c.1193A>G 10 p.(Tyr398Cys) ms rs760966818 1 0.001025 0.000009 - W H L 24.7 D C25 D
TERF2 NM_005652.4
chr16: 
69419852 c.23C>G 1 p.(Ala8Gly) ms - 1 0.001025 - - W W S 12.75 D C0 -
TERF2 NM_005652.4
chr16: 
69419819 c.56A>G 1 p.(Asp19Gly) ms rs773981277 1 0.001025 0.00012 - W W M 16.35 D C0 P
TERF2 NM_005652.4
chr16: 
69419801 c.74C>T 1 p.(Pro25Leu) ms rs749171225 2 0.002049 0.00043 - M W M 19.54 D C0 B
TERF2 NM_005652.4
chr16: 
69406163 c.693+9G>A - p.? intron rs191776266 4 0.004098 0.0037 0.002 - - - - - - -
TERF2 NM_005652.4
chr16: 
69404432 c.794G>A 5 p.(Arg265His) ms rs763347805 1 0.001025 0.000027 - M M S 28.3 D C0 P
TERF2 NM_005652.4
chr16: 
69401088 c.962C>T 7 p.(Pro321Leu) ms - 1 0.001025 - - W M M 21.2 D C0 B
TERF2 NM_005652.4
chr16: 
69395387 c.1346C>T 8 p.(Pro449Leu) ms - 1 0.001025 - - W W M 20.5 T C0 B
TERF2 NM_005652.4
chr16: 
69390938 c.1492G>A 10 p.(Glu498Lys) ms rs150757154 4 0.004098 0.0022 0.003 M H S 34 D C55 P
TERF2IP NM_018975.3
chr16: 
75682178 c.398G>A 1 p.(Arg133Gln) ms - 1 0.001025 0.00022 - W H S 23.4 D C35 B
TINF2 NM_001099274.1
chr14: 
24711501 c.38G>T 1 p.(Arg13Leu) ms - 1 0.001025 - - M H M 27 D C0 D
TINF2 NM_001099274.1
chr14: 
24711477 c.62A>G 1 p.(Gln21Arg) ms rs367835995 1 0.001025 0.00023 - N M S 0.001 T C0 B
TINF2 NM_001099274.1
chr14: 
24711465 c.74G>C 1 p.(Gly25Ala) ms rs202093758 1 0.001025 0.0024 0.001 W M S 12.31 T C0 B
TINF2 NM_001099274.1
chr14: 
24709976 c.710G>A 6 p.(Gly237Asp) ms rs17102313 1 0.001025 0.00015d - W H M 7.836 T C0 B
TINF2 NM_001099274.1
chr14: 
24709965 c.721C>T 6 p.(Pro241Ser) ms rs17102311 1 0.001025 0.000063d - W H M 23.4 T C0 D
TINF2 NM_001099274.1
chr14: 
24709952 c.734C>A 6 p.(Ser245Tyr) ms rs142777869 3 0.003074 0.00073 - N W L 22.7 D C15 B
AN = allele number, NT = nucleotide (PhyloP score), AA = amino acid, GD = Grantham distance, Spl = splicing effect
Variant type: ms = missense, fs = frameshift, ns = nonsense, syn = synonymous, del = in-frame deletion, 
dup = in-frame duplication
Evolutionary Conservation/Distance: N = not, W = weak, M = moderate, H = high, S = small, L = large
In-Silico Prediction Tools: T = tolerated, D = deleterious (SIFT), B = benign, P = possibly damaging, D = probably 
damaging (PolyPhen-2), + = likely affects splicing, ± = possibly affects splicing 
a in European (Non-Finnish) population
b Possible classifications in Align GVGD are C0, C15, C25, C35, C45, C55 and C65. Variants in class C0 have the least 
probability of being pathogenic, variants in class C65 have the highest probability of being pathogenic. 
See also http://agvgd.hci.utah.edu/classifiers.php 
b HumVar trained PolyPhen-2 model used for prediction
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73958245 c.1193A>G 10 p.(Tyr398Cys) ms rs760966818 1 0.001025 0.000009 - W H L 24.7 D C25 D
TERF2 NM_005652.4
chr16: 
69419852 c.23C>G 1 p.(Ala8Gly) ms - 1 0.001025 - - W W S 12.75 D C0 -
TERF2 NM_005652.4
chr16: 
69419819 c.56A>G 1 p.(Asp19Gly) ms rs773981277 1 0.001025 0.00012 - W W M 16.35 D C0 P
TERF2 NM_005652.4
chr16: 
69419801 c.74C>T 1 p.(Pro25Leu) ms rs749171225 2 0.002049 0.00043 - M W M 19.54 D C0 B
TERF2 NM_005652.4
chr16: 
69406163 c.693+9G>A - p.? intron rs191776266 4 0.004098 0.0037 0.002 - - - - - - -
TERF2 NM_005652.4
chr16: 
69404432 c.794G>A 5 p.(Arg265His) ms rs763347805 1 0.001025 0.000027 - M M S 28.3 D C0 P
TERF2 NM_005652.4
chr16: 
69401088 c.962C>T 7 p.(Pro321Leu) ms - 1 0.001025 - - W M M 21.2 D C0 B
TERF2 NM_005652.4
chr16: 
69395387 c.1346C>T 8 p.(Pro449Leu) ms - 1 0.001025 - - W W M 20.5 T C0 B
TERF2 NM_005652.4
chr16: 
69390938 c.1492G>A 10 p.(Glu498Lys) ms rs150757154 4 0.004098 0.0022 0.003 M H S 34 D C55 P
TERF2IP NM_018975.3
chr16: 
75682178 c.398G>A 1 p.(Arg133Gln) ms - 1 0.001025 0.00022 - W H S 23.4 D C35 B
TINF2 NM_001099274.1
chr14: 
24711501 c.38G>T 1 p.(Arg13Leu) ms - 1 0.001025 - - M H M 27 D C0 D
TINF2 NM_001099274.1
chr14: 
24711477 c.62A>G 1 p.(Gln21Arg) ms rs367835995 1 0.001025 0.00023 - N M S 0.001 T C0 B
TINF2 NM_001099274.1
chr14: 
24711465 c.74G>C 1 p.(Gly25Ala) ms rs202093758 1 0.001025 0.0024 0.001 W M S 12.31 T C0 B
TINF2 NM_001099274.1
chr14: 
24709976 c.710G>A 6 p.(Gly237Asp) ms rs17102313 1 0.001025 0.00015d - W H M 7.836 T C0 B
TINF2 NM_001099274.1
chr14: 
24709965 c.721C>T 6 p.(Pro241Ser) ms rs17102311 1 0.001025 0.000063d - W H M 23.4 T C0 D
TINF2 NM_001099274.1
chr14: 
24709952 c.734C>A 6 p.(Ser245Tyr) ms rs142777869 3 0.003074 0.00073 - N W L 22.7 D C15 B
AN = allele number, NT = nucleotide (PhyloP score), AA = amino acid, GD = Grantham distance, Spl = splicing effect
Variant type: ms = missense, fs = frameshift, ns = nonsense, syn = synonymous, del = in-frame deletion, 
dup = in-frame duplication
Evolutionary Conservation/Distance: N = not, W = weak, M = moderate, H = high, S = small, L = large
In-Silico Prediction Tools: T = tolerated, D = deleterious (SIFT), B = benign, P = possibly damaging, D = probably 
damaging (PolyPhen-2), + = likely affects splicing, ± = possibly affects splicing 
a in European (Non-Finnish) population
b Possible classifications in Align GVGD are C0, C15, C25, C35, C45, C55 and C65. Variants in class C0 have the least 
probability of being pathogenic, variants in class C65 have the highest probability of being pathogenic. 
See also http://agvgd.hci.utah.edu/classifiers.php 
b HumVar trained PolyPhen-2 model used for prediction
d Common variant (MAF>1%) in one or more non-European populations
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SUPPLEMENTARY FIGURE S1. Families with a (likely) pathogenic variant in BAP1. 
Symbols quarter-filled in upper left corner (red) represent melanoma, symbols quarter-filled in lower 
right corner (green) represent other cancers, symbols filled with a square in upper left corner (black) 
represent benign skin lesions. Age of onset in years is shown in parentheses. Unconfirmed cancer 
diagnoses are also shown in parentheses with “?”. Probands are indicated with an arrow point and M 
(=mutation). 
CM = cutaneous melanoma, BCC = basal cell carcinoma, NHL = Non-Hodgkin lymphoma, b = year of birth, 
dec = age deceased
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In this thesis, we performed several genotype and phenotype studies in hereditary and 
familial melanoma patient cohorts. In the first part, our studies focused on patients with 
the p16-Leiden founder mutation in the CDKN2A gene. This founder mutation is the major 
cause of the familial melanoma-pancreatic cancer syndrome in the Dutch population. Since 
many p16-Leiden mutation carriers live in the vicinity of Leiden and are under frequent 
dermatologic and/or pancreatic cancer (PC) surveillance at Leiden University Medical 
Center (LUMC), the relatively large and homogeneous p16-Leiden cohort of the LUMC is 
unique in its kind. We studied the cancer phenotype (chapter 2) and modifiers of cancer risk 
(chapters 2 and 3) in these p16-Leiden mutation carriers. We also evaluated the p16-Leiden 
PC surveillance program by studying the role of precursor lesions in the development 
and early detection of PC (chapter 4), by reflecting on the surgical management of 
early-stage screen-detected PC (chapter 5) and by studying potential biomarkers for 
the early detection of PC (chapter 6). The LUMC has also been the primary sequencing 
facility for CDKN2A in the Netherlands since 1998 and therefore, a large collection of 
DNA samples and clinical information of melanoma families from across the Netherlands 
has been acquired in the last two decades. In the second part of this thesis, our studies 
focused on this familial melanoma cohort, of which ~85% do not harbour a germline 
CDKN2A mutation. We studied which clinical features are associated with the presence 
of a CDKN2A mutation in a melanoma family and created a scoring system to predict 
CDKN2A mutation probability (chapter 7). Furthermore, we genetically characterized 
melanoma families without a CDKN2A mutation for variants in other (candidate) melanoma 
predisposition genes (chapter 8). In this final chapter, we discuss the main findings of 




THE EXTENDED CANCER PHENOTYPE OF CDKN2A 
The CDKN2A gene is primarily a melanoma predisposition gene, and up to 40% 
of melanoma-prone families harbour a germline mutation in CDKN2A.1,2 In many 
CDKN2A-mutated melanoma families, a clear excess of PC has also been reported,3,4 
and the lifetime risk for PC is estimated to be approximately 15-20% for carriers of the 
p16-Leiden founder mutation.5,6 Because of the frequent co-occurrence of these two 
cancers in CDKN2A-mutated families, the condition is sometimes referred to as familial 
melanoma-pancreatic cancer syndrome (MIM #606719^). There is now increasing evidence 
that CDKN2A mutation carriers are also at risk for cancers at sites other than skin and 
pancreas, in particular cancer of the upper respiratory tract, i.e. head and neck region 
(larynx, pharynx and oral region), and possibly also cancer of the lower respiratory tract 
(lung). Head and neck cancers and lung cancer were initially reported in several case 
studies of CDKN2A-mutated families with various mutations.7-9 In a large study by de Snoo 
et al in 2008, a cohort of 221 p16-Leiden mutation carriers and 668 first-degree relatives 
was retrospectively evaluated for the occurrence of any cancer and significant risks were 
found for cancers of the lip, mouth and pharynx (RR 10.8) and cancers of the respiratory 
system including laryngeal cancer (RR 5.7).6 In chapter 2, we aimed to confirm the findings 
of the de Snoo et al study by prospectively evaluating a cohort of 150 p16-Leiden mutation 
carriers that were participating in the PC surveillance program and we again found a 
particular excess of cancers of the lip, mouth and pharynx (n=3, RR 18.8) and cancers of the 
respiratory system (n=4, RR 4.6). Since two of the four respiratory system cancers in our 
study were laryngeal cancers, a total of five cancers were located in the head and neck 
cancer region, making it the third most frequent cancer site in these p16-Leiden mutation 
carriers (following skin and pancreas). This number is striking considering the relatively low 
incidence of head and neck cancers in the general population (approximately 3000 new 
cases each year in the Netherlands; age standardized rate 9 per 100.000).10 A study with 
very similar results was concomitantly published by a Swedish group that assessed cancer 
risks in a cohort of 120 individuals with a specific Swedish CDKN2A founder mutation 
(p.Arg112dup).11 In this study, significantly increased risks other than melanoma and PC 
were again observed for cancers of the upper digestive tract (including oral region and 
pharynx; RR 17.1) and respiratory tract (including larynx; RR 15.6), and the majority of these 
cancers were indeed located in the head and neck region. In a subsequent collaboration 
study with the Swedish group (chapter 7), we further investigated the occurrence of 
cancers in the head and neck region* in CDKN2A mutation carriers by incorporating this 
^ Mendelian Inheritance in Man; Catalog of Human Genes and Genetic Disorders (http://www.omim.org) 
* In chapter 7, the term upper airway cancer (UAC) is used as a synonym for cancers of the head and neck region 




clinical feature and four additional features in a CDKN2A mutation probability scoring 
system (CM-Score). We showed that the presence of these cancers in Dutch melanoma 
families was significantly associated with the presence of a germline CDKN2A mutation 
(OR 6.0). Since the scoring system could accurately predict CDKN2A mutation status in 
both the Dutch training cohort and the Swedish validation cohort, we demonstrated that 
cancers in the head and neck region are indeed an important component of the CDKN2A 
cancer phenotype in different populations with different CDKN2A mutations. Therefore, 
it might be more appropriate to use the term ‘CDKN2A-associated cancer predisposition 
syndrome’ when referring to the familial melanoma-pancreatic cancer syndrome, because 
this term better reflects the broader tumour spectrum to which CDKN2A mutation 
carriers are predisposed to. It should however be noted that ~80% of both Dutch and 
Swedish CDKN2A-mutated families in chapter 7 had a CDKN2A founder mutation located 
in exon 2 (p16-Leiden and p.Arg112dup, respectively), which might indicate a possible 
genotype-phenotype correlation between specific CDKN2A (exon 2) mutations and head 
and neck cancers. Yet, case studies reporting a high incidence of head and neck cancers 
in CDKN2A-mutated families have not been confined to families with mutations in exon 2; 
Cabanillas et al reported a melanoma family with multiple cases of head and neck cancer 
and a truncating CDKN2A mutation in exon 1α.8 Replication studies in large cohorts with 
different CDKN2A mutations are needed to further explore possible genotype-phenotype 
correlations. Only one such study has recently been published, in which 29 American 
CDKN2A-mutated melanoma families were evaluated over a relatively long period of four 
decades. No increased risk for cancers other than melanoma or PC were found in this 
study. Unfortunately, the specific CDKN2A mutations found in these families were not 
reported.12 
MODIFIERS OF CANCER RISK IN CDKN2A MUTATION 
CARRIERS
NON-GENETIC MODIFIERS
Several phenotypic characteristics known to be associated with increased melanoma 
risk in the general population, such as the number of dysplastic nevi, poor tanning ability 
and sunburns in childhood, have also been shown to modify melanoma risk in carriers 
of a germline CDKN2A mutation.13 Therefore, early patient education on sun protection 
is essential for carriers and their first-degree relatives. Interestingly, the most important 
non-melanoma cancers associated with CDKN2A mutations, i.e. PC, head and neck 
cancer and lung cancer, are strongly related to tobacco use in the general population.14,15 




developing PC in the setting of familial PC (FPC).16 We investigated in chapter 2 if tobacco 
use is also associated with a higher risk of PC and other tobacco-related cancers in 
p16-Leiden mutation carriers. In total, 27% of current smokers in the cohort developed 
a tobacco-related cancer versus 7% of the former- and never-smokers. Current smokers 
therefore had a fourfold increased risk of developing these types of cancers (P=0.002). 
These findings were confirmed in the Swedish CDKN2A cancer risk study, where 
ever-smokers had an odds ratio of 9.3 for developing tobacco-related cancers compared to 
never-smokers.11 Thus, tobacco use seems a significant modifier of cancer risk in CDKN2A 
mutation carriers and carriers should be strongly discouraged to smoke. 
GENETIC MODIFIERS
A well-established modifier gene of melanoma risk in germline CDKN2A mutation carriers 
is MC1R, a gene involved in skin pigmentation.17,18 In contrast, little is known about genetic 
modifiers that might influence the risk of other cancers such as PC in CDKN2A mutation 
carriers. Since there is notable interfamilial variability in the occurrence of PC among 
p16-Leiden families that might not be fully explained by differences in tobacco use or 
other non-genetic risk factors among mutation carriers, we investigated in chapter 3 
whether common Single Nucleotide Polymorphisms (SNPs) that are associated with PC 
in the general population might influence PC risk in p16-Leiden families. We genotyped 
seven PC-associated SNPs in a cohort of 185 p16-Leiden mutation carriers of whom 50 
were diagnosed with PC, but found no significant association with PC for any of these 
SNPs. The study might have been underpowered for a detectable effect but it might 
also be possible that other PC-associated SNPs that were not genotyped in this study 
modify PC risk in p16-Leiden families. No additional studies have yet been performed 
that investigate SNPs as potential genetic modifiers of PC in CDKN2A-mutated families. 
However, Yang et al investigated if patients with PC and a germline CDKN2A mutation 
might also have one or more rare variants in 24 other (putative) PC-related genes.19 In this 
study, nominally significant associations between PC and rare variants in the mismatch 
repair (MMR) genes were found, and some patients had more than one rare variant in 
PC-related genes. However, no loss-of-function variants were detected in these patients 
and only a subset of variants was classified as potentially deleterious. Therefore, the 




PANCREATIC CANCER SURVEILLANCE AND 
-MANAGEMENT OF P16-LEIDEN MUTATION CARRIERS
P16-Leiden mutation carriers are offered yearly PC surveillance at the LUMC from the 
age of 45. Promising results of this program and several other PC surveillance programs 
worldwide have been published in the last two decades, however, the diagnostic yield of 
these programs varies greatly.20-22 One explanation might be that there are differences 
in the definition of diagnostic yield among these programs. For instance, some programs 
included histologically confirmed lower-grade precursor lesions (PanIN1-2) in their 
diagnostic yield and it can be questioned if the resection of these lesions is relevant in 
these patients. Moreover, cystic duct lesions detected with pancreatic imaging might very 
well be benign or lower-grade lesions if there is no histological confirmation, and including 
such lesions in the diagnostic yield of a surveillance program can cause significant bias. 
There are also differences in which high-risk individuals are included in the surveillance 
programs. Most programs largely focus on individuals from FPC families, but some also 
include a significant number of individuals with a germline mutation in a known cancer 
predisposition gene such as CDKN2A or BRCA1/2. Since the PC surveillance program of 
the LUMC is almost entirely focused on CDKN2A mutation carriers, the majority of which 
have the p16-Leiden founder mutation, it is distinctive from other PC surveillance programs 
worldwide. To further explore possible phenotypic differences between high-risk groups 
that might influence diagnostic yield, we studied in chapter 4 the frequency and behaviour 
of precursor lesions and PC in two different surveillance cohorts, that is, the LUMC p16-
Leiden cohort (n=116) and a German FPC cohort (n=125). We reported substantially more 
diagnoses of PC in the p16-Leiden cohort (7% versus 0.8% in the FPC cohort), but cystic 
duct lesions were much more common in the FPC cohort (42% versus 16% in the p16-Leiden 
cohort). Histological examination of cystic lesions in the FPC cohort often revealed IPMN or 
PanIN2-3 lesions, whereas in the p16-Leiden cohort few such lesions were seen. Yet, cystic 
lesions in the p16-Leiden cohort frequently showed growth or malignant transformation 
compared to cystic lesions in the FPC cohort. Recently, our findings were confirmed in 
a similar study by Konings et al that compared the prevalence of cystic lesions and their 
natural behaviour between 88 FPC individuals and 98 carriers of a germline mutation that 
predisposes to PC (of which 64 were CDKN2A mutation carriers (65%)).23 In this study, 5% 
of mutation carriers had a pancreatic cyst >10 mm compared to 16% in FPC individuals, but 
cysts in mutation carriers were more likely to grow or develop radiological features that 
suggest high-grade dysplasia (16% vs 2% in FPC individuals). Interestingly, the only two 
patients that developed PC in this study were a CDKN2A mutation carrier (exact mutation 
not reported) and a patient with the rare but highly penetrant Peutz-Jeghers syndrome. 




for PC than FPC individuals. Furthermore, these studies suggest that precursor lesions in 
these carriers might have a higher malignant potential compared to precursor lesions in 
FPC individuals. However, the role of precursor lesions in the development of PC in p16-
Leiden mutation carriers has been questioned in a recent study by Ibrahim et al that found 
a similar malignancy rate in p16-Leiden mutation carriers with a cystic lesion compared 
to those without cystic lesions.24 Still, 50% of larger cysts (>10 mm) progressed to PC in 
this study. The authors also reported a particular high growth rate of PC of approximately 
15 mm/year and thus confirmed previous observations of aggressively growing tumours 
in p16-Leiden mutation carriers.20 Taken together, p16-Leiden mutation carriers have a 
particularly high risk for aggressively growing PCs, and cystic lesions, especially when >10 
mm, are often instable at follow-up and might precede the development of PC in some 
carriers. Therefore, a more intensive PC surveillance program, for instance semi-annual 
surveillance with alternating MRI/MRCP and EUS, might be considered for this group if 
future studies show this program to be cost-effective.
The ultimate goal of PC surveillance is to improve survival of high-risk individuals, through 
timely resection of early-stage PC or its high-grade precursor lesions. In 2016, a large 
multicentre study by Vasen et al was the first to show a beneficial effect of regular 
surveillance on survival.25 In the subset of CDKN2A-p16-Leiden mutation carriers (n=178), 
the resection rate of PC was high (75% compared to 15% in sporadic PC) and patients with 
screen-detected PC had a substantial improved 5-year survival rate (24% compared to 
only 4-7% in symptomatic sporadic PC). The survival benefit in the FPC subset (n=233) was 
less clear, since only one PC and a few high-grade precursor lesions were detected in this 
subset. However, Canto et al recently demonstrated a positive effect of surveillance on 
survival in FPC individuals as well.26 In this large (n=354) and long-term follow-up (16 years) 
surveillance study, which mainly included FPC individuals, nine of ten PCs detected during 
surveillance were resectable and the 3-year survival rate of these patients was greatly 
improved to 85%. An additional ten individuals had a resection of one or more high-grade 
precursor lesions and none of these patients died during follow-up (median 7.9 years). 
In general, the survival rate after surgical resection of PC is largely determined by the 
chance of local disease recurrence or distant metastases. In the Vasen et al surveillance 
study, the resection margin was free of cancer in 78% of p16-Leiden mutation carriers that 
underwent surgery, and 56% had cancer-free lymph nodes.25 However, in patients with 
a hereditary predisposition for PC such as p16-Leiden, the occurrence of other primary 
cancers (melanoma in particular) might also influence survival. For instance, one p16-Leiden 
mutation carrier with PC reported by the Vasen et al study died 10 months after diagnosis 
from melanoma metastases. Also, second primary melanomas are frequently seen in p16-




the same tissue is characteristic for many hereditary forms of cancer. Therefore, it is very 
well conceivable that p16-Leiden mutation carriers who underwent a partial resection for 
PC are still at risk for a second primary PC in the remnant pancreas, and developing such a 
second primary PC will also influence survival. In chapter 5, we report the first p16-Leiden 
mutation carrier with a second primary PC after a partial resection. This patient had a small 
(5 mm) early-stage PC that was detected during surveillance and developed a second 
primary PC 4.5 years later that was also detected by continuing surveillance. Subsequently, 
several additional p16-Leiden mutation carriers with a second primary PC (synchronous and 
metachronous) have been reported by our group,27,28 and more patients will probably be 
diagnosed in the future because of improved survival of p16-Leiden mutation carriers with 
a screen-detected PC, as reported by Vasen et al.25 The development of a second primary 
PC in these patients can only be completely prevented when a total pancreatectomy of 
the first cancer is performed. Prevention of a second primary PC is especially relevant for 
patients that are diagnosed with an early-stage and prognostically favourable PC, and we 
therefore recommend to consider a total pancreatectomy as one of the surgical options 
in these patients. Although a total pancreatectomy is a major operation, the post-surgical 
outcomes and quality of life are, present-day, comparable to those who underwent a 
partial pancreatectomy.29,30 The disadvantages of a total pancreatectomy, such as the 
development of (brittle) diabetes, should however be carefully discussed with these 
patients and shared-decision making is essential. Future studies that assess the actual risk 
for developing a second primary PC are needed and results from these studies might aid 
in the difficult decision of what type of surgery should be performed in p16-Leiden mutation 
carriers with an early-stage PC. 
To further improve PC surveillance programs, some important limitations of the current 
surveillance programs need to be considered. The most challenging limitations are the 
suboptimal diagnostic performance of imaging modalities that are currently being used 
(MRI/MRCP and EUS) and the fact that extensive surgery (partial or total pancreatectomy) 
is the only way to remove a suspicious lesion. Pancreatic lesions might not always be 
clearly visible or properly interpreted by the radiologist, and patients that had surgical 
resection for a non-relevant lesion on histologic examination (false-positives) have 
repeatedly been reported.31,32 The Vasen et al surveillance study showed that at least 
5 out of 13 FPC individuals that had a surgical resection of a suspicious lesion had a 
non-relevant (precursor) lesion on histological examination.25 In the p16-Leiden subset, 
only two patients without PC had surgery for suspicious lesions. One of these patients had 
multifocal PanIN1-2 and branch duct (BD-)IPMNs combined with severe multifocal fibrosis 
(we also reported this patient in chapter 4), but the second patient only had one low-grade 




it is very important to minimize the amount of false-positive findings and unnecessary 
resections in otherwise healthy individuals participating in a PC surveillance program.32 
When these individuals do develop PC, a successful surveillance program should be able 
to consistently detect it in the earliest possible stage (high sensitivity; few false-negatives). 
One way to improve the diagnostic performance of surveillance programs is to add (serum) 
biomarkers to the program that can differentiate between PC, relevant precursor lesions 
and non-relevant or no lesions. Among several types of biomarkers that are currently being 
investigated in this context, microRNA panels and global protein profiling (proteomics) 
are relatively new and results are encouraging.33-35 In the LUMC, a specific proteomic 
biomarker signature for PC was previously identified in cohorts of patients with sporadic 
PC.36-38 In chapter 6, we investigated this biomarker signature in a cohort of 66 p16-Leiden 
mutation carriers, of which 5 had developed PC. We could accurately distinguish patients 
with PC from patients without PC using this biomarker signature. Many included p16-Leiden 
mutation carriers had a (recent or non-recent) medical history of one or more melanomas 
(62%), but this did not influence the biomarker signature. The patient with histologically 
confirmed multifocal PanIN1-2 and BD-IPMNs previously reported in chapter 4 could also 
be distinguished from controls. The results of this preliminary study are very promising, but 
additional studies that include more patients with PC and with (relevant and non-relevant) 
precursor lesions will be needed before this biomarker test can be implemented in the 
p16-Leiden PC surveillance program. 
The effectiveness of a cancer surveillance program does not only depend on its technical 
performance, but also on the motivation of participants and their adherence to the 
surveillance protocol. Adherence might be jeopardized when participants experience 
significant psychological distress, which is imaginable when there is a continuing risk for a 
highly lethal form of cancer such as PC that might already have occurred in (close) family 
members. Factors that determine or influence psychological distress should therefore be 
identified and recognized in an early stage.39 Several recent studies that have investigated 
the psychological feasibility of PC surveillance in high-risk groups have shown that most 
participants have a positive attitude towards the program and find that the advantages of 
PC surveillance outweigh the limitations.40-42 Approximately one third of participants worry 
significantly about the possibility of getting cancer, but this does not affect their mood or 
interfere with their daily activities.40,41 Cancer worries decrease each following year and 
getting a positive surveillance result does not influence the level of cancer worries.41,42 
The only reported predictor of cancer worries is having a first degree relative with PC 
under the age of 50 years.42 Importantly, anxiety and depression levels of participants are 
comparable with the general population and stable during follow-up.40,41 Based on these 




GENETIC TESTING AND COUNSELLING OF MELANOMA 
FAMILIES: CDKN2A AND BEYOND
Identifying a causative germline mutation such as p16-Leiden in a melanoma family is 
relevant, since carriers can be enrolled in targeted cancer surveillance programs and 
their family members have the possibility to undergo presymptomatic genetic testing. 
Moreover, gene-specific lifestyle advices and patient education on early cancer symptoms 
can be given to confirmed carriers. For instance, CDKN2A mutation carriers are strongly 
advised to refrain from smoking and to seek medical advice in an early stage when there 
are possible signs of head and neck cancer (hoarseness, dysphagia, ulcers in mouth 
or throat), as we discussed in chapter 2. Knowledge about individual mutation status 
might also influence reproductive choices, since most cancer predisposition syndromes 
(CDKN2A included) have an autosomal dominant inheritance pattern with a 50% risk for 
(future) offspring to inherit the predisposition. Pre-implementation genetic diagnosis (PGD) 
is an assisted reproductive technique that can prevent a future child from inheriting this 
predisposition, but is, by definition, only available for patients with a known underlying 
germline mutation and has indeed been performed for CDKN2A mutation carriers in the 
Netherlands.43 Although some patients might experience significant psychological distress 
from CDKN2A testing, several studies have shown that, in general, CDKN2A testing in 
melanoma families does not result in increased psychological distress or cancer worries 
among carriers and may even enhance compliance with lifestyle advices such as sun 
protection behaviour.44-48 
Genetic testing for hereditary melanoma can thus be beneficial for patients and their 
family members and should therefore be routinely offered to melanoma families. However, 
the chance of identifying a causative germline mutation strongly depends on the cancer 
burden in a family and therefore, selection criteria for performing germline CDKN2A 
analysis were proposed in 2009.49 These criteria are based on the total number of 
melanomas and PCs in a family but do not include age at melanoma diagnosis or the 
presence of other cancers in a family such as head and neck cancers. Recently, a French 
melanoma research group suggested to add age at melanoma diagnosis (<40 years) to the 
2009 criteria in order to improve the detection rate of CDKN2A mutations.50 In chapter 7, 
we included all the above mentioned features in a multivariate logistic regression model 
and found significant associations with the presence of a germline CDKN2A mutation for 
every feature in a cohort of 1227 melanoma families. For further practical purposes we 
developed CM-Score, a non-computerized scoring system that can accurately predict 
CDKN2A mutation status based on the five clinical features from the logistic regression 




daily clinical practice to address questions on heritability of melanoma patients before 
genetic testing is performed. In our model, median age at melanoma diagnosis <50 years 
and the presence of head and neck cancer† in a family were both strong predictors for 
a germline CDKN2A mutation (OR 8.5 and 6.0, respectively). We therefore propose to 
add these features to the current Dutch referral criteria for germline CDKN2A diagnostics 
as shown in table 1. By adding these features, the overall mutation detection rate will 
likely improve and genetic testing of families with a very low probability for a CDKN2A 
mutation (<5%) will be more avoided. Of note, these criteria for CDKN2A diagnostics and 
our CM-Score system are only applicable to melanoma index patients and families and 
are not designed for families with familial pancreatic cancer (FPC). Yet, germline CDKN2A 
mutations are also found in FPC families without any occurrence of melanoma, and genetic 
testing for CDKN2A mutations is therefore recommended to these families as well.51,52
TABLE 1. Proposed referral criteria for germline CDKN2A diagnostics
Familial melanoma
(diagnostic criteria)
	 family with three relatives with melanoma, of which two are first-degree relatives (all 
first- and second-degree relatives)
	 family with two first-degree relatives with melanoma, of which one has multiple 
primary melanomas
Other families 	 family with two first-degree relatives with melanoma with a mean age at diagnosis 
<50 years
	 family with two first- or second-degree relatives with melanoma and one first- or 
second-degree relative with pancreatic cancer or head and neck cancer (larynx, 
pharynx, oral region)
	 person with three or more primary melanomas
	 person with a juvenile melanoma (<18 years)
	 person with both melanoma and pancreatic cancer or head and neck cancer  
(larynx, pharynx, oral region)
The parts in italic are the proposed additions to the current referral criteria.
Although the CDKN2A gene is the most important melanoma predisposition gene that 
should be part of any genetic test for hereditary melanoma, several other high- and medium-
penetrance melanoma predisposition genes are currently known and could potentially be 
tested in addition to CDKN2A (see table 2 in chapter 1).1,2 Pathogenic germline mutations 
in these genes are however much more rare and the yield when tested separately is 
very low (approximately 0-1%; MITF 0-3%).53-57 But when these genes are incorporated in 
† In chapter 7, the term upper airway cancer (UAC) is used as a synonym for cancers of the head and neck region 




a multi-gene panel test for hereditary melanoma, the diagnostic yield of genetic testing can 
increase significantly. We performed such a multi-gene panel test in chapter 8, and report 
an additional 4% diagnostic yield in established melanoma predisposition genes in a cohort 
of 451 non-CDKN2A/CDK4 melanoma families. The most important genes in our panel were 
MITF (p.E318K variant) and BAP1, in which we found pathogenic mutations in 15 (3.4%) and 3 
(0.7%) families, respectively. Conversely, in the genes involved in telomere integrity, we only 
detected two variants of uncertain significance (VUS) in this large cohort, suggesting a minor 
role for these genes in the Dutch population. The additional yield of 4%, a number comparable 
to that reported by similar studies in non-BRCA1/2 breast cancer families,58,59 sufficiently 
justifies multi-gene panel testing in familial melanoma, but the increased chance of finding 
a VUS in one of the genes should be carefully discussed with the patient before such a test 
is requested.60 When a patient is hesitant about multi-gene panel testing, or when there is a 
particularly high probability for a germline CDKN2A mutation based on the presence of PCs 
and/or head and neck cancers in a family (and consequently a high CM-Score, as discussed 
in chapter 7), then targeted CDKN2A diagnostics might be more appropriate as an initial test. 
The referral criteria for CDKN2A diagnostics proposed in table 1 can also be applicable when 
a multi-gene panel test is being considered in a melanoma patient or family, because most 
patients with a germline mutation in one of these genes are expected to have a (familial) 
melanoma phenotype. One clear exception is BAP1, which we also recommend to test if 
there are occurrences of uveal melanoma, malignant mesothelioma, renal cell carcinoma or 
multiple basal cell carcinomas in a melanoma patient or his/her family members.61,62 In our 
multi-gene panel test, we additionally included several candidate melanoma predisposition 
genes, of which the most interesting variants were found in the genes OCA2, BRIP1 and 
POLE. Because of the exponential increase of WES/WGS technologies and possibilities in 
recent years, new candidate genes are continually being discovered by research groups 
worldwide.63-66 These candidate genes have the potential to be added to a diagnostic gene 
panel test for hereditary melanoma in the future, which will likely result in a further increase 
in diagnostic yield of the panel. Moreover, adding a melanoma-specific polygenic risk score 
(PRS) to the panel will enable us to even better differentiate between patients with a higher 
and lower genetic risk for melanoma. This individual risk stratification is an integral part of 
personalized medicine and will further enhance the selection of patients that should or 
should not be offered dermatologic surveillance. The development of a PRS model based on 
common susceptibility SNPs derived from large Genome Wide Association Studies (GWAS) 
is part of a current research project of our group and recently, promising results of melanoma 
PRS models have been published by others.67-69 Altogether, there is great potential for the 
individual patient to undergo multi-gene panel testing and future research will undoubtedly 





SUMMARY AND CONCLUDING REMARKS 
The studies in this thesis were aimed at I) better understanding the clinical phenotype 
of CDKN2A-p16-Leiden mutation carriers and improving the PC surveillance program for 
these carriers, and II) improving genetic testing for hereditary melanoma. In part I, we 
have shown that CDKN2A-p16-Leiden mutation carriers have an increased risk for several 
types of cancer including head and neck cancers, and therefore we have introduced 
the term ‘CDKN2A-associated cancer predisposition syndrome’. We have demonstrated 
that smoking is an important modifier of cancer risk in p16-Leiden mutation carriers and 
we therefore argued that smoking should be actively discouraged. We have also shown 
that, when compared to individuals from FPC families, p16-Leiden mutation carriers have 
a higher risk for (aggressively growing) PC and a lower frequency of precursor lesions of 
PC, but precursor lesions in these carriers might have a particular high malignant potential. 
Future studies should assess the feasibility of a more intensive PC surveillance program 
for this group. Since it is very likely that p16-Leiden mutation carriers that have been 
curatively treated for PC have a substantial risk for developing a second primary PC in the 
longer term, we have recommended to consider a total pancreatectomy when an early-
stage and prognostically favourable PC is diagnosed in these carriers. Furthermore, we 
have demonstrated that a specific proteomic biomarker test for the early detection of PC 
is a very promising candidate for implementation in the PC surveillance program. In part 
II, we created a scoring system (CM-Score) to predict CDKN2A mutation probability and, 
based on several strong predictive features in this model, we have proposed to update 
the current Dutch referral criteria for CDKN2A diagnostics. Lastly, we have demonstrated 
that multi-gene panel testing in non-CDKN2A melanoma families results in an additional 
4% diagnostic yield and that MITF and BAP1 are important genes to include in such a 
panel. We have hypothesized that future incorporation of melanoma candidate genes in 
the panel, supplemented with an individual PRS calculation, will most likely increase the 
diagnostic yield of the panel (although more VUSs will be found as well) and will improve 
individual cancer risk assessment and individual recommendations for cancer surveillance. 
Together with further improvement of complex cancer surveillance programs such as that 
for PC, we are confident that these developments will eventually lead to better survival and 
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Approximately 5-10% of melanoma patients have a familial predisposition for melanoma, 
and up to 40% of familial patients harbor a germline mutation in the major high-risk 
melanoma susceptibility gene CDKN2A. Carriers of a germline CDKN2A mutation have a 
70% lifetime risk for developing (multiple) melanoma, which generally occurs at a young 
age (<40 years). As CDKN2A-mutated melanoma families show pancreatic cancer (PC) as a 
second major type of cancer, the condition is sometimes referred to as familial melanoma-
pancreatic cancer syndrome. In the Netherlands, most of these CDKN2A families have 
a specific Dutch founder mutation known as p16-Leiden. In the first part of this thesis, 
our studies focused on patients with this p16-Leiden founder mutation. Our first aim was 
to investigate the full cancer phenotype associated with the p16-Leiden mutation and to 
study potential genetic and non-genetic modifiers of cancer risk. In addition to regular 
dermatologic surveillance, p16-Leiden mutation carriers are offered yearly MRI-based PC 
surveillance at Leiden University Medical Center. The second aim of this thesis was to 
evaluate and improve the p16-Leiden PC surveillance program by focusing on a) the role 
of precursor lesions (PanIN, IPMN) in the development and early detection of PC, b) the 
surgical management of early-stage screen-detected PC, and c) potential biomarkers for 
possible implementation in the PC surveillance program. The third and final aim of this 
thesis was to to evaluate and improve genetic testing for hereditary melanoma in general, 
a subject that will be addressed in the second part of this thesis. 
In chapter 1, we provide an introduction to familial and hereditary melanoma, the p16-
Leiden CDKN2A founder mutation, and the PC surveillance program in Leiden. 
In chapter 2, we studied the prospective risk of cancer in a cohort of 150 p16-Leiden 
mutation carriers participating in the PC surveillance program. As expected, melanoma and 
PC were the most frequently observed cancers in these individuals, but we also found an 
overall increased risk for other cancers, most notably cancers in the head and neck region 
(lip, mouth, pharynx, and larynx). Moreover, a higher than expected number of (unrelated) 
individuals had a carcinoid tumor or a medical history of sarcoidosis. The risk for developing 
a tobacco-related cancer such as PC or head and neck cancer was increased fourfold 
for current smokers compared to former- and never-smokers. We concluded that active 
intervention to quit or refrain from smoking is very important to the prevention of these 
frequently occurring cancers, and that p16-Leiden mutation carriers should be advised to 
contact their doctor if they have complaints of hoarseness, dysphagia or ulcers in mouth 
or throat. An annual inspection of the mouth and throat might potentially contribute to the 




Among p16-Leiden families, there can be striking variability in the number of family 
members diagnosed with PC. Although tobacco use might explain some of this variability, 
it is also possible that there are additional genetic risk factors (modifiers) in these 
carriers that influence PC risk. In chapter 3, we performed a case-control study of 185 
p16-Leiden mutation carriers, of whom 50 were diagnosed with PC, and investigated 
whether a diagnosis of PC was associated with any of seven selected Single Nucleotide 
Polymorphisms (SNPs) that were derived from large genome wide association studies 
(GWAS) of sporadic PC. In our analyses we found no significant associations with any of 
these SNPs. We then hypothesized that either the cohort was too small to detect an effect, 
that some of the controls might develop PC in the future and therefore could have biased 
the results, or that modification of PC risk in p16-Leiden mutation carriers might actually be 
due to other SNPs that were not selected in this study. 
The studies presented in chapters 4 to 6 focused on the p16-Leiden PC surveillance 
program. In chapter 4, we compared the frequency and behavior of precursor lesions and 
PC in the p16-Leiden PC surveillance cohort (n=116) to a German Familial Pancreatic Cancer 
(FPC) surveillance cohort (n=125). We showed that the frequency of PC was ten times 
higher in the p16-Leiden cohort, but MRI-detected cystic lesions of the pancreatic ducts 
were much more frequent in the FPC cohort. Resected specimens in the FPC cohort also 
frequently revealed IPMN and PanIN2-3 precursor lesions, which were only rarely seen 
in the p16-Leiden cohort. However, as precursor lesions in p16-Leiden mutation carriers 
more often progressed to PC, these lesions appear to have a higher malignant potential in 
p16-Leiden mutation carriers. These findings suggest that a more intensive PC surveillance 
program might be considered for this high-risk group.
In chapter 5, we described two high-risk patients (one p16-Leiden mutation carrier and 
one BRCA2 mutation carrier) who developed a second primary PC two to four years after 
a partial resection of an early-stage (T1-2N0M0) PC. These cases point to a probable 
increased risk for developing a second primary PC in high-risk patients who survive 
long enough after the initial diagnosis. We therefore discussed the advantages and 
disadvantages of total pancreatectomy (TP) and concluded that TP should be considered 
in high-risk patients (p16-Leiden mutation carriers in particular) diagnosed with an early-
stage and prognostically favorable PC. 
An important limitation of current PC surveillance programs is the suboptimal diagnostic 
performance of imaging modalities. Deciding whether a patient actually needs pancreatic 
surgery can therefore be challenging. In chapter 6, we evaluated a previously identified 




program as an additional, non-invasive, screening modality. Using this biomarker signature, 
we could accurately distinguish cases with PC (n=5) from controls without PC (n=61). We 
could also distinguish the only patient with histologically confirmed precursor lesions 
(multifocal PanIN1-2 and IPMN) from other controls. Importantly, the biomarker signature 
was not disturbed by a (recent or non-recent) medical history of melanoma. Since this was 
a preliminary study with limited sample size, additional studies will be needed before this 
biomarker test can be implemented in the current PC surveillance program. 
Chapters 7 and 8 comprise the second part of this thesis, in which we focused on genetic 
testing for hereditary melanoma. In chapter 7, we studied the association between 
germline CDKN2A mutations and the presence of five clinical features in a melanoma 
family. One of these features, the presence of head and neck cancer(s) in a family, had 
not been previously studied in relation to the probability of a CDKN2A mutation. Using 
multivariate logistic regression analysis, significant associations were found for every 
feature in a large cohort of 1227 Dutch melanoma families (13.7% with a CDKN2A mutation). 
For practical purposes we further developed CM-Score, a non-computerized scoring 
system derived from the logistic regression model. In a predominantly Swedish familial 
melanoma validation cohort (n=421; 9.0% with a CDKN2A mutation), CM-Score showed a 
good ability to discriminate between families with and without a CDKN2A mutation (Area 
under the Curve 0.94). The commonly used threshold of 10% mutation probability was 
approximated to a CM-Score of 16 out of 49 points; the mutation probability below this 
score was very low (≤4%). We therefore concluded that CDKN2A diagnostics should at 
least be recommended to families with a CM-Score ≥16 points.
Although the CDKN2A gene is the most important melanoma predisposition gene that 
should be part of any genetic test for hereditary melanoma, several other high- and 
medium-penetrance melanoma predisposition genes are currently known and could 
potentially be tested in addition to CDKN2A. In chapter 8, we performed multigene panel 
testing of 30 established and candidate melanoma predisposition genes in a cohort of 451 
Dutch melanoma-prone families without a known CDKN2A (or CDK4) mutation. We found 
pathogenic mutations in BAP1 (n=3 families) and MITF (p.E318K variant) (n=15 families), 
which together resulted in a diagnostic yield of 4.0%. In the BAP1 families, there were no 
reported diagnoses of uveal melanoma or malignant mesothelioma, both of which are 
major BAP1-associated cancers. Based on these findings, we concluded that both BAP1 and 
MITF genes should always be included in a multigene panel test for cutaneous melanoma. 
In the known melanoma predisposition genes involved in telomere integrity (POT1, ACD, 
TERF2IP, TERT), we only identified two variants of uncertain significance, in ACD and 




Additionally, we found several variants of interest in candidate melanoma predisposition 
genes, in particular in OCA2, BRIP1 and POLE, but more research is warranted before 
these or other candidate genes can be included in regular diagnostic testing for hereditary 
melanoma.
In the final chapter, chapter 9, we discuss the main findings of the studies presented in 
this thesis in the context of the most recent literature. In this chapter, we introduce the 
term “CDKN2A-associated cancer predisposition syndrome” and we propose a revision of 
the current referral criteria for CDKN2A diagnostics in familial melanoma. We emphasize 
that CDKN2A mutation carriers are a distinctive group within PC surveillance programs 
and we discuss the possible implications that this may have for clinical practice. In the 
future, improved referral criteria combined with increasing possibilities for elaborate 
multigene panel testing will enable us to better identify individuals with a high genetic risk 
for melanoma and other cancers. Together with further improvement of complex cancer 
surveillance programs such as that for PC, we are confident that these developments will 





Melanoom is de meest agressieve vorm van de frequent voorkomende typen huidkanker. 
Als melanoom niet vroegtijdig ontdekt en behandeld wordt, kan het in potentie uitzaaien 
naar andere organen zoals hersenen, longen, lever en botten. In Nederland worden er 
jaarlijks ongeveer 6000 patiënten met melanoom gediagnosticeerd. Van alle patiënten 
met melanoom heeft ongeveer 5-10% een naast familielid die ook melanoom heeft 
gehad. Bij maximaal 30-40% van deze patiënten met een familiaire belasting kan een 
erfelijke aanleg voor het ontwikkelen van melanoom worden vastgesteld (zie figuur). De 
belangrijkste erfelijke eigenschap (gen) waarin afwijkingen (mutaties) worden gevonden in 
deze families is het CDKN2A-gen. CDKN2A-mutatiedragers hebben een sterk verhoogd 
risico (tot 70%) op het ontwikkelen van melanoom en krijgen vaak meerdere melanomen. 
De gemiddelde leeftijd waarop het eerste melanoom wordt vastgesteld is 39 jaar; ruim 15 
jaar jonger dan de gemiddelde leeftijd van diagnose in de algemene bevolking. Naast een 
verhoogd risico op melanoom hebben CDKN2A-mutatiedragers ook een verhoogd risico 
op andere vormen van kanker, met name alvleesklierkanker (pancreatic cancer). Daarom 
spreekt men in dit kader ook wel van het “familial melanoma-pancreatic cancer syndrome”. 
In Nederland komt een hele specifieke mutatie in het CDKN2A-gen veel voor, namelijk een 
19 baseparen deletie in exon 2 die p16-Leiden wordt genoemd. Van alle families met een 
CDKN2A-mutatie gaat het in 80% om de p16-Leiden mutatie. Deze specifieke mutatie is 
terug te voeren tot een gemeenschappelijk verre voorouder (anno 1707) woonachtig in 
de omgeving van Leiden en heeft zich verspreid onder vele nakomelingen waarvan het 
merendeel in de regio is blijven wonen. De p16-Leiden mutatie wordt daarom een founder 
mutatie genoemd, en de regio waar de meeste p16-Leiden mutatiedragers wonen een 
genetisch isolaat. Omdat het merendeel van de p16-Leiden mutatiedragers in de regio 
Leiden woont, is een groot deel van deze personen onder periodieke dermatologische 
controle in het Leids Universitair Medisch Centrum (LUMC). 
Het is gebleken dat het risico op alvleesklierkanker bijzonder hoog is voor p16-Leiden 
mutatiedragers, ongeveer 15-20% met een gemiddelde leeftijd van diagnose op 58 jaar. 
Alvleesklierkanker is een van de meest dodelijke vormen van kanker. Het wordt meestal 
pas in een gevorderd stadium ontdekt en heeft dan een zeer slechte prognose (5-jaars 
overleving <5%). Vanwege dit sterk verhoogde risico en de sombere prognose komen 
alle personen met een aangetoonde p16-Leiden mutatie in aanmerking voor periodiek 
onderzoek (surveillance) naar alvleesklierkanker vanaf de leeftijd van 45 jaar. In het LUMC 
bestaat deze surveillance uit een jaarlijks MRI-onderzoek gecombineerd met magnetic 
resonance cholangiopancreatography (MRCP) en optioneel een endo-echografie (EUS). 




een zo vroeg mogelijk stadium te ontdekken en te behandelen. De belangrijkste precursors 
van alvleesklierkanker zijn pancreatic intraepithelial neoplasms (PanIN, graad 1 tot 3) 
en intraductal papillary mucinous neoplasms (IPMN). Deze precursors, in het bijzonder 
IPMN, kunnen worden gedetecteerd met beeldvorming van de alvleesklier omdat ze zich 
manifesteren als kleine cysteuze afwijkingen van de afvoerkanalen van de alvleesklier. 
Een eerste evaluatie van het Leidse surveillanceprogramma voor alvleesklierkanker in 
2011 toonde aan dat kleine tumoren en mogelijke precursors ontdekt en geopereerd 
kunnen worden, maar dat p16-Leiden mutatiedragers ook vaak agressieve (snelgroeiende) 
tumoren hebben.
FIGUUR Bij ongeveer 5-10% van alle mensen met melanoom komt melanoom ook in de familie voor. 
Bij slechts een deel hiervan kan een erfelijke oorzaak worden vastgesteld, meestal een verandering 
(mutatie) in het CDKN2A-gen.
Hoewel het CDKN2A-gen het belangrijkste hoog-risico gen voor melanoom is, en als 
zodanig ook altijd getest zou moeten worden in families met een reële verdenking op een 
erfelijke aanleg voor melanoom, zijn er een aantal andere, veelal nieuw ontdekte genen 
die eveneens een sterke of matig-sterke associatie hebben met familiair melanoom. Dit 
zijn: CDK4, BAP1, MITF, TERT, POT1, ACD en TERF2IP (zie figuur). Mutaties in deze genen 
zijn echter veel zeldzamer dan mutaties in het CDKN2A-gen en voor de meeste van deze 
genen is er nog veel onduidelijk over de precieze risico’s op melanoom en eventuele 
andere vormen van kanker. Bovendien is het nog niet bekend wat de frequentie is van 
mutaties in deze genen in de Nederlandse populatie. Ook zijn er meerdere kandidaat 
melanoomgenen beschreven die vaak gevonden zijn met genoombrede sequencing 
(whole exome sequencing; WES) van grote melanoomfamilies, maar waarvan nog niet 
duidelijk is wat hun precieze rol is in de erfelijkheid van melanoom. Samen met het 




een genenpanel voor erfelijk melanoom en worden getest in melanoomfamilies. Hierdoor 
kan de opbrengst van genetisch onderzoek naar erfelijk melanoom verbeteren.
Dit proefschrift heeft drie doelstellingen:
1) Het bestuderen van het gehele spectrum aan kankers bij p16-Leiden mutatiedragers, 
en onderzoeken of er andere genetische en niet-genetische factoren van invloed zijn 
op de hoogte van het risico op alvleesklierkanker
2) Het evalueren en verbeteren van het surveillance programma voor alvleesklierkanker 
bij p16-Leiden mutatiedragers
3) Het evalueren en verbeteren van genetische tests voor erfelijk melanoom 
De studies in het eerste deel van dit proefschrift (hoofdstukken 2 tot en met 6) zijn 
gericht op personen met de p16-Leiden mutatie en hebben betrekking op de eerste 
twee doelstellingen. De studies in het tweede deel (hoofstukken 7 en 8) zijn gericht op 
personen met familiair melanoom in het algemeen, het merendeel zonder CDKN2A/p16-
Leiden mutatie, en hebben betrekking op de derde doelstelling.
Hoofdstuk 1 is een inleiding waarin de huidige kennis over familiair en erfelijk melanoom, 
de p16-Leiden founder mutatie in het CDKN2A-gen en het surveillance programma voor 
alvleesklierkanker in Leiden wordt besproken. 
In hoofdstuk 2 bestuderen we het risico op kanker in een cohort van 150 p16-Leiden 
mutatiedragers die in de tijd werden gevolgd (prospectief). Zoals verwacht kwamen 
melanoom en alvleesklierkanker het meeste voor, maar er werd ook een globaal verhoogd 
risico op andere vormen van kanker gezien, met name kankers in het hoofd-hals gebied 
(lip, mond- en keelholte). Daarnaast had een hoger dan verwacht aantal (niet-verwante) 
personen een carcinoïde tumor of een medische voorgeschiedenis van sarcoïdose. 
Het is bekend dat zowel alvleesklierkanker als kanker in het hoofd-hals gebied sterk 
geassocieerd is met roken in de algemene bevolking. In deze studie hadden p16-Leiden 
mutatiedragers die rookten een viermaal verhoogd risico op deze vormen van kanker 
vergeleken met niet-rokers. We concluderen daarom dat het belangrijk is om roken actief 
te ontmoedigen om zo deze frequent voorkomende kankers te kunnen voorkomen. 
Bovendien moet aan p16-Leiden mutatiedragers geadviseerd worden om laagdrempelig 
contact op te nemen met hun (huis)arts als er aanhoudende klachten zijn van heesheid, 
slikklachten of zweren in de mond- en keelholte. Jaarlijkse inspectie van de mond- en 
keelholte zou kunnen helpen om kanker in dit gebied in een vroeg stadium te ontdekken.
Het aantal personen met alvleesklierkanker in een p16-Leiden familie kan sterk variëren. 




er bij sommige p16-Leiden mutatiedragers additionele genetische risicofactoren aanwezig 
zijn die het risico op alvleesklierkanker beïnvloeden. In hoofdstuk 3 onderzoeken we 
in een cohort van 185 p16-Leiden mutatiedragers, waarvan 50 met alvleesklierkanker, of 
het hebben van alvleesklierkanker geassocieerd is met zeven verschillende genetische 
risicovarianten (Single Nucleotide Polymorphisms; SNPs) die we selecteerden op basis 
van grote genoomwijde associatiestudies van niet-erfelijk alvleesklierkanker. We vonden 
daarbij geen associatie met deze SNPs. We veronderstellen dat het cohort wellicht te klein 
was om een associatie te vinden, dat sommige personen ten onrechte in de controlegroep 
zaten omdat ze misschien op latere leeftijd alvleesklierkanker krijgen en daardoor mogelijk 
een vertekenend beeld hebben kunnen geven, of dat er geheel andere SNPs zijn die het 
risico op alvleesklierkanker bij p16-Leiden mutatiedragers daadwerkelijk beïnvloeden.
De studies in hoofdstukken 4 tot en met 6 zijn gericht op het surveillance programma 
voor alvleesklierkanker bij p16-Leiden mutatiedragers. In hoofdstuk 4 vergelijken we de 
frequentie en het beloop van precursors van alvleesklierkanker en alvleesklierkanker zelf 
tussen het Leidse p16-Leiden surveillance cohort (n=116) en een Duits surveillance cohort 
van personen uit families met familiair alvleesklierkanker (familial pancreatic cancer; 
FPC) (n=125). We toonden aan dat de frequentie van alvleesklierkanker in het p16-Leiden 
cohort tien keer hoger was, maar dat op de MRI zichtbare cysteuze afwijkingen van de 
afvoerkanalen van de alvleesklier (oftewel precursors) veel vaker voorkwamen in het 
FPC-cohort. Resectiepreparaten in het FPC-cohort toonden vaak IPMN en PanIN2-3 
precursors, die slechts zelden werden gezien in het p16-Leiden cohort. P16-Leiden 
mutatiedragers ontwikkelden echter vaker alvleesklierkanker uit een precursor. Precursors 
bij p16-Leiden mutatiedragers hebben daarom mogelijk een hogere kwaadaardigheid in 
vergelijking met precursors bij personen uit FPC-families. We concluderen daarom dat een 
intensiever surveillance programma kan worden overwogen voor p16-Leiden mutatiedragers. 
In hoofdstuk 5 beschrijven we twee hoog-risico patiënten (één p16-Leiden mutatiedrager 
en één BRCA2 mutatiedrager) die een tweede primaire alvleesklierkanker ontwikkelden na 
een gedeeltelijke alvleesklierverwijdering vanwege een vroeg-stadium (T1-2N0M0) kanker 
twee tot vier jaar eerder. Deze gevallen illustreren dat er zeer waarschijnlijk een verhoogd 
risico is voor het ontwikkelen van een tweede primaire alvleesklierkanker bij hoog-risico 
patiënten die lang genoeg overleven na de eerste diagnose. We hebben daarom de voor- 
en nadelen van een totale alvleesklierverwijdering (totale pancreatectomie; TP) besproken 
en geconcludeerd dat een TP moet worden overwogen bij hoog-risico patiënten (p16-
Leiden mutatiedragers in het bijzonder) die gediagnosticeerd worden met een vroeg-




Een belangrijke beperking van huidige surveillance programma’s voor alvleesklierkanker is 
het feit dat de gebruikte beeldvormende technieken (MRI/MRCP en EUS) een suboptimaal 
vermogen hebben om relevante afwijkingen in de alvleesklier betrouwbaar te detecteren 
of te onderscheiden van minder relevante afwijkingen. De beslissing of een patiënt wel of 
geen alvleesklieroperatie moet ondergaan kan daarom soms erg moeilijk zijn. In hoofdstuk 
6 bestuderen we of een eerder geïdentificeerde, op eiwitten gebaseerde (proteomics) 
biomarker signatuur voor alvleesklierkanker in bloed toegevoegd zou kunnen worden 
aan het Leidse surveillance programma, als een additionele niet-invasieve test bovenop 
de gebruikte beeldvormende technieken. We konden met deze biomarker signatuur een 
nauwkeurig onderscheid maken tussen p16-Leiden mutatiedragers met alvleesklierkanker 
(cases; n=5) en p16-Leiden mutatiedragers zonder alvleesklierkanker (controles; n=61). 
De enige patiënt met histologisch (door de patholoog) bevestigde precursors (meerdere 
PanIN1-2 en IPMN) kon ook onderscheiden worden van andere controles. Bovendien 
werden de biomarker profielen niet verstoord door een (recente of niet-recente) diagnose 
van melanoom. Hoewel de resultaten veelbelovend zijn, is dit is een kleine voorstudie 
met een beperkt aantal patiënten. Er is daarom meer onderzoek met een groter aantal 
patiënten nodig voordat deze biomarker test ingevoerd kan worden in het huidige 
surveillance programma voor alvleesklierkanker.
De hoofdstukken 7 en 8 vormen het tweede deel van dit proefschrift, waarin we ons 
richten op personen met familiair melanoom in het algemeen met als doel het verbeteren 
van genetische tests voor erfelijk melanoom. In hoofdstuk 7 bestuderen we de 
associatie tussen CDKN2A-mutaties en de aanwezigheid van vijf klinische kenmerken 
in een melanoomfamilie, namelijk 1) het aantal familieleden met melanoom, 2) het 
aantal familieleden met multipele melanomen, 3) gemiddelde leeftijd van diagnose van 
melanoom in een familie, 4) aanwezigheid van alvleesklierkanker in een familie en 5) 
aanwezigheid van kanker in het hoofd-hals gebied in een familie. Het laatstgenoemde 
kenmerk was nog niet eerder in dit kader onderzocht. Met een specifieke statistische 
analyse (multivariate regressieanalyse) vonden we significante associaties voor elk 
klinisch kenmerk in een groot cohort van 1227 Nederlandse melanoomfamilies (13.7% 
met een CDKN2A-mutatie). Op basis van dit regressiemodel ontwikkelden we een 
praktisch en niet-computergestuurd scoresysteem genaamd CM-Score. Met behulp 
van een grotendeels Zweeds validatiecohort (n=421 melanoomfamilies; 9.0% met een 
CDKN2A-mutatie) toonden we aan dat CM-Score goed onderscheid kan maken tussen 
families met en zonder een CDKN2A-mutatie (Area under the Curve 0.94). In de praktijk 
wordt, voor het verrichten van genetisch onderzoek in een familie met een mogelijke 
erfelijke aanleg voor kanker, vaak een drempelwaarde van 10% kans op het vinden van 




uit 49 punten. De kans op een CDKN2A-mutatie is erg laag bij families met een lagere 
score (<4%). We concluderen daarom dat analyse van het CDKN2A-gen in ieder geval 
aangeboden moet worden aan families met een CM-Score van 16 punten of meer. 
In hoofdstuk 8 onderzoeken we wat de opbrengst in van een multi genen paneltest 
bij 451 Nederlandse melanoomfamilies zonder mutatie in het CDKN2A(of CDK4)-gen. In 
totaal includeerden we 30 genen in de paneltest, bestaande uit 9 bekende hoog-risico en 
matig-hoog risico melanoomgenen en 21 kandidaat melanoomgenen. In 18 families 
vonden we een pathogene (ziekte veroorzakende) mutatie in een van de 9 bekende 
melanoomgenen, wat resulteerde in een diagnostische opbrengst van 4.0%. Drie van 
deze families hadden een pathogene mutatie in het BAP1-gen en 15 families hadden 
een pathogene mutatie in het MITF-gen (p.E318K variant). Het BAP1-gen is geassocieerd 
met verschillende vormen van kanker, waaronder huidmelanoom. De twee belangrijkste 
en meest frequent voorkomende vormen van kanker bij BAP1-mutatiedragers, namelijk 
oogmelanoom en maligne mesothelioom (borstvlieskanker), kwamen opmerkelijk genoeg 
niet voor in onze drie BAP1-families. Op basis van deze resultaten concluderen we dat 
BAP1 en MITF altijd moeten worden opgenomen in een multi genen paneltest voor 
erfelijk huidmelanoom. In de vier bekende melanoomgenen die een functie hebben in de 
integriteit van telomeren (POT1, ACD, TERF2IP, TERT) vonden we slechts twee varianten van 
onduidelijke betekenis (in ACD en TERF2IP). Waarschijnlijk spelen deze telomeergenen dus 
maar een kleine rol in de Nederlandse melanoompopulatie. Daarnaast vonden we diverse 
varianten in de 21 kandidaat melanoomgenen, in het bijzonder in OCA2, BRIP1 en POLE. 
Er is echter meer onderzoek nodig voordat deze genen of andere kandidaatgenen in de 
reguliere genetische diagnostiek naar erfelijk melanoom opgenomen kunnen worden. 
Tot slot bespreken we in hoofdstuk 9 de belangrijkste bevindingen van de studies in 
dit proefschrift in de context van recente literatuur. We introduceren in dit hoofdstuk de 
term “CDKN2A-geassocieerd tumorpredispositie syndroom” en doen een voorstel voor 
aanpassing van de huidige verwijscriteria voor CDKN2A analyse bij familiair melanoom. 
Ook benadrukken we de bijzondere positie die CDKN2A mutatiedragers hebben 
binnen surveillanceprogramma’s voor alvleesklierkanker en we bespreken wat dat zou 
kunnen betekenen voor de klinische praktijk. In de toekomst zal een verbetering van 
de verwijscriteria in combinatie met de toenemende mogelijkheden van multi genen 
paneltests ons in staat stellen om personen met een genetisch hoog risico op melanoom 
en andere vormen van kanker beter te kunnen identificeren. Samen met een verdere 
verbetering van complexe surveillanceprogramma’s zoals dat voor alvleesklierkanker zal 
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